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ABSTRACT 
 
Heart rate (HR) is one of most easily measured exercise test variables. Although easily measured, the HR 
reflects a complex, integrated physiologic response: autonomic tone, central and peripheral reflexes, 
hormonal influences, and factors intrinsic to the heart are all important. During the last two decades 
exercise test derived HR variables have raised wide interest as prognostic markers of mortality and 
cardiac events both in asymptomatic persons and in patients with cardiovascular disease (CVD). The 
results of properly controlled studies suggest a possible bimodal relationship of HR to prognosis, in which 
both high HR at low workload and inappropriately low HR at maximal or near maximal workload are 
associated with adverse prognosis. 
Workload achieved at HR of 100 beats/min (WL100) and HR increase from 40% to 100% of maximal 
work capacity (HR40-100) were assessed using a maximal, symptom-limited exercise test on an 
electrically braked cycle ergometer. The complete data on exercise test variables was available for 1679 
men in a population based sample of men. During the follow-up of eleven years, deaths were ascertained 
by linkage to the National Death Registry, and the classification of acute myocardial infarctions was 
carried out according to the multinational MONICA project protocol. 
A new variable, HR40-100, quantifying an inappropriately low HR at maximal or near maximal workload 
was at least as strong a predictor of outcome as previously established related variables. A one standard 
deviation (SD) decrement in HR40-100 (13 beats/min) was related to an increased risk of all-cause death 
(relative risk, RR 1.3, 95% confidence interval, CI 1.1 to 1.6) and acute myocardial infarction (RR 1.3, 
95% CI 1.1-1.6) in men without coronary heart disease (CHD) at baseline after adjustment for age, 
cardiovascular risk factors and exercise test variables. After exclusion of men whose test was possibly 
terminated prematurely because of submaximal effort, symptoms, or findings which could be interpreted 
to indicate latent CHD, a low HR40-100 still was an independent predictor of outcome. A one SD 
decrement in WL100 was related to an increased risk of CVD death (RR 1.7, 95% CI 1.3-2.4) and all-cause 
death (RR 1.7, 95% CI 1.3-2.2) in men without CHD at baseline and in men with known or suspected 
CHD at baseline after adjusting for risk factors, respectively. The exclusion of men who had an outcome 
event during the first two years of follow-up did not affect the results. A low WL100 was associated with a 
high resting HR and a low maximal oxygen uptake, but in survival analyses a low WL100 still provided 
additional prognostic information beyond these variables. 
A blunted HR increase during the maximal exercise test is associated with an increased risk of death and 
adverse cardiac events in men without CHD at baseline. The association is particularly strong when the 
HR increase during the latter half of the test is considered. On the other hand, a low workload achieved at 
a submaximal HR of 100 beats/min predicts CVD and CHD mortality in men without CHD and all-cause 
death in men with known or suspected CHD. Contrary to previous interpretations, an exaggerated HR 
response at a low workload seems to indicate an increased risk by itself instead of being only a surrogate 
marker of a low cardiorespiratory fitness. The findings of the current thesis support the hypothesis that a 
bimodal relationship exists between HR and prognosis in which both an exaggerated HR response at 
submaximal workload and a blunted HR response at maximal or near maximal workload are associated 
with an adverse prognosis. In the current study sample several exercise test variables predict outcomes 
independent of each other and conventional risk factors. This emphasizes the importance of measuring 
several variables at submaximal and maximal workload and during recovery phase to maximize the 
prognostic yield obtained from the exercise test. 
 
National Library of Medicine Classification: WG 141.5.F9, WG 300 
Medical Subject Headings: Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/mortality; 
Coronary Artery Disease; Exercise Test; Finland; Follow-Up Studies; Heart rate; Men; Myocardial 
Infarction; Risk Factor 
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TIIVISTELMÄ 
 
Sydämen sykintätaajuus, syke, on eräs helpoimmin mitattavista kuormituskoemuuttujista. Näennäisestä 
yksinkertaisuudestaan huolimatta mitattu syke on monimutkaisen säätelyn lopputulos, jossa autonomisen 
hermoston reflekseillä, hormonaalisilla tekijöillä ja sydämessä itsessään vaikuttavilla tekijöillä on 
kullakin oma osuutensa. Edeltäneiden kahden vuosikymmenen aikana kuormituskokeenaikaisen sykkeen 
on lukuisissa tutkimuksissa havaittu olevan yhteydessä kuolleisuuteen ja sydän- ja 
verisuonitautitapahtumiin sekä oireettomilla tutkittavilla että sydän- ja verisuonitautipotilailla. 
Tutkimusten perusteella sykkeen ja ennusteen yhteys on mahdollisesti kaksijakoinen niin, että sekä 
korostunut sykkeen nousu kevyessä kuormituksessa että toisaalta heikentynyt sykkeen nousu 
maksimikuormituksessa ovat yhteydessä huonoon ennusteeseen. 
Tässä itä-suomalaisessa väestöpohjaisessa seurantatutkimuksessa tehtiin maksimaalinen kuormituskoe 
1679 miehelle. Kuormituskokeessa määritettiin työmäärä, jonka tutkittava saavutti ennen sykkeen 
kohoamista yli 100 lyöntiä/min, ja sykkeen nousu välillä 40-100% tutkittavan maksimaalisesta 
suorituskyvystä. Tutkimuksessa selvitettiin näiden kahden sykemuuttujan ennusteellista merkitystä. 
Seurattavat päätetapahtumat 11 vuoden seuranta-aikana olivat kokonaiskuolleisuus, kuolleisuus 
sepelvaltimotautiin ja muihin sydän- ja verisuonisairauksiiin, sekä akuutti sydäninfarkti. Nämä 
päätetapahtumat luokiteltiin hyödyntäen sairaalapoistotietoja ja valtakunnallisen kuolinsyyrekisterin 
tietoja.    
Tutkimuksen keskeisinä löydöksinä todettiin, että heikentynyt sykkeen nousu välillä 40-100% tutkittavan 
maksimaalisesta suorituskyvystä ennustaa ennenaikaisen kuoleman ja akuutin sydäninfarktin riskiä 
miehillä, joilla ei ollut sepelvaltimotautia seurannan alkaessa. Tämä uusi heikentynyttä sykkeen nousua 
maksimikuormituksessa kuvaava muuttuja oli vähintään yhtä voimakas ennustaja kuin aikaisemmissa 
tutkimuksissa käytetyt vastaavaa ilmiötä kuvaavat muuttujat. Tämä tutkimus osoitti toisaalta sen, että 
matala saavutettu työmäärä ennen sykkeen kohoamista yli 100 lyöntiä/min ennustaa sydän- ja 
verisuonitautikuoleman riskiä miehillä, joilla ei ollut sepelvaltimotautia seurannan alkaessa. Sama 
muuttuja ennusti ennenaikaisen kuoleman riskiä myös miehillä, joilla oli todettu tai epäilty 
sepelvaltimotauti seurannan alkaessa. Matala työmäärä ennen sykkeen kohoamista yli 100 lyöntiä/min oli 
yhteydessä korkeaan leposykkeeseen ja huonoon kardiorespiratoriseen kuntoon, mutta elinaika-
analyyseissä sen havaittiin kuitenkin tuovan ylimääräistä ennustearvoa näiden kahden ennestään tunnetun 
vaaratekijän lisänä. Kokonaisuutena tulokset tukevat hypoteesia, että sekä korostunut sykkeen nousu 
kevyessä kuormituksessa että heikentynyt sykkeen nousu maksimikuormituksessa ovat yhteydessä 
huonoon ennusteeseen. 
Tämä väestötutkimus vahvistaa kliinisen kuormituskokeen merkitystä arvioitaessa myöhempien 
sydäntapahtumien ja enneaikaisen kuoleman vaaraa, sillä usealla kuormituskoemuuttujalla havaittiin 
olevan ennusteellista lisäarvoa perinteisiin vaaratekijöihin nähden. Tutkitut sykemuuttujat ennustivat 
päätetapahtumia sekä sepelvaltimotautia sairastamattomilla miehillä että sitä sairastavaksi todetuilla tai 
epäillyillä miehillä. Koska syke on eräs helpoimmin mitattavista kuormituskoemuuttujista, sykevasteen 
arviointi sekä kevyessä että maksimaalisessa kuormituksessa kannattaa ottaa huomioon arvioitaessa 
tutkittavan ennustetta kuormituskoetulosten perusteella. 
 
 
Yleinen suomalainen asiasanasto: sydän- ja verisuonitaudit, epidemiologia; sydän- ja verisuonitaudit, 
riskitekijät; syke; sydäninfarkti, miehet, Suomi 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“A man’s nature and way of life are his fate, 
and that which he calls his fate is but his disposition.” 
 
 Menander (342-291 B.C.) 
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1. INTRODUCTION 
 
Coronary heart disease (CHD) is the leading cause of death in the developed world (1) 
and may become the leading cause of death in the entire world (2). Although the 
incidence of CHD has been decreasing over the last two decades, the prevalence is 
expected to increase given the growing elderly population (3-5). It is important to 
implement cost-effective strategies that direct the appropriate individuals to the optimal 
risk reduction procedures through risk prediction (4-6). There is a growing awareness of 
the need to apply statistical techniques to develop evidence-based scores for better 
decision making (7). The goal of risk prediction through statistical methods is to 
provide a logical estimate as to the likelihood of the occurrence of important deleterious 
clinical events (3-5). The most important outcome is death, but the future risk of 
nonfatal clinical outcomes is also an important element of risk evaluation (3-5). Based 
on the worldwide epidemiological experience, the evaluation of cardiovascular risk is 
based on four time-honoured classical cardiovascular disease (CVD) risk factors: age, 
serum cholesterol, resting systolic blood pressure and smoking status (8).  
Exercise testing is not recommended in low-risk asymptomatic subjects due to both 
lacking evidence of its value and because false positive exercise electrocardiograms 
(ECGs) are common (9). However, the real issue is not to identify CHD, but to predict 
outcome (10). Because of this, increasing attention has been focused on the exercise test 
as a prognostic, as opposed to diagnostic, modality (11,12). It is well known that several 
exercise test indices in addition to ECG findings, such as exercise capacity (9,13), heart 
rate (HR) (14,15) and blood pressure (BP) responses (16) to exercise, are strong 
predictors of CVD events.  
Exercise is the body’s most common physiologic stress, and it places major demands 
on the cardiovascular system (17). The exercise test provides a precise and powerful 
noninvasive tool that permits the study of the regulation of the cardiovascular system 
under rigorously controlled and highly reproducible conditions, which include the full 
range of its functional capacity (18). The adaptations that occur during an exercise test 
allow the body to increase its resting metabolic rate up to 20 times, during which time 
cardiac output may increase as much as six times (17,19). The obvious advantage to the 
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researcher is that more is learned about how a system operates when it is forced to 
perform than when it is idle (18). Acute exercise can elicit cardiovascular abnormalities 
that are not evident at rest, and it can be used to determine the adequacy of 
cardiovascular function (19). 
Heart rate is one of the most easily measured exercise test variables. Although easily 
measured, the HR reflects a complex, integrated physiologic response: autonomic tone, 
central and peripheral reflexes, hormonal influences, and factors intrinsic to the heart 
are all important (20-22). Recently, the changes in HR during and after exercise have 
emerged as powerful measures of risk for future CVD event in their own right (23). An 
interesting fact from the viewpoint of basic exercise physiology is that the mechanisms 
mediating the association of exercise HR variables and an increased risk of outcomes 
are largely unknown (24-26).  
Office-based assessment of conventional risk factor burden is necessary, but may not 
accurately estimate risk of future CVD events (27). There is a need for easily available 
non-invasive methods to detect individuals with an increased risk of CVD events who 
would probably benefit most from preventive measures (28). The main aim of the 
current study is identify variables derived from exercise test HR which might serve as 
useful predictors for future CVD events and possibly provide additional prognostic 
information to conventional risk factors in a population-based sample of middle-aged 
men.  
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2. REVIEW OF LITERATURE 
 
2.1 Sinoatrial node  
 
The normal heart beat starts in the sinoatrial (SA) node (20,21,29). The normal HR is 
determined by the firing frequency of SA node (20,21,29). The SA node is a small, 
flattened, ellipsoid strip of specialized cardiac muscle and associated fibroelastic 
connective tissue about 3 mm wide, 15 mm long, and 1 mm thick (29-31). It contains 
clusters of cells, poor in contractile filaments, where the automatic activity resides 
mostly in the pacemaker or P cells (32). Near the periphery of the SA node lie also 
another group of cells which are called as transitional cells (33). The SA node is located 
in the superior lateral wall of the right atrium immediately below and slightly lateral to 
the opening of the superior vena cava, near the superior end of the sulcus terminalis 
(20,29,34). Its primary source of blood is from the SA nodal artery, which originates 
from the right coronary artery in about 60% of humans (29,35,36). 
The normal cardiac impulses starts at the SA node, passes through the atrial tissue 
through preferential internodal tracts to the atrioventricular (AV) node where it slows, 
and then continues down the His-Purkinje system to the ventricular myocardium, where 
the wave of depolarization terminates when there is no further tissue to depolarize 
(20,31,37). Further conduction occurs only after a new impulse is formed in the SA 
node (38). 
Many cardiac cells, especially the cells of the heart’s specialized conducting system, 
have the capability of self excitation, a process that can cause automatic rhythmical 
discharge and conduction (39). The resting potential of a typical cardiac cell is -80 to -
90 millivolts (mV) (38,39). When it is depolarized to a certain threshold level (threshold 
potential), an action potential is produced as a result of a complex series of ionic shifts 
(37-39). The appearance of the action potential of SA nodal cells is different from that 
of the typical myocyte (38,39). The normal resting potential of these cells is higher (-55 
to -60 mV), and the spontaneous diastolic depolarization is much more pronounced (38-
40). The slope of the diastolic depolarization determines the rate at which a cell will 
 22 
 
spontaneously depolarize (automaticy) until it reaches the threshold potential, thus 
generating an action potential that is then propagated to surrounding cells (38,39,41).  
The spontaneous cyclic depolarization of primary pacemaker cells in the SA node 
that establish intrinsic HR arises from the unique time-dependent characteristics of a 
variety of depolarizing and hyperpolarizing currents (37,39,42). The ionic basis of SA 
node pacemaker activity is such that action potential configuration is determined mainly 
by outward hyperpolarizing K+ current, IK, and two depolarizing inward currents, ICa 
and If, that are carried primarily by Ca2+ and Na+, respectively (37,40,43). At the 
termination of one SA node action potential, the membrane voltage does not stabilize to 
a negative level but slowly creeps up with an approximately constant slope, until it 
reaches the threshold for a new SA node action potential (39,44). The gradual 
membrane depolarization has been attributed to an overall diminution in the net 
conductance of hyperpolarizing K+ currents and a constant background inward current 
caused by the spontaneous inward movement along the concentration gradient for Na+ 
ions (37,45,46). A major role, however, in the generation and control of the diastolic 
depolarization is played by a prominent increase in the inward depolarizing current If 
(37,39,46). An initial membrane depolarization leads to the activation of a transient (T-
type) Ca2+ current (ICa,T) which results in Ca2+ influx into a confined subsarcolemmal 
space between the sarcolemma and sarcoplasmic reticulum, and [Ca2+] in the 
subsarcolemmal space begins to increase (37,42). This triggers the focal release of Ca2+ 
(sparks) from sarcoplasmic reticulum Ca2+ release channels, further increasing [Ca2+] in 
the space (37). This in turn leads to the activation of forward Na+-Ca2+ exchange (INCX) 
and further membrane depolarization toward a threshold potential (37). Since the 
stoichiometry of the exchange is three Na+ for one Ca2+, the current is electrogenic and 
mediates a net inward current, INaCa (37,42). The interrelated actions of ICa,T, 
sarcoplasmic reticulum Ca2+ initiates, and INaCa creates a positive feedback loop that 
culminates in a progressive membrane depolarization to the threshold potential (37). 
Once threshold is achieved, an L-type inward Ca2+ current (ICa,L) rapidly activates, and 
an action potential is triggered (42,43,47). 
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The SA node usually has the fastest diastolic depolarization and thus functions as the 
normal pacemaker of the heart (20,21,29). If the SA node fails, the AV node has the 
next fastest pacemaker rate (approximately 40-60 beats/min) (21,38,39). 
 
2.2 Cardiac innervation 
 
The normal myocardium is richly innervated by the autonomic nervous system (31,48). 
The heart is supplied by autonomic nerve fibers from superficial and deep cardiac 
plexuses from which three major cardiac nerves project into the heart (35,49). These 
nerve networks lie between the bifurcation of the trachea and the ascending aorta, and 
superior to the bifurcation of the pulmonary artery (35). The parasympathetic supply is 
from preganglionic cardiac branches of the vagus nerves (21,50,51). The cell bodies of 
the parasympathetic postganglionic fibers constitute intrinsic ganglia in the vicinity of 
SA and AV nodes (20,48,50). The postganglionic parasympathetic fibers innervate 
primarily the atria. There are a few projections to the ventricles, however, and there is 
increasing evidence to show that the vagal nerves innervate the ventricular myocardium 
as well (48,52,53). The cell bodies of cardiac afferent vagal neurons are contained 
within the nodose ganglia inferior to the jugular foramen (35,50,54). The central fibers 
of these bipolar neurons continue to ascend in the vagus to enter the brain stem 
(35,50,54). 
Both pre- and postganglionic cardiac parasympathetic fibers release acetylcholine as 
neurotransmitter (48,50,51). The effects of acetylcholine on the heart are mediated by 
muscarinic M2-receptors, but the neural transmission between pre- and postganglionic 
fibers of both the sympathetic and parasympathetic systems is mediated by nicotinic 
NN-receptors (35,50,51). Once acetylcholine has been secreted, it persists in the tissue 
for a few seconds. Thereafter, most is split into acetate and choline by the enzyme 
acetylcholinesterase (48,55).  
The sympathetic supply is from postganglionic cardiac sympathetic fibers (20,21,51). 
The cell bodies of pre- and postganglionic fibers are located in the intermediolateral cell 
columns of the lateral horns of the superior five or six thoracic segments of the spinal 
cord, and in the cervical and superior thoracic paravertebral ganglia of the sympathetic 
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trunks, respectively (20,21,51). Sympathetic nerve terminals are located throughout the 
atria and ventricles (20,21,56). The cardiac afferent sympathetic neurons have their cell 
bodies in the C6-T6 dorsal root ganglia, and they enter the dorsal horn of the spinal cord 
(35,50,57). They synapse on cells in the outer part of the dorsal horn, the axons of the 
second-order neurons immediately decussate and ascend through the spinothalamic tract 
to reach the thalamus (50,57).    
Pre- and postganglionic cardiac sympathetic fibers release acetylcholine and 
noradrenaline as neurotransmitters, respectively (20,50,51). In addition to innervation 
directly from sympathetic nerve endings, the sympathetic nervous system may have an 
effect indirectly by stimulating the adrenal medulla to secrete adrenaline and 
noradrenaline into the circulating blood (50,51,58). These two hormones can further 
bind to adrenergic receptors in the heart (50,51,58). The effects of noradrenaline and 
adrenaline on the heart are mediated by α1-, β1- and β2-adrenergic receptors (50,51,58). 
β1 is the most abundant subtype of adrenergic receptor in the heart, representing 
approximately 75% of total (20,51,58). Noradrenaline excites mainly α-receptors, but 
also excites the β-receptors to a lesser extent (39,59). Adrenaline excites both types of 
receptors approximately eqally (39,59). Noradrenaline is removed from the secretory 
site in three ways: (i) reuptake into the adrenergic nerve endings (accounting for 
removal of 50%-80% of the secreted noradrenaline); (ii) diffusion away into the 
surrounding body fluids; and (iii) destruction by enzymes (32,48,55).  
The latency of the response of the SA node to vagal stimulation is very short 
(18,21,48). After a single stimulus, the maximum response has been reported to occur 
within only 400 milliseconds (18,48,60). Thus, vagal stimulation results in a peak 
response either in the first or in the second beat after its onset (21,48). On the other 
hand, following the onset of sympathetic stimulation, there is a latent period of up to 5 
seconds. This is followed by a progressive increase in HR, which reaches a steady level 
in 20 to 30 seconds (18,21,48). Both parasympathetic and sympathetic preganglionic 
fibers are myelinated, whereas postganglionic fibers do not have a myelin sheath 
(50,61). The fact that parasympathetic postganglionic fibers are clearly shorter than 
sympathetic postganglionic fibers partly explains the slower cardiac responses to 
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sympathetic stimuli than to parasympathetic stimuli, because the neural transmission is 
faster in myelinated fibers (39). 
The HR is determined from the ECG as the reciprocal of the time interval between 
two successive R peaks (which reflect depolarization of ventricles) and expressed as 
beats/minute (17,20). The intrinsic HR, in the absence of any neurohumoral influence, 
is about 100 to 120 beats/min and declines with age (21,62,63). Without neurohumoral 
influence maximal HR at peak exercise is 18-24% lower than with intact neurohumoral 
influence (63,64). In the intact, unblocked individual, the HR at any time represents the 
net effect of the vagal (parasympathetic) and the sympathetic nerves, which play a key 
role in the regulation of the HR by modulating the intrinsic pacemaker activity of the 
heart (19,36,65). In resting conditions, both autonomic divisions are thought to be 
tonically active with the vagal effects dominant (20,36,51). In normal adults at rest, the 
HR is about 70 to 85 beats/min and the normal range is 60 to 100 beats/min (29,65,66). 
SA and AV nodes are the most densely innervated regions of the heart and are most 
affected by changes in autonomic tone, allowing for neural regulation of the HR 
(37,48). There is some asymmetry in the distribution of autonomic fibers to the heart, 
and the SA node is predominantly innervated by fibers from the right side (21,29,67). 
Weak to moderate vagal stimulation will slow the HR often to as little as one-half 
normal (39,48). Strong vagal stimulation of the heart can stop the heartbeat for a few 
seconds, but then the heart usually “escapes” and beats at a rate of 20 to 40 beats/min 
thereafter, paced by a pacemaker elsewhere than in the SA node (21,36,39). Increased 
vagal input into the SA node results in the release of acetylcholine from nerve endings 
in the SA node and the released acetylcholine binds to muscarinic receptors (37,39,48). 
Acetylcholine can directly activate a specific class of K+ channels (KACh) in SA node 
cells, which produces a hyperpolarizing current that opposes the effects of depolarizing 
currents during diastole (37,42,48). Also, the release of acetylcholine slows HR by 
suppressing membrane-bound adenylate cyclase activity via a G-protein-coupled M2-
adenylate cyclase mechanism (see next paragraphs) (42,46,47). The former mechanism 
is more prominent at higher levels of vagal activation and explains acetylcholine-
mediated action potential hyperpolarization (37,42). The latter mechanism occurs at 
lower levels of vagal activation and provides a conceptual explanation for a reduction in 
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the rate of diastolic depolarization without prominent membrane hyperpolarization 
(37,42). Besides these mechanisms vagal activation may affect diastolic depolarization 
by inducing an upward shift in action potential threshold (37). The net effect of these 
three mechanisms is to prolong the time required for diastolic depolarization to proceed 
to an action potential threshold (37).  
An increase in sympathetic activity forms the principal method of increasing HR 
above the intrinsic level generated by the SA node to the maximal levels achieved 
(21,68,69). Strong sympathetic stimulation can increase the HR in adult humans to 180 
to 200 beats/min (39,70). Sympathetic stimulation, either directly from sympathetic 
nerve endings in the heart (noradrenaline) or indirectly by means of circulating 
adrenaline, accelerates the pacemaker activity of SA node cells (46,47,56). This 
manifests itself as a marked increase in the rate of diastolic depolarization and an 
increase in the amplitude of the pacemaker action potential (37,43).  
The increase in the rate of diastolic depolarization results from cyclic adenosine 
monophosphate-mediated enhanced intracellular Ca2+ handling and from an increase in 
the magnitude of If (42,46,47). The binding of sympathetic neurotransmitter to β-
adrenergic receptor leads to the G-protein-mediated activation of a membrane-bound 
adenylate cyclase, the formation of cyclic adenosine monophosphate, and subsequent 
activation of a cyclic adenosine monophosphate-dependent protein kinase A (42,46,47). 
The active catalytic subunits of protein kinase A phosphorylates sarcoplasmic reticulum 
Ca2+ pumps and sarcoplasmic reticulum Ca2+ release channels leading to enhanced 
sarcoplasmic reticulum Ca2+ loading as well as increased  Ca2+ sparks frequency (37). 
These events culminate in a faster increase in [Ca2+] in the subsarcolemmal space and a 
more robust activation of a depolarizing INCX (37). On the other hand, the channels 
mediating If are activated by cyclic adenosine monophosphate through the direct 
binding, and not by protein kinase A-mediated phosphorylation (46,47). The net effect 
of these cyclic adenosine monophosphate-mediated processes is a shortening of 
diastolic depolarization and an increase in HR (42,46,47). Still one possible β-
adrenergic-mediated mechanism involves stimulation of Na+-K+-pump activity (32). 
The consequent hyperpolarization changes the pacemaker potential in early diastole into 
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the zone required for activity of the If current, so that less time is required to activate 
this current to initiate the following diastolic depolarization (32). 
 
2.3 Regulation of heart rate by central nervous system 
 
All levels of the central nervous system contribute to the regulation of cardiovascular 
activities, but the main cardiovascular regulating centers are located in the brain stem 
(20,29,48). Located bilaterally mainly in the reticular substance of the medulla and 
lower third of the pons is an area called the vasomotor center (35,39). The center 
transmits parasympathetic impulses through the vagus nerves to the heart and 
sympathetic impulses through the spinal cord and peripheral sympathetic nerves to the 
heart and blood vessels of the body (39,48). From the viewpoint of cardiovascular 
control the most important parts of the vasomotor center are the nucleus tractus 
solitarius, the ventrolateral medulla, the dorsal motor nucleus and the nucleus ambiguus 
(71). The nucleus tractus solitarius, which lies in the posterolateral portions of the 
medulla and lower pons, receives sensory nerve signals from thoracic and abdominal 
organs mostly via vagus nerves and from the carotid sinuses via the glossopharyngeal 
nerves (56,72,73). The output signals from the nucleus tractus solitarius controls the 
activities of those areas in the vasomotor center, which in turn regulate the descending 
parasympathetic and sympathetic output (72-74). Widespread areas of the higher 
nervous centers can either excite or inhibit the vasomotor center (56,67,75). The more 
lateral and superior portions of the reticular substance cause excitation, whereas the 
more medial and inferior portions cause inhibition (39). The hypothalamus can exert 
either powerful excitatory or inhibitory effects on the vasomotor center: the 
posterolateral portions cause mainly excitation, whereas the anterior part can cause mild 
excitation or inhibition, depending on the precise part of the anterior hypothalamus 
stimulated (39,75,76). Of various parts of the cerebral cortex, anterior temporal lobe, the 
orbital areas of the frontal cortex, the anterior part of the cingulate gyrus, the amygdala, 
the septum and the hippocampus can all either excite or inhibit the vasomotor center, 
depending on the precise portion of these areas that is stimulated and on the intensity of 
the stimulus (39,76). 
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The parasympathetic efferent preganglionic neurons are located for the most part in 
the nucleus ambiguus of the medulla. Lesser numbers are located in the dorsal motor 
nucleus and the regions in between these two medullary nuclei (20,77,78). 
Parasympathetic activity to the SA node originates from the central nervous system 
rather than from peripheral ganglia (76), and severing of the preganglionic fibers, 
leaving only postganglionic innervation intact, releases the heart from parasympathetic 
inhibition (79). Preganglionic cardiac vagal fibers are tonically active, with a firing 
pattern that is pulse synchronous and most active during expiration and reduced during 
inspiration (respiratory sinus arrhythmia) (71,79). The cardiac vagal neurons in the 
nucleus ambiguus, however, do not display any pacemaker-like activity such as 
repetitive or phasic depolarizations or action potentials, but in the absence of synaptic 
activity those neurons are normally silent (71,80). Synaptic input to cardiac vagal 
neurons are therefore important in maintaining normal heart rate and cardiac function 
(79). A major pathway to the nucleus ambiguus originates from the nucleus tractus 
solitarius, and electrophysiological experiments demonstrate that the pathway is 
glutamergic (52,81,82). It is still unknown whether the nucleus tractus solitarius 
neurons relays sensory information project directly to cardiac vagal neurons, or whether 
there are synapses within the nucleus tractus solitarius before the sensory information is 
ultimately communicated to cardiac vagal neurons (71,79). Cardiac vagal neurons also 
have excitatory input from cholinergic nicotinic neurons, which are possibly involved in 
the respiratory sinus arrhythmia (79), and from dopaminergic neurons, which induce 
bradycardia via activation of D2-receptors (83).  
The ventrolateral medulla consists of rostral (rVLM) and caudal (cVLM) parts. A 
population of rVLM neurons (premotor neurons) project onto the interomediolateral cell 
column of the spine and constitute the main and final integration center in the brainstem 
for generating the sympathetic outflow to cardiovascular effector organs (71,72,84). 
Under normal conditions rVLM transmits signals continuously to the sympathetic 
preganglionic fibers in interomediolateral cell column via glutamergic transmission 
(39,71,84). This tonic sympatho-excitatory activity of rVLM is, however, continuously 
inhibited by gamma-aminobutyric acid-mediated transmission from cVML (71,72,84). 
cVML in turn receives tonic glutamergic excitatory input from the nucleus tractus 
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solitarius (71,72). Hence the tonic sympatho-excitatory transmission from rVLM to 
sympathetic preganglionic fibers is modulated by the degree of inhibitory drive from 
cVLM neurons, which in turn are under the control of the nucleus tractus solitarius 
(71,72,84).  
 
2.4 Factors modulating heart rate response to neural stimulation 
 
A complex interaction between sympathetic and vagal activity may be more important 
in the modulation of the HR than either branch alone (29). Postganglionic sympathetic 
and vagal fibers often lie side by side in the walls of the heart (48,85). Therefore, the 
neurotransmitters and neuromodulators released from nerve fibers of one autonomic 
division can influence the release of transmitters from the nerve endings of the other 
division (48,86). When both divisions of the autonomic nervous system are stimulated 
simultaneously, the resultant cardiac effect is often different from the algebraic sum of 
the individual responses obtained by stimulating the nerves from the two divisions 
separately (48,87). A prominent feature of such cardiac autonomic interactions is that 
the vagal effects tend to predominate over the sympathetic effects with respect to the 
control of HR (accentuated antagonism) (48,79,87). Two major mechanisms have been 
suggested to explain the antagonist effects of vagal stimulation on sympathetically 
induced responses (48,79,87). The first is a presynaptic mechanism, in which 
acetylcholine reduces the amount of noradrenaline released from sympathetic nerve 
terminals (48,79,88). The second is a postsynaptic mechanism, in which acetylcholine 
reduces the magnitude of the response to a given adrenergic stimulus (48,79,87). This 
second mechanism presumably involves inhibitory Gi-protein-dependent inhibition of 
cyclic adenosine monophosphate synthesis (79,89).  
On the other hand, intense sympathetic stimulation attenuates the chronotropic 
responses to vagal stimulation in the case when sympathetic stimulation antecedes vagal 
stimulation (90). This profound inhibition of vagal efficacy by antecedent sympathetic 
activity is believed to be mediated by the release of a specific neuromodulator, 
neuropeptide Y, from the sympathetic nerve endings (91). Neuropeptide Y inhibits 
acetylcholine release from vagal nerve endings (90). Additionally, catecholamines can 
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reduce the release acetylcholine by binding to α-adrenergic receptors in the presynaptic 
region of the parasympathetic nerve fibers (69). Finally, a high concentration of 
noradrenaline released into the synaptic cleft by a sympathetic postganglionic fiber may 
limit the subsequent release of further noradrenaline through binding to α2-receptors on 
the presynaptic nerve terminal (a negative feedback mechanism) (20,69).   
Opioids modulate parasympathetic control of HR via receptors in the SA node (92), 
prejunctionally on vagal nerve terminals (93), or within nearby parasympathetic ganglia 
(93) resulting in attenuation of vagally mediated bradycardia. Angiotensin II exerts 
inhibitory effect upon the cardiac vagal nerves (94) while having a facilitatory effect on 
the sympathetic ganglia (18,95,96). Nitric oxide facilitates parasympathetic control of 
HR by increasing central (97) and peripheral (98-100) vagal neuronal activity. 
Additionally, nitric oxide might have an inhibitory effect on sympathetic control of HR 
(101). Vasopressin (or antidiuretic hormone), although having the vasonstrictor action 
in vascular system, can increase cardiac vagal activity to some extent (102).    
Besides the pre- and postsynaptic interactions described above, processing probably 
occurs within the intrinsic cardiac nervous system, which involves afferent neurones, 
local interconnecting neurones as well as both parasympathetic and sympathetic efferent 
postganglionic neurones (78). Intrinsic cardiac ganglionic interactions represent the 
organ component of the hierarchy of intrathoracic nested feedback control loops, which 
provide rapid and appropriate reflex coordination of efferent autonomic outflow to the 
heart (78). 
The chronotropic response of the SA node to a fixed neuronal stimulus can vary as a 
result of the change in receptors number and activity (32,58). The number of receptors 
per unit area of the SA node sarcolemma (the receptor density) is not fixed, but can rise 
or fall in response to certain physiological or pathophysiological circumstances, 
processes called up- and downregulation (32,58). For example, in congestive heart 
failure there is a chronic high-level exposure to catecholamines, which causes a 
reduction in the number of β1-receptors, whereas β2-receptor density remains constant 
(32,103,104). The second form of the changed response is uncoupling, which refers to a 
state of the receptor where there is no loss in density, but functional activity is 
diminished (58,103). The underlying molecular mechanisms of uncoupling are the 
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increased levels of inhibitory Gi-proteins, leading to a reduced ratio of Gs/Gi and an 
impaired Gs-mediated coupling between the β-receptor and adenylate cyclase (103,104). 
The third form of the changed response is a change in receptor affinity (32). For 
example, β-agonist catecholamines induce or stabilize a high affinity form of the β-
adrenergic receptor, which is specific for agonists and binds antagonists rather weakly 
(32).  
The chronotropic response of the SA node to neural stimulation also involves genetic 
variation, which is still poorly understoood (105-107). The Arg389Gly (108,109) and 
Ser49Gly (58) polymorphisms of the β1-adrenergic receptor are associated with 
difference in HR at rest, but this has not been a consistent finding, however (110). 
During exercise there is no difference between Arg389Gly genotypes (111-113). The 
gene GNAS1 encodes α-subunit of the stimulatory G-protein that couples β1-adrenergic 
receptor with the adenylyl cyclase (106). The T393C polymorphism of GNAS1 
modulates HR response when values at rest, maximal exercise and recovery are 
considered together (106). The Arg16Gly polymorphism of the β2-adrenergic receptor is 
associated with difference in HR at rest (107,114), but during low or high intensity 
exercise the difference in HR does not persist between genotypes (107). The rs324640 
polymorphism of the muscarinic M2-receptor gene is associated with a difference in HR 
recovery after exercise, but maximal HR is not different between the genotypes (105).   
 
2.5 Mechanisms controlling heart rate  
 
Although easily measured, the HR reflects a complex, integrated physiologic response: 
autonomic tone, central and peripheral reflexes, hormonal influences, and factors 
intrinsic to the heart are all important (Figure 1) (20-22). Some reflexes may increase 
HR through a decrease in vagal tone, an increase in sympathetic activity, or both, 
whereas others exert the opposite effects (21,22). In the intact human cardiovascular 
system several reflexes and control mechanisms operate simultaneously, and the 
interactions are quite complex (21,22).  
  The relative importance of neural control mechanisms in determining the 
cardiovascular response to exercise is dependent upon the type of exercise (static or 
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dynamic), the intensity of the exercise, the time after the onset of exercise (immediate, 
steady state, exhaustion, etc.), and the effectiveness of blood flow to meet the increased 
metabolic needs of the contracting muscle (22,115). Control mechanisms for the 
cardiovascular response during exercise are somewhat redundant, rather than additive, 
and they impinge on the same regulatory neurons in the vasomotor center of medulla, 
and, possibly, other sites, where integration of afferent information occurs (115,116). 
Besides neurally mediated reflexes, some humoral factors, such as cortisol, glucagon, 
growth hormone and thyroxine may play a minor role in modifying the control of HR 
(20,29,55).  
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Figure 1. The overview of mechanisms influencing heart rate. See text for the more detailed discussion 
about the effects mediated by each individual mechanism.  
 
2.5.1 Arterial baroreceptors and cardiopulmonary low-pressure baroreceptors 
The function of the arterial baroreceptors is to maintain a normal BP (117-119). The 
arterial baroreceptors include carotid and aortic baroreceptors, which are spray-type 
nerve endings located in the walls of the large arteries (29,50,119). Carotid receptors lie 
in the wall of the internal carotid artery on either side (21,29,120). Each send impulses 
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centrally in the sinus nerve (of Hering), a branch of the glossopharyngeal nerve 
(50,120,121). Aortic arch receptors on the left lie within the aortic arch, but those on the 
right lie at the origin of the right subclavian artery and in the adjacent regions of the 
brachiocephalic artery (29,120,122). From the aortic receptors, activity travels centrally 
in small vagal branches (50,120,121). The nerve endings in the carotid sinus and aortic 
arch are activated by expansion of the arterial wall when BP is increased, and this 
stretching result in increases in discharge frequency in their afferent nerves (arterial 
baroreflex) (118,119,122).  
Afferent nerves transmit the baroreceptor activity to the nucleus tractus solitarius, 
which modulates autonomic outflow to buffer the rise in pressure (21,29,119). 
Conversely, a fall in BP reduces baroreceptor discharge and trigger adjustments that 
oppose the hypotension (21,118,119). The baroreceptors respond much more to a 
rapidly changing pulsatile pressure than to a stationary pressure (39,69). In dogs, arterial 
rheoreceptors that respond to increased blood flow by sensitizing the function of 
baroreceptors have been identified in the carotid sinus (123). The existence of 
rheoreceptors in humans is not known.       
Because mean arterial BP equals cardiac output times total peripheral resistance, the 
nucleus tractus solitarius can induce changes in BP by affecting either cardiac output, 
total peripheral resistance, or both via modulation of neural output (18,118,124). In 
response to a hypertensive stimulus, there is a rapid decrease in HR due to increased 
vagal discharge to the heart (18,121,125). In hypotensive stimulus there is an initial 
rapid increase in HR with withdrawal of vagal tone, followed by a slower rise in HR 
due to increased sympathetic discharge (18,121,125). The increase in total peripheral 
resistance (vasoconstriction) plays a major role in response to a hypotensive stimulus. In 
contrast, a decrease in HR is more important in response to a hypertensive stimulus 
(18,125). At rest roughly one third of the changes in arterial BP during carotid 
baroreceptor stimulation are due to changes in HR and two-thirds are dependent on 
alterations in total peripheral resistance, but the corresponding estimate for the overall 
baroreflex (carotid and aortic parts combined) is not known (126). Previously it was 
assumed that aortic baroreceptors operates over a higher range of arterial pressures than 
carotid receptors (21,39,127), but more recent studies have shown that both 
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baroreceptor populations operate over the same range of pressures (128). The estimated 
contribution of carotid baroreflex to overall baroreflex control is from 30% to 50 % 
(128,129). Aortic and carotid baroreceptors summate in their reflex effects (21,125). 
Because the relationship between total baroreceptor input and response is sigmoid, the 
type of summation (linear, inhibitory or facilitatory) depends critically on the size of the 
stimulus and the magnitude of the step in pressure to the baroreceptors (21,125,130). 
The fact that during exercise BP and HR rise linearly with increases in work rate, 
whereas at rest the corresponding increases would induce powerful opposing reflexes 
through the baroreflex has puzzled physiologists for over a century (131,132). The 
current view is that the arterial baroreflex is reset in direct relation to the intensity of 
dynamic exercise without a change in sensitivity of the reflex (133-135). The resetting 
moves the baroreflex set point to the higher BP level so that baroreflex does not oppose 
the rising arterial BP but even actively tries to elevate BP (via further vagal withdrawal 
and/or sympathetic excitation to the heart and/or sympathetically mediated 
vasoconstriction) until the new set point is achieved (136-138). During exercise changes 
in arterial BP during carotid baroreceptor stimulation are mostly due to changes in total 
peripheral resistance so that only at light workload HR contributes to changes in BP 
(138,139). The central command is probably the primary regulator of baroreflex 
resetting during exercise (138,140,141). The muscle chemoreflex is also able to reset 
baroreflex, but in normal dynamic exercise it acts more as a modulator of central 
command-induced resetting (138,141,142). 
Cardiopulmonary low-pressure baroreceptors monitor blood volume by sensing 
changes in the filling pressure of the chambers of the heart and pulmonary arteries and 
veins, as well as changes in cardiac contractility and afterload (18,143,144). Increases in 
these stimuli activate mechanically sensitive receptors in these structures, stimulating 
vagal afferent fibers that signal the nucleus tractus solitarius to inhibit sympathetic 
nervous system activity (18,124,144). The latter results in systemic vasodilatation and a 
reduction in total peripheral resistance, but physiological changes in cardiopulmonary 
low-pressure receptor activity cause little if any change in HR (18,124,144). When 
central venous pressure is normal, cardiopulmonary low-pressure baroreceptors 
tonically inhibit vasoconstriction induced by arterial baroreflex (18,144,145). 
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The cardiopulmonary low-pressure baroreceptors are not reset by the central nervous 
system during exercise, but they continuously inhibit arterial baroreceptor-induced 
vasoconstriction (18,118,144). If this tonic inhibition is eliminated by lower body 
negative pressure during exercise at a fixed workload, mean arterial BP and HR do not 
change, but total peripheral resistance increases and stroke volume decreases (146). 
Likewise, cardiopulmonary low-pressure baroreceptors inhibit the muscle metaboreflex-
mediated vasoconstriction during dynamic exercise (147).  
 
2.5.2 Central command and peripheral afferents  
Central command is the term for motor command signals originating from subthalamic 
neurons involved in locomotion which is believed to be a primary stimulus mediating 
the autonomic nervous system adjustments to exercise (118,148,149). These signals 
activate separately both somatomotor and cardiovascular control systems at the onset of 
exercise (115,149,150). Activation is in direct proportion to the number of motor units 
required to maintain a given force of contraction (18,143,150). The magnitude of a 
central command- mediated cardiovascular response during exercise can be independent 
of force production (e.g. imagined exercise) and dictated more by an individual’s 
perception of effort (18,116,151). Central command increases HR, cardiac output, and 
also BP immediately at the onset of exercise by rapid vagal withdrawal, but command 
signals have a minimal effect on the sympathetic nervous system-mediated 
vasoconstriction (116,150,152). Because both locomotor and cardiovascular responses, 
much like the responses to exercise, can be induced by either electrical or chemical 
stimulation of cells in hypothalamic locomotor region and in mesencephalic locomotor 
region, the current view is that these two neuroanatomical areas are strongly involved in 
the central command (115,116,152). Both these areas have connections with the 
vasomotor center in medulla, which enables them to influence cardiovascular control 
(18,116,152).  
Originally it was thought that the central command acts as a pure feed-forward 
control mechanism (18,143). The close relationship of the central command with the 
number of motor units recruited and with the perception of effort suggests an important 
role for feedback from exercising muscles (18,124,153). Brain mapping studies have 
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showed that two regions of the cerebral cortex, the insular cortex and the medial 
prefrontal cortex, may function to interpret feedback signals from active muscles and 
elicit appropriate autonomic adjustments via connections to the vasomotor center (153).  
The muscle chemoreflex is elicited from chemosensitive group III and IV afferent 
fibers in the muscle whenever muscle blood flow falls below the critical level needed to 
maintain adequate oxygen transport to the muscle (148,150,154). Release of hydrogen 
from the working muscles might signal the onset of the reflex, it may actually stimulate 
not chemically sensitive afferents but rather the conversion of monoprotonated 
phosphate to its diprotonated form (143,155). Excitatory action potentials from muscle 
sensory afferents project to the brain via synaptic transmissions in the dorsal root of the 
spinal cord (115,124,154). This exerts effects on the vasomotor center in medulla 
(primarily cVLM and rVLM), which in turn inhibit vagal and/or stimulate sympathetic 
preganglionic neurons, thus producing efferent autonomic nervous system responses to 
the heart and arterial vasculature (115,124,154). The muscle chemoreflex has a distinct 
threshold, and in mild exercise this reflex is not tonically active (18,143,150). As the 
severity of exercise increases to moderate, the margin for any blood flow error 
decreases and the reflex is tonically active (18,143). The baroreflex normally buffers the 
muscle chemoreflex by limiting chemoreflex-induced peripheral vasoconstriction so 
that the rise in arterial BP by the muscle chemoreflex occurs almost solely via an 
increase in cardiac output (i.e. rise in HR) (156).  
Besides chemosensitive fibers, group III and IV afferent fibers in muscle also contain 
mechanosensitive fibers (115,148,154). These fibers are excited by mechanical stimuli 
(stretch and compression) in the active muscle (115,124,154). Their role in control of 
HR is not well understood (121,157), but it has been shown that a passive cycling of the 
legs significantly increased HR above baseline within one second of the onset of limb 
movement (158). In studies utilizing static muscle contraction this fast tachycardic 
response is vagally mediated (159), but evidence also exists for a slower 
sympathetically mediated tachycardiac response induced by mechanosensitive fibers 
(160). Since mechanoreceptor discharge quickly returns toward control levels during 
sustained static contractions, it is unlikely that these afferents contribute importantly to 
the maintained tachycardia in static exercise (157). It is not known, however, whether 
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this waning occurs to the same extent during dynamic contractions as well (18). 
Nevertheless, the muscle-heart reflex is not necessary for the vagally mediated increase 
in HR that occurs at the onset of exercise. This increase has been shown to be evoked 
by attempted exercise in subjects paralyzed with curare-like drugs (i.e. an absent 
afferent input from muscles) (161). 
In addition to responding to chemical and mechanical stimuli, many group III and IV 
sensory afferents are thermosensitive (18,143,155). Muscle temperature, which is 
normally well below 37°C in the limbs, can increase above 40°C during severe exercise 
(18,143). Thus, it is possible that these afferents could be stimulated and provide 
feedback to the central nervous system regarding the thermal status of the active muscle 
fibers (18,143). While this remains a possibility, experimental findings are insufficient 
to determine the role of this mechanism in autonomic nervous system-mediated 
cardiovascular control during exercise (18,124). 
 
2.5.3 Respiratory sinus arrhythmia, arterial chemoreceptors, and pulmonary and 
cardiac receptors 
Respiratory sinus arrhythmia refers to the rhythmic variations HR, occurring at the 
frequency of respiration (21,55,79). Typically HR accelerates during inspiration and 
decelerates during expiration (21,55,79) as a result of complex central and reflex 
intearactions involving both vagal and sympathetic branches of autonomic nervous 
system (162). During exercise respiratory sinus arrhythmia gradually disappears despite 
gradually increasing respiration (163,164).  
Peripheral arterial chemoreceptors are situated in the aortic and carotid bodies 
(21,29,50). They excite nerve fibers that pass through carotid nerves and the vagus 
nerves into the vasomotor center (39,50,74). Activity in their afferent nerves is 
increased by arterial hypoxia, hypercapnia, or acidemia (29,50,165). The primary effect 
of aortic body chemoreceptor stimulation on HR is excitatory (166). Conversely, carotid 
chemoreceptor stimulation causes a pronounced and consistent bradycardia, but with 
intact respiratory control it is normally counterbalanced by tachycardia accompanying 
the respiratory response induced by the same stimulation (29,55,167). Because exercise 
normally is associated with maintenance of PaO2, normal or reduced arterial carbon 
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dioxide, and maintenance of blood pH within acceptable limits, the arterial 
chemoreceptors are not normally activated and therefore likely do not play an important 
role in HR control during conventional dynamic exercise at sea level (20,124). 
The lungs are richly innervated and lung inflation, with moderate pressures, 
stimulates airways stretch receptors which results in a reflex increase in HR (168,169). 
The reflex response during hyperinflation of the lung and also during pulmonary 
congestion is to cause bradycardia (21). Because breathing frequency, tidal volume and 
minute ventilation all increase during exercise, it is possible that reflexes activated by 
lung inflation participate in HR control during exercise. At present, however, there is no 
compelling evidence for it (124).  
Atrial receptors are concentrated near the junctions of the superior and inferior venae 
cavae and the pulmonary veins with the atria (20,21,29). The afferent fibers are 
contained in the vagus and the efferent pathway within the sympathetic nerves 
(21,29,170). Atrial receptors are stimulated mainly by stretching due to increases in 
atrial volume, which results in a reflex increase in HR (20,21,29). Because of the 
relatively slow time-course of sympathetic responses, the tachycardia following to 
stimulation of atrial receptors requires up to 30 seconds to reach a stable level (21).  
Some authors suggest that a larger stimulation of atrial receptors via the increased 
venous return during exercise may be an important mechanism mediating a normal 
exercise-induced tachycardia (69,170,171). On the contrary, other authors conclude that 
the tachycardic reflex mediated by the atrial receptors is weak or nonexistent in humans 
and thus it does not play any role in exercise-induced tachycardia (18). A direct stretch 
of SA node can also increase HR to some extent, and this mechanism may be operative 
in exercise when venous return is increased (39,172). The mechanism might be 
augmented after heart transplantation (29,172), but in the normal heart this mechanism 
is largely masked or overridden by other reflex mechanisms (173). A rise in the 
temperature of the blood reaching SA node as the consequence of muscular work may 
also increase HR via a direct effect on SA nodal tissue (39,172). 
Ventricular mechanoreceptors are situated mainly in the left ventricle. Afferent 
nerves travel either in the vagus or in the sympathetic nerves (170,174). Both 
populations of receptors can be divided into mechanosensitive and chemosensitive 
 39 
 
endings (170,174). Normally their activity does not modulate HR either at rest or during 
exercise, but in the ischemic myocardium their activation results in powerful reflex 
responses (21,78,174). The vagal afferents mediate reflex cardio-inhibitory, sympatho-
inhibitory and vasodepressor responses, while activation of sympathetic afferents results 
in cardio-accelerator, sympatho-excitatory, vasodepressor responses (170,174). Both 
mechanical and chemical stimuli may be involved in activation of receptors, but 
chemical stimuli are more important for triggering of reflexes (21,170,174). The anginal 
pain is mediated by sympathetic afferent fibers and causes tachycardia (21,170,174).  
The vagal afferents are located nearer to the endocardial than to the epicardial 
surface, while the reverse is true for the sympathetic afferents (174). Thus 
subendocardial ischemia stimulates vagal afferents, resulting in bradycardia, whereas 
transmural ischemia more likely induces tachycardia mediated by sympathetic afferents 
(174). Left ventricular vagal afferents are preferentially distributed in the inferoposterior 
wall. In contrast, sympathetic afferents appear to be more uniformly distributed 
throughout the wall of the left ventricle (174). This probably explains why bradycardia 
usually occurs when the circumflex branch is occluded or when ischemia involves the 
inferior and lateral wall of the left ventricle (170,174). Occlusion of the anterior 
descending branch or ischemia involving the anterior wall is likely to result in an 
increase in HR (170,174). The chemical stimuli that activate receptors involve 
substances resulting from myocardial ischemia, including bradykinin, prostaglandins 
and adenosine (170,174). The bulging or dyskinesis of the ischemic zone may stimulate 
mechanosensitive vagal afferents, but the increase in discharge lasts only approximately 
two minutes. In contrast, the increased discharge of chemosensitive vagal afferent 
persists for the duration of the ischemic event (174). 
 
2.6. Heart rate response to exercise: a synthesis 
 
In 1990 Rowell & O’Leary introduced an overall model as to how adjustments of the 
autonomic nervous system to large-muscle dynamic exercise may be mediated (136). 
This hypothesis represents the most compelling integrative scheme attempting to 
explain the primary signals involved and how those signals may interact to produce 
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autonomic nervous system adjustments to exercise (124). The key concept in the model 
is that BP is the primary variable controlled during exercise and control of HR serves as 
an adjunct in this scheme (136,150,175).  
From a resting value up to a rate of 100 beats/min during dynamic upright exercise 
HR increases rapidly primarily due to the activation of vagal withdrawal (51,65,73). 
The activation of vagal withdrawal is mainly due to augmented central command 
(136,150,157). The central command also resets the arterial baroreflex immediately to a 
higher operating point. Normally the baroreflex does not elicit an increase in 
sympathetic nervous system activity, however, because the rise in cardiac output (due to 
fast HR increase) is rapid enough to raise arterial BP to its new operating point 
(136,157,175). If any difference between the prevailing level of BP and a new, higher 
baroreflex operating point is detected by baroreceptors they can raise HR via further 
inhibition of parasympathetic tone (136,150,157). In this setting the muscle chemoreflex 
is not activated. The exact role of the afferents from muscle mechanreceptors is 
unknown, but in all probability their effect is negligible (136,150,157).  
During moderate exercise, when HR exceeds 100 beats/min, the activation of vagal 
withdrawal by central command still increases cardiac output, but not enough 
(136,150,175). The fast vagal component of the rise in cardiac output is not sufficient to 
raise cardiac output to a level that is needed to compensate fully the vasodilation in 
active muscle (136,150,175). Consequently, arterial BP cannot be increased 
immediately to its new, reset operating point so there is a pressure error detected by 
baroreceptors (136,150,175). As a consequence of this error, sympathetic nervous 
system activity to both the heart and to the resistance vessels increase in correct the 
pressure error (136,150,175).  
The sympathetically mediated increase in HR and cardiac output is much slower (by 
15- to 20-fold) than the parasympathetically mediated rise (136,150,175). Thus 
vasoconstriction in resistance vessels all over the body (including active skeletal 
muscle) becomes a necessary adjunct to increased cardiac output to raise arterial BP as 
quickly as possible to minimize the pressor error (136,150,175). As workload increases, 
HR increases due to further sympathetic nervous system activation (20,73,164). The 
increase in sympathetic nervous system activity can occur due to the arterial barofeflex 
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(via further baroreflex resetting), the muscle chemoreflex (after a threshold has been 
passed after which this reflex becomes tonically active), or muscle mechanoreceptor 
activation (20,150,157). 
 Besides direct neural excitation SA node is also stimulated by an increased level of 
circulating adrenaline, which is secreted from the adrenal medulla (23,73,176). 
Adrenaline secretion is increased only during moderate to heavy exercise (typically 
50% of maximal oxygen consumption or above) and sympathoadrenal activation 
becomes progressively greater as exercise intensity increases up to maximum 
(58,176,177). As exercise approaches maximal levels, parasympathetic activity wanes 
and sympathetic nervous system activity increases such that at maximal oxygen 
consumption (VO2max) little parasympathetic tone remains and sympathetic activity is 
greatly elevated (136,157,164). Because during severe exercise HR is at or near 
maximal level, any further pressor response (i.e. to a fall in a baroreceptor activity or 
further muscle afferent activation) can only occur via peripheral vasoconstriction in that 
cardiac output is already at maximal levels (121,136,157). 
Pharmacological blockade studies have proved the differential contributions of the 
two autonomic branches during exercise (178). Blockade of vagal control with atropine 
(muscarinic receptor antagonist) reveals that most of the initial response to exercise, up 
to a HR of approximately 100 beats/min, is attributable to the withdrawal of tonic vagal 
activity (164,179,180). Withdrawal of vagal tone has been confirmed using time and 
frequency domain analyses of HR variability as well (163,164). Conversely, blockade 
of sympathetic control with β-adrenergic receptor antagonist reveals the importance of 
augmented sympathetic activity during moderate and heavy exercise (181-183). During 
light exercise, with workloads of 25% to 40% of VO2max, plasma noradrenaline levels or 
directly measured muscle sympathetic nervous activity do not significantly increase, 
confirming the finding that the sympathetic nervous system is more important in the 
later stages of exercise (136,150,175).  
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2.7 Central circulatory response to exercise 
 
During dynamic upright exercise cardiac output (i.e. stroke volume times HR) increases 
somewhat linearly in proportion to the oxygen consumption (VO2), approximately 6 
l/min of cardiac output per 1 l/min of VO2 (19,171,184). An appropriate increase in HR 
contributes significantly to attaining high levels of cardiac output (23,29,67). Of the two 
major components of cardiac output, HR and stroke volume, HR is responsible for 
approximately two thirds of the total increase in cardiac output during dynamic upright 
exercise (17,185,186). When a normal human exercises maximally in the upright 
position, the HR increase is 150-300% of resting, while the stroke volume increase is 
about 10-100% (29,187,188).  
The stroke volume normally reaches its maximum or almost maximum by the time 
the cardiac output has increased only halfway to its maximum, after which any further 
increase in cardiac output must occur by increasing the HR (19,189,190). Thereafter 
stroke volume levels off (191-193), or there is a small decline (193-195) or increment 
(196-198) at maximal work intensity.  
An increase in HR accompanying dynamic exercise also results in an increase in the 
force of myocardial contraction (i.e. frequency-force relationship, or the staircase 
phenomenon) (20,37,143). The increase in force is secondary to a transient imbalance in 
cellular Ca2+ influx and efflux (favoring influx), an increase in sarcoplasmic reticulum 
Ca2+ content, and a larger sarcoplasmic reticulum Ca2+ release during each excitation-
contraction coupling cycle (18,37,143). Although a sufficient increase of HR is essential 
to raise cardiac output at heavier workloads, the absolute cardiac output which a person 
can attain is determined by the magnitude of maximal stroke volume (68,184,199). 
The relationship between HR and VO2 or work intensity is approximately linear 
(19,200,201). It has been suggested that the HR might increase relatively less than VO2 
as the work rate becomes very heavy (171,202,203), but two studies have shown the 
opposite (204,205). In both studies HR rose slightly more steeply above anaerobic 
threshold (approximately 50-60% of VO2max) than below anaerobic threshold, but the 
HR/work intensity -relationship was linear (205).  
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The linear relationship between HR and VO2 or work intensity is widely employed in 
a number of submaximal exercise tests (200,206-216), in which VO2max is estimated 
based on HR measured in a single or several submaximal workloads (69,217,218). By 
utilizing a linear HR-workload relationship a straight line is fitted to measured HR 
values (69,217,218). This line is extrapolated to the predicted maximal HR; the 
corresponding estimated maximal workload can then be approximated (69,217,218). 
VO2max can then be estimated by using the relationship between work rate and VO2 
(69,217,218). 
 
2.8. Factors modulating heart rate response to exercise 
 
In the same person under standardized conditions, the variation from day to day in HR 
at a given VO2 is 3-5 beats/min depending on the relative workload (%VO2max), 
provided the state of training is the same (219-221). The HR at a given VO2 is related to 
the maximal stroke volume (222,223), but it is not a measure of maximal 
cardiorespiratory fitness, unless the maximal HR is considered (69,224). Despite 
limitation some researchers have, however, considered the workload which a person can 
attain at some predetermined HR as a good estimate of cardiorespiratory fitness (225-
227). There is a tendency for persons with a low resting HR to have a low HR at a fixed 
submaximal workload (14,228,229), but this has not been observed consistently 
(171,230). Concerning maximal HR, persons with a high maximal HR have a higher 
HR at the same relative workload compared with the persons with a low maximal HR 
(230,231). Furthermore, an inverse (229) or non-existent (230) relationship has been 
observed between maximal HR and HR at a fixed submaximal workload, which 
emphasizes a fundamental difference when expressing a submaximal workload in terms 
of either relative or absolute work. 
The physiological limit on maximal HR in normal subject is determined by the 
steepness of the diastolic depolarization slope of SA nodal cells before they reach 
threshold potential, thus generating an action potential that is then propagated to 
surrounding cells (38,39). When HR reaches 195 beats/min in humans during severe 
exercise, ventricular diastolic filling time is only 0.12 seconds compared to 0.55 
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seconds at rest (HR 70 beats/min) (41,143,232). It seems logical that a limit would be 
approached where an increase in HR would not effectively increase cardiac output due 
to decreased diastolic filling; not only would the heart receive less blood to pump, but 
the degree of coronary artery perfusion would decrease (17,20). Although this 
theoretical limitation is reasonable, there is little experimental work to support it 
(17,20,196).  
Age. HR at a given submaximal VO2 (and workload) has been reported to be the 
same for individuals of the same gender and state of training regardless of age 
(14,229,233). On the other hand, HR at a fixed submaximal workload has also been 
suggested to be higher (15,226,234) or lower (228,235,236) in older subjects, but in 
these observations the state of training may differ between individuals.  
The decline of maximal HR with age is a well-known phenomenon (217,237,238). A 
comprehensive review of the literature compiling over 23 000 subjects aged 5 to 81 
years revealed that age alone accounted for 75% of the variability in maximal HR; other 
factors added only about 5% (239). Of mechanisms underlying age-related decrease in 
maximal HR, cardiac chronotropic responsiveness to β-adrenoceptor stimulation has 
been shown to be preserved (240) or reduced (241-243) in the elderly. Subclinical 
atherosclerosis accompanying aging has also been proposed as a mechanism (69). The 
slope of the decay of exercise maximal HR with age is very similar to the slope of the 
intrinsic HR with age, suggesting that the decline of maximal HR is independent of 
autonomic influence, but has more to do with the SA node and the myocardium 
(20,244,245). The age-related decline in maximal HR is steeper in men who have a low 
cardiorespiratory fitness (246) and are physically inactive (17). 
Gender. HR at a given submaximal workload is higher in women (229,247,248). 
Maximal HR does not differ between genders (17,239,249) or is slightly lower 
(229,250,251) in women. Menstrual cycle. In women HR at a fixed submaximal 
workload has been reported to be higher during the mid-luteal phase (252), but most 
studies have reported no change in submaximal (253-255) or maximal HR (255-257) 
during the menstrual cycle. 
Body height and weight. The persons with the heavier body weight have been 
reported to have a lower HR at a fixed submaximal workload (222,236), and the 
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association is more pronounced when lean body weight is considered instead of total 
body weight (258,259). Height and body weight (lean or total) do not affect on maximal 
HR (20,51,222). Obesity. The overweight persons have a higher HR at a fixed 
submaximal workload than normal weight persons. The relationship is valid especially 
when exercising on a treadmill, but also when on a cycle ergometer (251,260,261). In 
two studies, however, there was no relationship between body mass index (BMI) and 
HR at a given submaximal workload on a treadmill (14,262), and in one study (228) an 
inverse relationship was observed between BMI and HR at a given submaximal 
workload on a cycle ergometer. Overweight has not been reported to have an effect on 
maximal HR (20,51,261), except one study in which overweight was associated with 
lower maximal HR (263). 
Mode of exercise. HR is slightly higher at a given submaximal VO2 on a cycle 
ergometer than on a treadmill (264,265). Maximal HR probably does not differ between 
a cycle ergometer and treadmill (266-268), although it has been suggested to be slightly 
lower with cycle ergometer testing (29,239,269). Both HR at a given submaximal 
workload and maximal HR are lower on a cycle ergometer in the supine position 
(29,184,270). Total mass of working muscles. The HR at a given submaximal 
workload is higher when the dynamic exercise is performed with the arms than with the 
legs (171,271,272). The maximal HR with arm exercise is 88-100% of the maximal HR 
in leg exercise (171,273,274). Exercise protocol. Large increments in workload 
combined with a short duration of the step may result in HR not rising to a steady state 
level at that workload (275). Consequently, HR at that submaximal workload is lower 
than the actual HR at the identical work provided that steady state would have been 
achieved (275). The maximal HR is not markedly different between protocols as long as 
the same exercise mode is used (268,276). Pedal frequency. When exercising with 
cycle ergometer, HR at a fixed submaximal workload may be slightly lower with a 
pedal frequency of 40 to 50 revolutions/minute than at clearly higher pedal frequencies 
(277). 
Habituation. Habituation to repeated exercise tests has been found to lead to a 
reduction in HR response to a fixed submaximal workload, but the habituation effect is 
difficult to separate from a training response (278,279). Other studies have, however, 
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shown no appreciable habituation effect (220). True maximal effort. Maximal effort 
should always be confirmed objectively before an attempt is made to measure a 
maximal HR (29). Objective measures of appropriate maximal effort include respiratory 
exchange ratio >1.10 and blood lactate level >7-8 mmol/l (17,20,29). Older individuals 
might be more afraid to achieve true maximal exertion but this effect may disappear on 
repeated testing (20). Even if the true VO2max is achieved in exercise it is still possible 
that maximal HR is even slightly higher than HR measured at the workload 
corresponding to VO2max (280). Sampling interval of HR measurement. The 
difference between measured HR and true HR (determined by the last 30 seconds of 
each minute during exercise) is inversely related to sampling interval (281). The 6-
second rhythm strip at the end of each minute represents a reasonable balance between 
convenience and precision for measuring HR during exercise (281). 
Environment. A hot environment causes a higher HR at a fixed submaximal 
workload than exercise at a low ambient temperature (171,282,283). Also a high 
relative humidity elicits a higher HR at a fixed submaximal workload (70). Maximal 
HR can even reach slightly higher values under hyperthermia than in normothermia 
(18). Again, HR at a given submaximal workload is lower in a cold environment (284) 
and also maximal HR is lower compared with neutral temperature (285). Emotional 
factors, nervousness, excitement and apprehension may raise the HR during exercise of 
light and moderate intensity (69,171,217). The heavier the workload, however, the less 
pronounced is this nervous effect on the HR such that it does not affect maximal HR 
(69). Dehydration. In dehydrated state HR at a given submaximal workload is higher 
than in euhydrated state (171,190,238), whereas acute expansion of blood volume 
decreases HR (286-288). Acute plasma volume expansion does not affect maximal HR 
(289), but in a dehydrated state maximal HR might be slightly higher than in the 
euhydrated state (18).  
Level of fitness. HR at a fixed workload seems to be inversely related to a maximal 
cardiorespiratory performance of a subject (238,290,291), although maximal HR 
modulates this relationship (69). A high cardiorespiratory fitness accelerates the rate of 
attainment of the steady-state HR at submaximal work (275,292). Maximal HR has 
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been reported to be the same (293-295), higher (229,230,296) or lower (239,250,297) in 
subjects with a high cardiorespiratory fitness.  
Training. Within the same subject endurance-typed exercise training reduces HR at a 
given submaximal workload, and reduced physical activity has the opposite effect 
(29,298,299). The rate of attainment of the steady-state HR at submaximal work occurs 
more rapidly after training as well (300). Endurance training does not change the 
maximal HR or slightly reduces it (301-303). Cessation of endurance-type exercise 
training may increase maximal HR (304). HR at a given submaximal workload has been 
reported to be lower (14,251,271) and maximal HR (230) higher, respectively, in 
subjects with a higher level of self-reported physical activity. Bed rest. After prolonged 
bed rest HR at a given submaximal workload is higher than before bed rest 
(190,280,305). The maximal HR is either the same (280) or increased after the bed rest 
(305,306). 
Medications and alcohol. The effects of various medications on HR during exercise 
are summarized in Table 1. After acute ingestion of alcohol, HR at a fixed submaximal 
workload is increased (307) or unaltered (308) but maximal HR is not affected (307).  
Arterial oxygen content. A reduced arterial oxygen content in anemia or after 
hemoglobin blocked by carbon monoxide (as acutely after smoking) results in a higher 
HR at a fixed submaximal workload (171,238,311). Parenthetically, also smokeless 
tobacco increases HR at submaximal work (70,312). The increased blood hemoglobin 
concentration lowers HR at a given submaximal workload (218,313), but does not affect 
on maximal HR (313,314). Long-term smokers seem to have a lower HR at a given 
submaximal workload (262,315,316), but unaltered (14,15,317) and higher (318) HR 
values have also been reported. Long-term smokers have been reported to have a lower 
maximal HR (230,263,315). Thyroid gland function. Hyperthyroid patients may have 
a high HR at a fixed submaximal workload (238,319), whereas hypothyroid patients 
may have the reverse (320). 
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Table 1. Medications affecting heart rate during exercise (20,308,309). 
Medications Effect on heart rate during exercise (↑ = 
increase, ↓ = decrease, ↔ = no effect) 
atropine ↑ 
agents blocking β-adrenergic receptors ↓*† 
nitrates ↑ or ↔ 
calcium channel blockers 
              dihydropyridine agents 
              diltiazem, verapamil  
 
↑ 
↓ or ↔ 
digitalis ↓‡ 
hydralazine, minoxidil ↑ or ↔ 
centrally acting antihypertensives (clonidine,  
methyldopa, moxonidine) 
↔ or ↓ 
 
antiarrhytmic agents 
               quinidine, disopyramide 
               propafenone  
               amiodarone 
 
↑ or ↔ 
↔ or ↓ 
↓ 
bronchodilatators 
               sympathomometic 
               anticholinergic 
               methylxanthines  
 
↑ or ↔ 
↑ or ↔ 
↑ or ↔ 
psychotropic medications 
               antidepressants 
               major tranquilizers  
 
↑ or ↔ 
↑ or ↔ 
cold medications with sympathomimetic agents ↑ or ↔ 
thyroid medications ↑ 
anorexiants / diet pills  ↑ or ↔ 
 
* β-blockers with intrinsic sympathomimetic activity have a reduced effect. 
† The effect increases with a relative intensity of exercise (64,183,310). 
‡ Heart rate decreases in patients with controlled atrial fibrillation and possibly congestive heart 
failure, but heart rate is not significantly altered in patients with sinus rhythm. 
 
 
Circadian rhythm and seasons. HR display a circadian rhythm so that HR at a fixed 
submaximal workload is slightly higher at early afternoon (a peak around 13.30) 
compared with morning or late afternoon (321,322). On maximal HR the effect of 
circadian rhythm is negligible (322). HR at a fixed submaximal workload has been 
shown to be lower in the summer than in other seasons (251). Eating and sleeping 
before the test. HR at a fixed submaximal workload is increased for an hour or more 
after a heavy meal (70,217). An abnormally short sleep the night before exercise may 
raise HR at a fixed submaximal workload (70).   
Genetics. The heritability estimates for HR at workload of 50 Watts (W) in cycle 
ergometer, and walking at submaximal speed on treadmill have been reported as 57% 
(323) and 32% (324), respectively. The workload that a person can attain at a 
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submaximal HR of 150 beats/min is characterized by a significant familial resemblance, 
but the heritability as a percent of the age and gender-adjusted phenotypic variance is 
only <10% (325-327). The genetic effect on maximal HR has been shown to be 
significant in two studies with brothers and twins (328,329), but this has not been a 
consistent finding, however (330). The current view is that the genetic effect for 
maximal HR is about 50% (331). Familial data has indicated that maximal HR may be 
characterized by a maternal effect (332).  
 
2.9. Heart rate response to exercise and prognosis  
 
During the last two decades, novel exercise test-derived HR variables like chronotropic 
incompetence and HR recovery have excited widely as prognostic markers of mortality 
and cardiac events both in asymptomatic persons and in patients with CVD (10-12,23-
26,51,73,122,201,333-340). HR recovery is outside the scope of the present review, and 
therefore only HR variables measured during exercise test are discussed.  
 
2.9.1 Submaximal heart rate and cardiovascular disease events in asymptomatic 
persons 
Seven reports (14,15,227,341-344) from six separate follow-up studies have examined 
the relationship between submaximal HR and future CVD events in asymptomatic 
persons as summarized in Table 2. Six papers measured the HR at a fixed submaximal 
workload (14,15,341-344), and one paper (227) measured the workload which a person 
can attain at a fixed submaximal HR of 150 beats/min as the variable to quantify 
submaximal HR-work rate relationship. In two of the seven reports a high submaximal 
HR was found to be an independent predictor of a future CVD death (14,15). In one of 
the five papers that did not find an association survival analysis was not performed, the 
medications influencing HR were not explicitly reported, and the study sample included 
both healthy men and men with clinical evidence of definite or probable CHD (21.9% 
of the total sample) (341). Additionally, prevalent CHD was not controlled for in the 
analysis (341). Two separate reports from one study (342,343) did not find an 
association either, but in both reports neither survival analysis was performed nor the 
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medications influencing HR were reported. In the fourth paper with a negative finding 
(227), the workload achieved at HR of 150 beats/min did not predict future CHD events 
as such, but after adjustment for body weight it was a strong independent predictor. In 
the fifth report with negative finding all subjects were hypertensive asymptomatic 
persons who were referred for the further investigation of hypertension (344). 
Additionally, from the results of the study by Lauer et al (345), it can be deduced that a 
high HR at a fixed submaximal workload did not predict CHD events, although the 
researchers did not directly examined that particular variable in their data. 
Only one of the seven reports involved also women (344) and the negative finding 
was observed similarly in both genders. The length of the follow-up was addressed in 
one study (15) in which the exercise test was performed twice, enabling the researchers 
to calculate the results with two separate follow-up periods of about 15 and 20 years. 
They showed that the predictive value of HR at a fixed submaximal workload for future 
CHD death improved if a shorter follow-up after the second exercise test was used, even 
though the number of events decreased from 258 to 147 (15). 
In two studies which found a high submaximal HR to be an independent predictor of 
future CVD death (14,15), a high submaximal HR was interpreted as a marker of low 
cardiorespiratory fitness, which was to considered explain the association with CVD 
death. The conjecture that the association is mediated by low cardiorespiratory fitness is 
supported by the facts that HR at a fixed workload is inversely related to the maximal 
cardiorespiratory performance of a subject (238,290,291), and low cardiorespiratory 
fitness is a major risk factor for future CVD event in asymptomatic persons (339,346). 
Indirect support for the association between a high submaximal HR and increased 
risk of future CVD events is found from four follow-up studies (226,347-349). In these 
studies the actual submaximal HR was not reported, but either an age-adjusted value 
was used for analyses, or submaximal HR was utilized for indirect estimation of 
cardiorespiratory fitness (226,347-349). In all four studies (226,347-349), an estimated 
low cardiorespiratory fitness was associated with an increased risk of CVD events. 
Because a low cardiorespiratory fitness estimated from an indirect test is based on a 
high submaximal HR (69,217,218), it is presumable that persons with an increased risk 
of CVD death in all four studies also had a high HR at a fixed submaximal workload.   
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A high HR at a fixed submaximal workload, or a low workload attained at a fixed 
submaximal HR, has been shown to be associated with risk factors for CVD, such as a 
low serum high-density lipoprotein (HDL) cholesterol level (14,226); high serum total 
cholesterol (226,228), low-density lipoprotein (LDL) cholesterol (14) and triglyceride 
level (14); low HDL/total cholesterol ratio (226); low level of self reported physical 
activity (14,251,342); high resting systolic (15,228,236) and diastolic BP (14); 
diagnosed hypertension (350); and overweight (251,260,261) in asymptomatic persons. 
On the other hand, smokers seem to have a lower HR at a given submaximal workload 
than nonsmokers (262,315,316). Also left ventricular hypertrophy assessed from ECG 
has been reported to be related to a lower HR at a given submaximal workload (228).  
Total cholesterol and BP level were controlled for, however, in two studies (14,15) 
which found the association between submaximal HR and the increased risk of CVD 
death. Slattery and Jacobs (15) performed stepwise analysis which revealed that the 
predictive value of the HR at a fixed submaximal workload was attenuated most by 
resting systolic BP, but the association remained statistically significant. Furthermore, 
the associations of submaximal HR with total (351,352) and HDL cholesterol 
(14,262,353) level; overweight (14,228,262); a low level of self reported physical 
activity (228); and smoking (14,15,317) have not been observed consistently.  
 
2.9.2 Submaximal heart rate and cardiovascular disease events in patients with 
known or suspected coronary heart disease 
The relationship between HR at a fixed submaximal workload and mortality as well as 
CVD events in patients with known or suspected CHD has not been investigated in 
previous studies. However, indirect evidence is available from two studies (354,355) in 
which the HR increment from rest to submaximal workload was measured. Falcone et al 
(354) followed 458 men with angiographically verified CHD for six years. They found 
that patients whose HR rose 12 beats/min or more from rest to one minute at a workload 
of 25 W at the beginning of exercise test had 5.8 and 13.5 times higher risk of adverse 
cardiac event and cardiac death, respectively, than patients with a milder HR increment 
(354). Leeper et al (355), however, did not find any association between HR increment 
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from rest to a fixed submaximal workload and all-cause or CVD mortality after 
following 1959 patients (5% women) referred for exercise testing for 5.4 years.  
    Falcone et al (354) reasoned the rapid HR increment resulting from a premature vagal 
withdrawal which in turn might be a marker of sympathetic overactivity or a reduced 
vagal activity, known risk factors for death or cardiac event in CHD patients especially 
after myocardial infarction (356-358). The explanation offered by Falcone et al (354) is 
not supported by the findings from a previous study in which HR increase from rest to 
one minute was lower in 12 CHD or cardiomyopathy patients with depressed baroreflex 
sensitivity (a marker of vagal activity) than in patients with a normal baroreflex 
sensitivity (359). Accordingly, Leeper et al (355) argued that the rapid HR increment at 
the beginning of exercise test reflects a high, rather than low, vagal activity, and they 
further suggested the early acceleration of HR in the study by Falcone et al (354) to be a 
marker of a low cardiorespiratory fitness, a known risk factor for death or cardiac event 
in persons with known or suspected CHD (17,360). 
Some authors have suggested that a high HR at a fixed submaximal HR may result 
from an inadequate stroke volume increase accompanying an impaired left ventricular 
function originating from either myocardial ischemia (361-363) or from left ventricular 
dysfunction not directly related to ischemia (364). According to this view, a high 
submaximal HR is a baroreceptor-mediated compensatory mechanism as an attempt to 
preserve an adequate cardiac output rise during exercise in the face of an impaired left 
ventricular function (319,362). Hence, the association of a high submaximal HR with an 
increased risk of death could be explained by an impaired left ventricular function, a 
known risk factor for death in CHD patients (17). In accordance with this are the 
findings from two previous studies in dogs (365,366). The rise of HR at the early phase 
of an exercise stress was steeper in dogs with a healed myocardial infarction that were 
susceptible to ventricular fibrillation after experimentally induced coronary occlusion 
than in dogs that were resistant to ventricular fibrillation. The susceptibility to 
ventricular fibrillation was associated with a greater degree of left ventricular 
dysfunction which was possibly due to significantly higher proportion of transmural 
infarctions in susceptible dogs (365). 
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2.9.3 Chronotropic incompetence and cardiovascular disease events in 
asymptomatic persons 
Chronotropic incompetence is a term that has been used to describe inadequate HR 
responses to metabolic demand (51,340,367). The simpliest measure of chronotropic 
incompetence is the peak HR attained in an exercise test (9,230,342-344,368-370), but 
maximal HR can be expressed as adjusted for age (315,316,345,368,371-376) or resting 
HR (9,230,345,370,377) or both (376), as summarized in Table 3. Additionally, 
chronotropic incompetence can imply the HR at submaximal workload which is 
unexpectedly low related to an age-adjusted expected maximal HR 
(315,316,345,373,376). 
Seven reports (9,230,345,370,374,375,377) from five separate follow-up studies have 
found chronotropic incompetence to be an independent predictor of future CVD events 
in asymptomatic persons (Table 4). Additionally one report has found the same 
association after adjustment for age and gender (316), and four papers 
(342,343,368,371) from two follow-up studies have found the same association in 
unadjusted models without reporting results from multivariable models (Table 4). On 
the other hand, in one study maximal HR did not predict CVD deaths in multivariable 
models either in men or women (369). In another study maximal HR did not predict 
CVD events in hypertensive asymptomatic men and women (344). 
Chronotropic incomptence did not predict an outcome either in men or in women in 
two (344,369) out of the five studies that included both genders, whereas in two studies 
(371,375) the association was observed in men, but not in women. In the only study 
including exclusively women (374), the risk of CVD death was increased in women 
who did not achieve an age-adjusted target maximal HR. Other subgroup analyses have 
shown that chronotropic incompetence is associated with an increased risk of CVD 
death in men with both low and intermediate or high level of cardiorespiratory fitness 
(230), and in both younger (20-39 yrs) and older (40-59 yrs) men (370). In the study by 
Balady et al (375) chronotropic incompetence predicted CHD events in 144 high risk 
men (according to the Framingham Risk Score), but not in 1276 men with intermediate 
or low risk in age-adjusted model. 
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The length of the follow-up was addressed in two studies (345,375). In the study by 
Lauer et al (345) two of the three chronotropic incompetence variables used in the study 
remained independent predictors of combined fatal or nonfatal CHD event when 
analysis were restricted to men with at least two years of event-free follow-up, whereas 
all three chronotropic incompetence variables were independent predictors when the 
follow-up of 7.7 years was considered as a whole. In the study by Balady et al (375), the 
predictive value of chronotropic incompetence for combined fatal or nonfatal CHD 
event in men remained similar during both the first and the last 10 years of the total 
follow-up of 18.2 years. 
Chronotropic incompetence has been associated with smoking in several studies 
(263,316,370), but smoking was controlled for in the studies which found the 
association between chronotropic incompetence and an increased risk of CVD event 
(9,230,345,370,375,377). Chronotropic incompetence has been shown to predict CVD 
events both in smokers and nonsmokers (230,315,316). In the study by Lauer et al (315) 
a synergistic effect between chronotropic incompetence and smoking was observed for 
the risk of CHD event, whereas in the study by Sandvik et al (230) a synergistic effect 
was not observed. 
Chronotropic incompetence has not been shown to be associated with exercise 
induced ischemic changes in ECG (342,345). Bruce et al (368) observed, however, a 
synergistic effect between chronotropic incompetence and exercise-induced ischemic 
changes in ECG for the risk of combined fatal or nonfatal CHD event. 
Besides smoking, chronotropic incompetence has been shown to be associated with 
risk factors for CVD, such as a low HDL/total cholesterol ratio (345); high total 
cholesterol (230,370) and triglyceride level (230,370); impaired glucose tolerance 
(230); low level of self reported physical activity (230); low cardiorespiratory fitness 
(229,296,370); high resting systolic (343,345,370) and diastolic BP (230,345); 
diagnosed hypertension (345,350,378); increased left ventricular mass (372) and left 
ventricular cavity dilatation (373); carotid atherosclerosis (376); and overweight 
(263,345,370) in asymptomatic persons. Most of the aforementioned CVD risk factors 
were controlled for, however, in the seven studies (9,230,345,370,374,375,377) that 
found an association between chronotropic incompetence and the increased risk of CVD 
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events. Pardaens et al (344) performed stepwise analysis which revealed that a low 
maximal HR predicted CVD events in hypertensive subjects after adjustment for age, 
gender and resting HR. Further adjustment for CVD risk factors did not substantially 
alter the finding, but the prognostic value of maximal HR disappeared entirely after 
additional inclusion of VO2max in the model (344). Furthermore, the associations of 
chronotropic incompetence with total cholesterol levels (342), self-reported physical 
activity (342,345), and systolic BP (342) have not been observed consistently.  
Several mechanisms have been suggested to mediate the association between 
chronotropic incompetence and increased risk of CVD event (Table 5) 
(23,24,26,51,122,171,230,320,338,345,369,377,379,380). A latent CHD has been 
proposed to be a mediating factor (26,171,338). According to this view, abnormal 
myocardial wall motion and accumulation of metabolic by-products caused by ischemia 
irritate ventricular mechano- and chemoreceptors (174) leading to vagal activation and 
consequently attenuation of normal HR increase during exercise (24,26). The imbalance 
between oxygen demand and delivery may worsen further because of increased wall 
stress induced by ventricular dilatation, a condition shown to accompany chronotropic 
incompetence (373). The view is supported by the findings that chronotropic 
incompetence is an independent predictor of the presence of CHD in patients referred 
for exercise testing to diagnose CHD (382-384) and that chronotropic incompetence is 
associated with an advanced carotid atherosclerosis in asymptomatic men (376).  
 
Table 5. The summary of proposed mechanisms explaining the association of chronotropic 
incompetence with an increased risk of cardiovascular disease event. 
latent coronary heart disease (26,171,338) 
atherosclerosis of the artery supplying the sinoatrial node (338,369) 
sinoatrial node dysfunction (171,320,379) 
reduced bioavailability of nitric oxide within the sinoatrial node (26) 
systemic low-grade inflammation (381) 
sinoatrial node β-receptor downregulation due to chronic sympathetic activation (26,230) 
reduced baroreflex sensitivity (359,377)  
abnormal cardiovascular autonomic control (26,51,230) 
 
The relationship between myocardial ischemia, chronotropic incompetence and 
mortality has been directly studied in patients referred for exercise testing, and in these 
studies chronotropic incompetence was associated with ischemic findings assessed by 
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angiography (extent (385)), exercise echocardiography (presence (386) and extent 
(387)) and thallium imaging (presence (388) and extent (389)). Importantly, in each 
study (385-389) chronotropic incompetence was an independent predictor of death in a 
multivariable model that also included myocardial ischemia, suggesting that myocardial 
ischemia does not solely explain the association between chronotropic incompetence 
and mortality in this patient group. More specifically, latent CHD involving an artery 
supplying SA node has been proposed to explain the association between chronotropic 
incompetence and an increased risk of CVD events (338,369). Against this notion is the 
finding that in a group of patients with chronotropic incompetence the artery to the SA 
node was free of significant stenosis in 90% of cases (390).  
Other authors have suggested chronotropic incompetence to be a manifestation of SA 
node dysfunction, and consequently SA node dysfunction to be a link between 
chronotropic incompetence and an increased risk of CVD event (171,320,379). This 
view is supported by the observations that patients with SA node dysfunction, as 
evidenced by typical 12-lead and Holter ECG findings, often have an attenuated HR 
response to exercise (391-393), but this is not a consistent finding (171,379). 
Furthermore, Chin et al (390) did not find SA node dysfunction in 23 patients who had 
chronotropic incompetence in exercise.  
Routledge and Townend (26) have proposed that chronotropic incompetence might 
be caused by reduced bioavailability of nitric oxide within the SA node. Animal 
experiment (394) and study in human heart transplant recipients (395) have shown that 
nitric oxide exerts a tonic chronotropic effect on the SA node probably by causing 
activation of the If current. In persons with CHD, endothelial nitric oxide bioactivity is 
impaired as a result of reduced synthesis and inactivation by reactive oxygen species. 
This may further manifest itself as endothelial dysfunction and perhaps systemic low-
grade inflammation, known risk factors for future CVD events (26,396,397). In subjects 
undergoing investigation for angina, persons with chronotropic incompetence had raised 
markers of systemic low-grade inflammation compared with those having a normal HR 
response (381).  
Alternatively, chronotropic incompetence has been suggested to be a manifestation of 
SA node β-receptor downregulation as a result of chronic sympathetic activation 
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(26,230). This has been shown to be the case in patients with congestive heart failure 
(398), but it is not known whether this mechanism is also operative in asymptomatic 
persons. Routledge and Townend (26) have proposed that a SA node β-receptor 
downregulation in consequence of a chronic sympathetic activation could result from 
metabolic syndrome which may induce chronic sympathetic overactivation, particularly 
if hypertension is present (399). Chronic sympathetic overactivity may induce numerous 
unfavorable changes from the viewpoint of cardiovascular health, including 
hypertension (400-402); insulin resistance (403); a tendency to develop obesity (404); 
development of left ventricular (405) and vascular hypertrophy (406); an increased 
electrical instability of the heart, favoring life-threatening arrhythmias (407); occurrence 
of coronary thrombosis through increased blood viscosity (408), platelet activation 
(409) and development of a procoagulant state (410); and increased mechanical stress 
on the arterial wall via tachycardia (411).  
A reduced baroreflex sensitivity has also been mentioned as a link between between 
chronotropic incompetence and an increased risk of CVD events, and more specifically 
sudden cardiac death due to ventricular fibrillation (377). It has been shown that among 
patients who have had myocardial infarction and have similar left ventricular ejection 
fraction, the inability to sustain episodes of ventricular tachycardia was predicted by 
depressed baroreflex sensitivity (412,413). Impaired baroreflex sensitivity favors 
circulatory collapse during ventricular tachycardia, a condition that precipitates 
ventricular fibrillation and sudden death (377). Jouven et al (377) suggested that a 
reduced ability to increase HR during exercise to the maximum extent could be the 
clinical counterpart of an impaired baroreflex sensitivity. In cardiac patients the 
association between chronotropic incompetence and a reduced baroreflex sensitivity has 
been observed in CHD and cardiomyopathy patients (359) but not in patients with 
congestive heart failure (414).  
Finally, many investigators have supposed chronotropic incompetence to be a marker 
of abnormal cardiovascular autonomic control (26,51,230). This view is supported by 
the observations that the majory of patients with primary autonomic failure have a 
clearly abnormal HR response to exercise (222,415,416) and that in patients with 
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congestive heart failure chronotropic incompetence is related to reduced heart rate 
variability (a marker of depressed vagal activity) (414,417).  
Reduced heart rate variability is a risk factor for future CVD events in asymptomatic 
middle-aged (418) and elderly persons (419,420). The sympathetic nervous system and 
circulating catecholamimes can contribute to all three major mechanisms involved in 
the generation of cardiac arrhytmias (421), enhanced automaticy (40,422,423), triggered 
automaticy (early (424,425) and delayed (426,427) afterdepolarizations), and re-entry 
(428,429), in healthy or diseased myocardium. Quite the contrary, a high vagal activity 
protects from arrhytmias (430,431). Indeed, Freeman et al (51) have stated that HR 
response to exercise may help to identify persons with autonomic imbalance who are 
currently healthy and without CVD, but who are predisposed to to sudden cardiac death 
in the future. Likewise, among patients with CVD and concomitant autonomic 
imbalance, there might be a superimposed increase in the risk of CVD events (51).  
 
2.10 Summary 
 
The HR response to exercise, although simple to assess, reflects a complex, integrated 
physiologic response in which autonomic tone, central and peripheral reflexes, 
hormonal influences and factors intrinsic to the heart are all important (20-22). During 
the last two decades, the exercise test derived HR variables have generated wide interest 
as prognostic markers of mortality and cardiac events both in asymptomatic persons and 
in CVD patients (11,12,23-26,51,73,122,201,333-338,340). The results of the properly 
controlled studies (9,14,15,230,345,370,374,375,377) suggest a possible bimodal 
relationship of HR to prognosis in which both high HR at low workload and 
inappropriately low HR at maximal or near maximal workload (i.e. chronotropic 
incompetence) are associated with adverse prognosis (223). Indeed, in the Lipid 
Research Clinics Mortality Follow-up Study both a high HR at a fixed submaximal 
workload (14) and an inability to increase HR normally when approaching maximal 
wok capacity (316) were associated with an adverse prognosis in two papers from the 
same study sample.  
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A high HR at a fixed submaximal workload has consistently been interpreted as a 
marker of a low cardiorespiratory fitness, and therefore the association with CVD death 
has been explained by this mechanism (14,15,355). Interestingly, however, there are no 
published population-based follow-up studies exploring this hypothesis in which HR at 
a fixed submaximal workload and cardiorespiratory fitness have been entered into the 
same regression model predicting future CVD events. The mechanism mediating the 
association between chronotropic incompetence and an increased risk of CVD event is 
not known, although several possibilities has been presented 
(23,24,26,51,122,171,230,320,338,345,369,377,379,380).  
The hypothetical graph based on the results from previous studies 
(9,14,15,230,345,354,355,365,366,370,374,375,377) is shown in Figure 2. In essence, it 
is the theory proposed by Ramamurthy et al (223) in a graphic form. The hypothesis has 
a physiologically relevant basis, because HR increase from rest to maximal exercise is 
known to consist of two consecutive phases: the early rise up to a rate of 100 beats/min 
is controlled mainly by the parasympathetic nervous system (164,179,180), whereas the 
increase from 100 beats/min to maximum is controlled mainly by the sympathetic 
nervous system (181-183). In the current study the hypothesis presented in Figure 2 is 
further extended by suggesting that the predictive value of a high HR at a submaximal 
workload can be optimized if a submaximal HR response is quantified as a workload 
achieved at HR of 100 beats/minute (WL100). The HR of 100 beats/min is used, because 
it is the upper bound of the first, parasympathetically (164,179,180) controlled phase of 
the total HR rise during exercise and it has been proposed that an exaggerated HR 
response particularly during this phase indicates an adverse prognosis (354,365,366). 
Furthermore, the hypothetical graph in Figure 2 suggests that the predictive value of a 
blunted HR increase at maximal or near maximal workload is optimized if the HR 
increment particularly during the latter half of the exercise test is considered when 
quantifying chronotropic incompetence. The prognostic value of the two aforesaid new 
HR-derived variables, WL100 and the HR increment during the latter half of the exercise 
test, has not been studied formerly.  
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rate 
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Figure 2. The hypothetical heart rate response to incremental exercise in subjects with an increased risk 
of future cardiovascular disease events (dashed line) and in normal subjects (continuous line) based on the 
data from previous studies (9,14,15,230,345,354,355,365,366,370,374,375,377). 
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3. MAIN HYPOTHESIS AND AIMS OF THE STUDY 
 
The main hypothesis of the current thesis is that a bimodal relationship exists between 
HR and prognosis (Figure 2) in which both a low workload achieved at HR of 100 
beats/min (WL100) and a blunted HR increase particularly during the latter half of the 
maximal exercise test are associated with adverse prognosis. Accordingly, the aims of 
the study were:  
 
a) to examine whether a blunted HR increase during the latter half of the maximal 
exercise test better predicts CVD and CHD mortality than resting HR, HR reserve, or 
maximal HR in middle-aged men free of CHD. 
 
b) to investigate the association between WL100 and the risk of CVD death in middle-
aged men free of CHD. 
 
c) to study the association between WL100 and the risk of death in middle-aged men 
with known or suspected CHD and its prognostic value beyond other HR-derived and 
exercise test variables.  
 
d) to explore the association between HR increase from 40% to 100% of maximal work 
capacity in an exercise test (HR40-100) and the risk of acute myocardial infarction in 
middle-aged men without CVD and to compare the predictive value of HR40-100 with 
other variables describing chronotropic incompetence. 
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4. METHODS 
 
4.1 Study population 
 
The subjects were participants of the Kuopio Ischaemic Heart Disease Risk Factor 
Study (KIHD), a collaborative research project between the Kuopio Research Institute 
of Exercise Medicine and the Research Institute of Public Health, the University of 
Kuopio. The KIHD is an ongoing population study designed to investigate risk factors 
for CVD and related outcomes (432). The study involves men from East Finland, an 
area known for its high prevalence and incidence of CVD (432,433). The study protocol 
was approved by the Research Ethics Committee of the University of Kuopio and 
complies with the Declaration of Helsinki. Each participant gave written informed 
consent. The subjects are a representative age-stratified, age-balanced random 
population-based sample of men who lived in the city of Kuopio or neighbouring rural 
communities. Of the 3235 eligible men, 2682 (82.9% of those alive) were recruited in 
two cohorts. The first cohort consisted of 1166 54-year-old men (83.3% of those alive) 
enrolled in the study between March 1984 and August 1986; the second cohort was an 
age-stratified sample of 1516 42-, 48-, 54-, and 60-year-old men (82.6% of those alive) 
enrolled between August 1986 and December 1989. Table 6 describes the four follow-
up studies of the thesis. 
 
4.2 Examination protocol  
 
Examinations at baseline were carried out over two days, one week apart, and consisted 
of a wide variety of biochemical, physiological, anthropometric and psychosocial 
measures (432). Invitations to attend the first study visit and written instructions to 
complete a detailed self-administered questionnaire were mailed four weeks in advance. 
At the first visit, a trained interviewer checked the completed questionnaire and a nurse 
measured body height and weight and blood pressure. The subjects underwent a medical 
examination, during which information about medical history and use of medications 
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obtained from the self-administered questionnaire was checked. At the first visit, a 
maximal, symptom limited cycle ergometer test was performed (434-439).  
 
Table 6. The description of the study population and main variables* 
Study Total 
number 
of 
subjects 
Population Exercise HR-
derived variable 
Follow-
up time 
Main outcomes 
I 1378 without CHD and use 
of β-blockers 
heart rate increase 
at interval 40-
100% of maximal 
workload 
11.4 
years 
37 CHD deaths, 56 
CVD deaths 
II 1314 without CHD and use 
of HR-lowering 
medication 
workload achieved 
at HR of 100 bpm  
11.5 
years 
35 CHD deaths, 51 
CVD deaths 
III 365 known or suspected 
CHD 
workload achieved 
at HR of 100 bpm  
11.1 
years 
75 overall deaths 
IV 1176 without CVD and use 
of HR-lowering 
medication 
HR increase from 
40% to 100% of 
maximal work 
capacity 
11.0 
years 
106 acute myocar-
dial infarctions 
 
* HR, heart rate; CHD, coronary heart disease; CVD, cardiovascular disease; bpm, beats/minute. 
 
At the second visit seven days later blood specimens were taken between 8 and 10 
o’clock in the morning for laboratory determinations. For these blood samples, the 
subjects were instructed to fast and to abstain from smoking for 12 hours, to abstain 
from drinking alcohol for 3 days, and to abstain from using analgesics for 7 days. After 
the subjects had rested in a supine position for 30 minutes, blood was drawn with 
Terumo Venoject vacuum tubes (Tokyo, Japan). No tourniquet was used.  
 
4.3 Exercise testing 
 
HR response, cardiorespiratory fitness, exercise induced myocardial ischemia and BP 
response were assessed using a maximal, symptom limited cycle ergometer exercise test 
on an electrically braked cycle ergometer. For men examined before June 1986, the 
testing protocol comprised of a three-minute warm-up at 50 W followed by a step-by-
step increase in the workload by 20 W per minute (early protocol) (Tunturi EL 400, 
Turku, Finland). The remaining men were tested with a linear increase in the workload 
 72
by 20 W per minute (later protocol) (Medical Fitness Equipment 400L, Mearn, 
Netherlands). For safety reasons and to obtain reliable information, the test was 
supervised by an experienced physician with the assistance of a trained nurse. 
Submaximal effort at peak exercise was defined as respiratory exchange ratio at peak 
exercise below 1.00. It is an objective marker of premature termination of exercise test 
because normally respiratory exchange ratio rises much above 1.00 at peak exercise as a 
consequence of ventilatory compensation for metabolic acidosis (10,17,319). 
 
4.3.1 Assessment of heart rate response to exercise 
HR was recorded from ECG at rest, at the end of each 60-second interval during the 
exercise test, and at peak exercise. HR represents the prevailing value at that time point 
obtained from sample interval of approximately 3 seconds and measured digitally by 
electrocardiograph. Resting HR was expressed as the lowest HR value, whether 
measured in lying position before the test or while sitting on bicycle before the test. 
WL100 was recorded directly at HR of 100 beats/min or interpolated linearly as a 
function of HR by using resting HR and the nearest HR value above 100 beats/min. 
Chronotropic index at HR of 100 beats/min was calculated as ((100 – resting HR) / 
(maximal HR – resting HR)) / (workload at HR 100 beats/min / maximal workload). 
Chronotropic index at HR of 100 beats/min quantitatively expresses how steep the early 
rise of HR from rest to 100 beats/min is in relation to the overall steepness of HR rise 
during the exercise test. A value of roughly 1 means that the steepness of the early HR 
rise from rest to 100 beats/min is about the same as the HR rise from that time point to 
maximum. Correspondingly, a value larger than 1 means that the early HR rise is 
steeper than the HR rise from that time point to maximum. HR at 40, 60, 80, and 100 % 
of maximal workload was interpolated linearly as a function of HR by using the nearest 
HR values below and above the time point respectively. HR increase from rest to 50 W 
as well as HR increase from rest to 33% of maximal workload were calculated as the 
difference between HR at corresponding time point and resting HR (354,355). 
HR40-100 was calculated as maximal HR minus HR at the workload of 40% of 
maximal workload attained. All chronotropic incompetence variables listed in Table 3 
were defined accordingly except chronotropic response index at submaximal work 
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(submaxCRI). When calculating submaxCRI the workload of 100 W as the submaximal 
workload was used. The workload was expressed in Watts instead of METs to simplify 
the equation of submaxCRI, because Watts at rest are explicitly zero. SubmaxCRI was 
calculated according to the hypothetical situation in which the exercise test would have 
been stopped at 85% of age-adjusted expected maximal HR although in reality our 
subjects continued until their symptom-limited maximum. Age-adjusted expected 
maximal HR was calculated as 220 – age.  
 
4.3.2 Assessment of cardiorespiratory fitness, exercise electrocardiography and 
exercise blood pressure 
VO2max and exercise test duration were used as measures of cardiorespiratory fitness. 
Respiratory gas exchange was measured by the mixing chamber method with the use of 
a Mijnhardt Oxycon 4 analyzer (Gebr. Mijnhardt B.V., Netherlands) for men examined 
before June 1986 and by the breath-by-breath method with the use of a MGC 2001 
analyzer (Medical Graphics Corp., St. Paul, Minnesota, USA) for the remaining men. 
VO2max was defined as the highest value for VO2 recorded during a 30-second interval.  
ECG was recorded continuously with the Kone 620 electrocardiograph (Kone, Turku, 
Finland). The Mason-Likar lead system including V1, V5 and aVF lead connections 
was used (440). ECG was printed every 60 seconds intervals during exercise. Exercise 
ECGs were coded manually by one cardiologist. The criteria for ischemia in ECG 
during exercise was horizontal or downsloping ST depression with 0.5 or more mm at 
80 milliseconds after J point in studies I, II and IV, and horizontal or downsloping ST 
depression with 1.0 or more mm in study III, and any ST depression with 1.0 or more 
mm at 80 milliseconds after J point in all studies.  
Blood pressure was measured immediately before the test and every two minutes 
during and after the exercise test using cuff stethoscope method. The maximal systolic 
BP was the highest value achieved during the test. Systolic blood pressure (SBP) 
response was calculated as systolic BP at peak exercise minus systolic BP measured 
immediately before the test. BP was measured during recovery at regular 2 minutes 
intervals while subjects seated on the cycle without pedaling (437). Of these post-
 74
exercise measurements, systolic BP at 2 minutes recovery was selected as the main 
variable because it was available for all men.  
 
4.4 Biochemical analyses   
 
Fasting blood glucose was measured using the glucose dehydrogenase method (Merck, 
Darmstadt, Germany) after proteins had been precipitated with trichloroacetic acid. The 
main lipoprotein fractions (LDL, HDL) were separated from fresh serum samples using 
precipitation and ultracentrifugation (441). The cholesterol contents of lipoprotein 
fractions were measured enzymatically (Boehringer Mannheim, Mannheim, Germany) 
on the day after the ultracentrifugal spin. Blood hemoglobin was determined 
photometrically (Gilford Stasar III, Gilford Instrument Laboratories Inc., Oberlin, Ohio, 
USA) using the cyanmethemoglobin method (442) within a few hours of blood 
sampling.  
 
4.5 Resting blood pressure, body weight and body mass index 
 
Resting BP was measured between 8 and 10 o’clock in the morning by two trained 
nurses, one during 1984 to 1985 and another during 1986 to 1989, with a random-zero 
mercury sphyghomanometer (Hawksley, Lancing, UK). The measurement protocol 
included, after supine rest of five minutes, three measurements in the supine, one in the 
standing and two in the sitting position with five minute intervals. Blood pressure was 
read with an accuracy of two mmHg. The disappearance of sounds (Korotkoff’s fifth 
phase) was recorded as diastolic BP. In the present study the mean of all six 
measurements was used as systolic and diastolic BP. 
Body weight was measured using a balance scale. The subject wore light clothing and 
no shoes. BMI was computed by dividing body weight in kilograms by the square of 
body height in meters. 
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4.6 Smoking and alcohol consumption 
 
The current number of cigarette, cigars, and pipefuls of tobacco smoked daily and the 
duration of regular smoking in years were recorded using a self-administered 
questionnaire. Years smoked were defined as the sum of the years of smoking, 
regardless of when it had started, whether the subject had currently stopped smoking, or 
whether it had occurred continuously or during several periods. The lifelong exposure to 
smoking (“cigarette years”) was estimated as the product of years smoked and the 
number of tobacco products smoked daily at the time of the examination, or for ex-
smokers, at the time when they had smoked last time. Alcohol consumption was 
assessed with a structured quantity-frequency questionnaire using the Nordic Alcohol 
Consumption Inventory on drinking behavior over the previous 12 months. The average 
weekly consumption of alcohol in pure ethanol (g/week) was calculated based on the 
known alcoholic content of each beverage type and the reported doses and frequencies 
of drinking sessions (443). 
 
4.7 Baseline diseases and medications 
 
Medical history and the use of medications were assessed using a self-administered 
questionnaire. A physician reinterviewed the subjects regarding their medical history 
and the use of medications during a medical examination. Known or suspected CHD 
was defined as having either a history of myocardial infarction, angina pectoris on effort 
based on the London School of Hygiene Cardiovascular Questionnaire (444), or the use 
of nitroglycerin for chest pain once a week or more frequently. A prevalent CVD was 
defined as a history of CHD, cardiac insufficiency, cardiomyopathy, arrhytmias, stroke 
or claudication. Diabetes was defined as fasting blood glucose ≥6.7 mmol/l (445) or a 
clinical diagnosis of diabetes with either dietary, oral, or insulin treatment.  
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4.8 Collection and classification of follow-up events 
 
4.8.1 Mortality 
All deaths were ascertained by computer linkage to the Finnish National Death Registry 
using the Finnish social security number. There were no losses to follow-up. All deaths 
that occurred between study enrollment (from March 20, 1984 to December 5, 1989) 
and December 31, 1998 were included. Deaths from CVD and CHD were coded 
according to the Ninth International Classification of Diseases (ICD) codes (390-459 
and 410-414, respectively) (446) or the Tenth ICD codes (I00-I99 and I20-I25, 
respectively) (447).  
 
4.8.2 Acute coronary events 
The collection of data on and the diagnostic classification of nonfatal and fatal coronary 
events by the end of 1992 were performed as part of the multinational WHO MONICA 
(MONItoring of Trends and Determinants in CArdiovascular Disease) project, in which 
detailed information on all coronary events was collected prospectively (448,449). All 
KIHD participants lived at baseline in the province of Kuopio, one of the monitoring 
areas of the Finnish part of the WHO MONICA project (FINMONICA) (450). In the 
FINMONICA study, regional coronary register teams collected data on coronary events 
from hospitals and wards of health centers and classified the events (450,451). The 
sources of information included interviews, hospital documents, death certificates, 
autopsy records, and medico-legal reports. The FINMONICA coronary register data 
were annually cross-checked with data obtained from the computerized national hospital 
discharge and death registers. Data on coronary events from the beginning of 1993 to 
the end of 1998 were obtained by computer linkage to the national hospital discharge 
and death certificate registers. A physician collected and classified the coronary events 
using the same procedures as in the FINMONICA study (450,451).  
The diagnostic classification of coronary events was based on cardiac symptoms, 
ECG findings, cardiac enzyme elevations, autopsy findings, and history of CHD. Each 
suspected coronary event (ICD-9 codes 410-414 and ICD-10 codes I20-I25) was 
classified into 1) a definite acute myocardial infarction (AMI), 2) a probable AMI, 3) a 
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typical acute chest pain episode of more than 20 minutes indicating CHD, 4) an 
ischemic cardiac arrest with successful resuscitation, 5) no acute coronary event or 6) an 
unclassifiable fatal case. In the present study, definite AMIs, probable AMIs and 
prolonged chest pain episodes were used as outcomes. All chest pain episodes lead to 
hospitalization. If a subject had multiple nonfatal coronary events during the follow-up 
period, the first event after baseline was defined as the outcome.  
 
4.9 Statistical methods 
 
Statistical analyses were performed by using SPSS 11.5 for Windows (SPSS, Inc., 
Chicago, Illinois). Descriptive data are presented as mean and standard deviations 
(SDs), or medians and ranges, respectively, for continuous data and percentages for 
categorical data. Differences in baseline characteristics were examined using linear and 
logistic regression analyses after adjustment for age. Because of the skewed 
distribution, the exact Mann-Whitney U-test was used for age, smoking and alcohol 
consumption.  
The association of HR-derived and other exercise test variables with the risk of 
outcomes were analyzed using Cox proportional hazards’ models (452). In the Cox 
model, the hazard is assumed to equal the instantaneous death rate is given by the 
formula: hi(t)=h(t)Ci, where Ci=exp(B1X1i+ B2X2i+…+ BpXpi) (3-5). The model 
assumes that the hazard (h) of death for patient I at time t (h1(t)) equals the hazard of 
death for an “average patient” at the same time (h(t)) multiplied by the factor (Ci) that is 
the function of the prognostic profile of patient I; this is the proportional hazards 
assumption that gives the model its name (3-5). The proportional coefficient for patient 
i (Ci) is, in turn, a function of the values for that patient of a set of prognostic factors 
(X1i,…, Xpi), multiplied by a corresponding set of regression coefficients (B1,…, Bp) 
that measure the strength of the association between the prognostic factor and outcome 
of large number of subjects (3-5). Relative risks (RRs), adjusted for risk factors, were 
estimated as antilogarithms of coefficients from multivariable models. Their confidence 
intervals (CIs) were estimated under the assumption of asymptomatic normality of the 
estimates. The proportional-hazards assumption was verified by inspection of the plots 
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of Schoenfeld residuals for covariates (453). Linearity of associations was assessed with 
the Martingale residuals (454). No violations were observed. To detect the best cut-off 
point for a variable, the dichotomization cut-off point that maximized the log-rank test 
statistics was sought, and the predictive power of this categorized variable was tested by 
using Cox models. In further analyses, the sample was restricted to subjects who 
remained free of events during the first 2 years of follow-up. All tests for statistical 
significance were two-sided. A value of p less than 0.05 was considered statistically 
significant.   
 
4.9.1 Study I 
The analysis of variance (ANOVA) for repeated measures, adjusted for age and the 
length of follow-up, was used to detect whether the slopes of HR increase of men who 
died during follow-up and survivors differed from the beginning of the test or only later 
during the test. In order to eliminate dispersion from compound symmetry assumption 
(equal correlations between measurements) Greenhouse-Geisser corrected degrees of 
freedom were used when testing the effects in ANOVA. The Helmert contrasts, which 
compare HRs at each relative workload with the mean HRs of the next relative 
workloads, were used to locate the phase of the test (rest, 40, 60, 80, and 100 % of 
maximal workload) where the HR slopes of men who died during follow-up and 
survivors started to diverge. The statistically most significant contrast was used to 
construct a new variable. The correlations between the new HR variable and other HR-
derived variables were analyzed using Pearson’s correlation test. The new HR variable 
constructed according to ANOVA for repeated measures was entered into forced Cox 
proportional hazards’ regression models. Two different sets of covariates were used: 1) 
age and examination year, 2) age, examination year, alcohol consumption, BMI, 
cigarette smoking, CVD history, diabetes, serum LDL cholesterol, systolic BP at rest 
and myocardial ischemia during exercise. To compare the additional predictive value of 
HR40-100 and other exercise test variables, a stepwise Cox regression analysis was 
used. After entering the conventional risk factors, the additional predictive value 
brought into the model by HR40-100 and each exercise test variable was compared in 
turns. In supplementary analyses, the sample was restricted to subjects who had none of 
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the following: history of cancer, submaximal effort observed at peak exercise, history of 
CVD, history of chronic obstructive pulmonary disease, bronchial asthma or pulmonary 
tuberculosis, or dizziness, dyspnea, chest pain, arrhythmia, ischemic ECG changes or 
change in BP as a cause of discontinuation of a test. 
 
4.9.2 Study II 
A multiple stepwise linear regression analysis including resting HR, chronotropic index 
at HR of 100 beats/min, maximal HR, and VO2max was used to investigate the 
determinants of WL100. Cox proportional hazards’ regression models were fitted to 
compute the relative risk of death associated with a low WL100, expressed as a 
continuous or dichotomous variable. Age, examination year, and exercise test protocol 
were forced into the Cox models, and rest of the variables were chosen by backward 
stepwise selection (p-value >0.1 for removal) from conventional risk factors, including 
alcohol consumption, BMI, cigarette smoking, CVD history, diabetes, myocardial 
ischemia during the exercise test, serum LDL and HDL cholesterol, and systolic and 
diastolic BP at rest. The additional predictive value brought by WL100 beyond other HR-
derived and exercise test variables was explored by entering WL100 into a Cox model 
that included age, examination year, exercise test protocol, conventional risk factors 
chosen by stepwise selection, and the HR and exercise test variables in turns.  
The difference in WL100 between two different testing protocols was tested using 
linear regression analysis after adjustment for age. To address specifically the effect of 
two different exercise test protocols the stepwise selection was performed separately in 
corresponding subgroups. In supplementary analyses, the sample was restricted to 
subjects who had none of the following: history of cancer, history of CVD, history of 
chronic obstructive pulmonary disease, bronchial asthma or pulmonary tuberculosis, or 
dizziness, dyspnea, chest pain, arrhythmia, ischemic ECG changes or change in BP as a 
cause of discontinuation of a test. 
 
4.9.3 Study III 
Difference in WL100 between men who used HR-lowering medication and those who 
did not was tested with independent samples t-test. A multiple stepwise linear 
 80
regression analysis was used to investigate determinants of WL100. Cox proportional 
hazards’ regression models were fitted to compute the relative risk of death associated 
with a low WL100, expressed as a continuous or dichotomous variable. Age, 
examination year, exercise test protocol, and use of HR-lowering medication (beta-
blockers, digoxin, clonidine) were forced into the Cox models, and rest of the variables 
were chosen by backward stepwise selection (p-value >0.1 for removal) from 
conventional risk factors, including alcohol consumption, BMI, cigarette smoking, 
cardiac insufficiency, history of myocardial infarction, diabetes, myocardial ischemia 
during the exercise test, serum LDL and HDL cholesterol, and systolic and diastolic BP 
at rest. The additional predictive value brought by WL100 beyond other HR-derived and 
exercise test variables was explored by entering WL100 into a Cox model that included 
age, examination year, testing protocol, use of HR-lowering medication, conventional 
risk factors chosen by stepwise selection, and the HR and exercise test variables in 
turns. Because the use of HR-lowering medication affects WL100, the association of 
WL100 with mortality was examined separately in men who did not use HR-lowering 
medication and in men who used such medication. 
Difference in WL100 between two different testing protocols was tested using linear 
regression analysis after adjustment for age and use of HR-lowering medication. To 
address specifically the effect of two different exercise test protocols the stepwise 
selection was performed separately in corresponding subgroups. In supplementary 
analyses, the sample was restricted to subjects who had none of the following: history of 
cancer, history of cardiomyopathy, stroke or claudication, history of chronic obstructive 
pulmonary disease, bronchial asthma or pulmonary tuberculosis, or dizziness, dyspnea, 
chest pain, symptoms of cardiac insufficiency, arrhythmia, ischemic ECG changes or 
change in BP as a cause of discontinuation of a test. 
 
4.9.4 Study IV 
The difference in HR40-100 between men whose test was terminated because of reason 
potentially caused by latent CVD (dizziness, dyspnea, chest pain, arrhythmia, ischemic 
ECG changes or change in BP) or because of submaximal effort and other men was 
tested with the independent samples t-test. The Pearson correlation coefficients between 
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chronotropic incompetence variables were calculated. Cox proportional hazards’ 
regression models were fitted to compute the relative risk of AMI associated with a low 
HR40-100, expressed as a continuous or dichotomous variable. Two different sets of 
covariates were used: 1) age and examination year; and 2) age, examination year, 
alcohol consumption, BMI, cigarette smoking, diabetes, VO2max, myocardial ischemia 
during exercise test, serum LDL and HDL cholesterol, systolic and diastolic BP at rest, 
SBP response, and SBP at 2 minutes after peak exercise. Age and examination year 
were forced into the model, and backward stepwise selection, with a p-value of >0.10 
for removal, was used for the rest of the variables. In separate supplementary analyses, 
we excluded the subjects who died because of CHD within the next year after 
experiencing AMI, and men whose test was terminated because of reason potentially 
caused by a latent CVD or because of submaximal effort. Comparisons among 
chronotropic incompetence variables was addressed in a separate Cox model in which 
first stepwise selection was performed among the rest of the variables, and then forward 
stepwise selection was performed among chronotropic incompetence variables, with a 
p-value of <0.05 for entry. To study the joint effect of HR40-100 and SBP response to 
exercise, men with HR40-100 in the lowest quartile of HR40-100 and SBP response in 
the two highest quintiles of SBP response were compared with men who had a normal 
HR40-100 and SBP response. The cut-off point for SBP response was based on the 
results from a previous study in the same study population (439). 
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5. RESULTS 
 
5.1 Baseline characteristics 
 
The most important demographic and biochemical characteristics of all 1679 men 
according to baseline health status are presented in Table 7. The median age of the 
subjects was 52.4 (range 42.0-61.3) years. Among 1314 men with no CHD, 190 men 
with CVD were older, smoked less, had a higher diastolic BP, were more likely to have 
bronchial asthma, and were more likely to use antihypertensive medication (other than 
HR-lowering agents) or nitrates than 1124 men with no CVD after adjustment for age. 
Almost two thirds of self-reported CVDs were arrhytmias.  
In 365 men with known or suspected CHD, 90 (24.7%) men reported a history of 
myocardial infarction, 226 (61.9%) men angina pectoris diagnosed by a doctor, 284 
(77.8%) men angina pectoris on effort based on the London School of Hygiene 
Cardiovascular Questionnaire (444), and 61 (16.7%) men the use of nitroglycerine for 
chest pain at least once a week. Of these 365 men, 34.2% used HR-lowering 
medications and 14.0% reported symptoms of cardiac insufficiency. The men with 
known or suspected CHD were older, had a higher BMI, smoked more, had a lower 
HDL cholesterol concentration, and were more likely to have a history of stroke, cardiac 
insufficiency, cardiomyopathy, claudication, arrhytmias, or diabetes compared with 
1314 men with no CHD after adjustment for age. Additionally, the 365 men were more 
likely to use antihypertensive medication, nitrates, or calcium channel blockers. The use 
of lipid lowering medication or ACE-inhibitors was not very common at the time of 
baseline examination. 
 
5.2 Exercise test findings 
 
Among 1314 men with no CHD history, 190 men with CVD were had a lower VO2max, 
were more likely not to achieve 85% of age-adjusted expected chronotropic response at 
maximal workload, and were more likely to have the exercise test discontinued because 
of arrhytmias than 1124 men with no CVD after adjustment for age (Table 8). The 190  
 83
Table 7. Baseline characteristics of the men who had complete data on heart rate response 
to exercise test according to baseline health status  
Characteristics Mean (SD), median (range) or proportion 
 No CHD or 
CVD history 
(n=1124)‡ 
No CHD 
history but 
CVD history 
positive 
(n=190)‡ 
p-value for 
difference¶ 
Known or 
suspected 
CHD 
(n=365)‡ 
p-value for the 
difference# 
Number of 
CVD/CHD/all-cause 
deaths‡ 
36/25/110 15/10/23 0.01/0.04/ 
0.68 
37/30/75 <0.001/<0.001/ 
<0.001 
Number of AMIs* 102 22 0.51 85 <0.001 
Age, years 52 (42-61) 53 (42-61) 0.001 54 (42-61) <0.001 
Body mass index, 
kg/m2 
26.5 (3.3) 26.7 (3.5) 0.38 27.3 (3.7) <0.001 
Cigarette smoking, 
cigarette-years|| 
0 (0-2880) 0 (0-1400) 0.04 0 (0-2000) 0.008 
Alcohol consumption, 
g/week 
0 (0-889) 0 (0-728) 0.94 27 (0-2307) 0.44 
Serum HDL 
cholesterol, mmol/l 
1.33 (0.30) 1.30 (0.26) 0.17 1.26 (0.33) <0.001 
Serum LDL 
cholesterol, mmol/l 
3.98 (0.96) 4.00 (1.03) 0.88 4.05 (1.05) 0.60 
Diastolic blood 
pressure at rest, 
mmHg 
88.0 (10.0) 89.9 (10.4) 0.02 87.5 (10.1) 0.34 
Systolic blood 
pressure at rest, 
mmHg 
132.2 (15.1) 135.0 (16.8) 0.06 132.9 (17.6) 0.76 
Resting heart rate, 
beats/min 
68.0 (10.0) 68.3 (10.8) 0.67 66.9 (10.6) 0.08 
Blood hemoglobin, g/l 146.9 (8.8) 147.0 (9.8) 0.71 147.2 (9.5) 0.22 
      
Self-reported diagnoses or symptoms 
      
History of myocardial 
infarction, % 
0.0 0.0  24.7  
History of stroke, % 0.0 7.9  3.3 0.003 
Cardiac insuffi-
ciency, % 
0.0 13.2  14.0 <0.001 
Cardiomyopathy, % 0.0 7.5  3.6 0.004 
Claudication, % 0.0 9.5  7.9 <0.001 
Arrhytmias, %† 0.0 61.9  28.8 <0.001 
Chronic obstructive 
pulmonary disease, % 
5.7 7.9 0.34 8.8 0.13 
Bronchial asthma, % 2.3 5.8 0.02 5.5 0.06 
Pulmonary 
tuberculosis, % 
3.3 2.1 0.29 5.2 0.23 
Cancer, % 1.7 1.1 0.39 1.9 0.99 
Diabetes, %§ 3.5 4.7 0.49 7.1 0.02 
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Table 7. Continued 
Regular use of medications 
      
Antihypertensive 
medication, % 
2.4 7.9 0.001 38.1 <0.001 
β-blockers, % 0.0 0.0  32.3  
Nitrates, % 0.4 2.1 0.03 21.4 <0.001 
ACE-inhibitors, % 0.3 1.1 0.16 0.3 0.86 
Calcium channel 
blockers, % 
0.7 0.0  4.4 <0.001 
Clonidine, % 0.0 0.0  0.3  
Digoxin, % 0.0 0.0  6.6  
Medication for 
hypercholestero-
lemia, % 
   1.6  
 
* AMI, acute myocardial infarction. 
† Arrhytmias included extrasystolia, regular or paroxysmalatrial fibrillation and supraventricular 
tachycardia. 
‡ CVD, cardiovascular disease; CHD, coronary heart disease. 
|| Cigarette-years denotes the lifelong exposure to smoking which was estimated as the product of 
years smoked and the number of cigarettes smoked daily at the time of examination. 
§ Diabetes was defined as fasting glucose ≥6.7 mmol/l or use of medication for diabetes.  
¶ Difference between men with no coronary heart disease or cardiovascular disease history and men 
with no coronary heart disease history but positive cardiovascular disease history. Difference in 
age, smoking and alcohol consumption was tested with exact Mann-Whitney U-test. Differences in 
number of deaths and acute myocardial infarctions, self-reported diagnoses or symptoms, and 
regular use of medications were tested with logistic regression analysis and differences in rest of 
the variables with linear regression analysis after adjustment for age. 
# Difference between men with no coronary heart disease history and men with known or suspected 
coronary heart disease. Differences between groups were tested as explained in previous footnote.  
 
men were also more likely to have myocardial ischemia during exercise test, but their 
test was not discontinued more often because of ischemic ECG changes. Among 1314 
men with no CHD, HR40-100 and WL100 were not different between men with CVD 
and those without it.  
365 men with known or suspected CHD had a lower VO2max, maximal workload, SBP 
response and SBP at 2 minutes after peak exercise, and were more likely to have 
submaximal effort at peak exercise than 1314 men with no CHD after adjustment for 
age and use of HR-lowering medication. Men with known or suspected CHD were more 
likely to have chronotropic incompetence and have the exercise test discontinued 
because of dyspnea, chest pain or ischemic ECG changes. WL100 was not different 
between men with CHD and those without it. 
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Table 8. Characteristics of exercise testing in the men who had complete data on heart 
rate response to exercise test according to baseline health status  
Characteristics Mean (SD) or proportion 
 No CHD or 
CVD 
history 
(n=1124)|| 
No CHD 
history but 
CVD history 
positive 
(n=190)|| 
p-value for 
difference§ 
Known or 
suspected 
CHD 
(n=365)|| 
p-value for 
difference¶ 
Workload at heart rate of 
100 beats/min, Watts 
63 (31) 64 (33) 0.85 69 (34) 0.12 
Chronotropic index at 
heart rate of 100 
beats/min* 
1.13 (0.28) 1.12 (0.27) 0.59 1.12 (0.27) 0.98 
Heart rate increase from 
rest to 50 Watts, beats/min 
29 (9) 28 (10) 0.85 28 (10) 0.76 
Maximal oxygen 
consumption, ml/kg/min 
[METs] ‡‡ 
33.5 (7.4) 
[9.6 (2.1)] 
31.6 (6.7) 
[9.0 (1.9)] 
0.03 26.8 (7.0) 
[7.7 (2.0)] 
<0.001 
Maximal workload, Watts 211 (45) 203 (47) 0.53 168 (43) <0.001 
HR increase from 40% to 
100% of maximal work 
capacity, beats/min 
55 (13) 53 (15) 0.23 43 (15) <0.001 
Maximal heart rate as a 
proportion of age-adjusted 
expected maximal heart 
rate 
0.97 (0.09) 0.96 (0.11) 0.19 0.86 (0.13) <0.001 
Men unable to attain 90% 
of age-adjusted expected 
maximal heart rate, % 
19.5 25.8 0.05 57.5 <0.001 
Heart rate reserve, 
beats/min†† 
95 (19) 91 (21) 0.17 75 (22) <0.001 
Maximal heart rate, 
beats/min 
163 (16) 159 (19) 0.20 142 (22) <0.001 
SubmaxCRI at workload 
of 100 Watts# 
0.98 (0.13) 0.96 (0.14) 0.14 0.89 (18) 0.002 
MaxCRI** 0.95 (0.15) 0.92 (0.18) 0.16 0.77 (0.21) <0.001 
Men unable to attain 85% 
of age-adjusted expected 
chronotropic response at 
maximal workload, % 
24.1 29.5 0.11 61.5 <0.001 
Systolic blood pressure 
response, mmHg || || 
64 (23) 61 (24) 0.15 47 (24) <0.001 
Systolic blood pressure at 
2 minutes after peak 
exercise, mmHg 
184 (27) 187 (29) 0.56 181 (27) 0.03 
Myocardial ischemia 
during exercise test, 0.5 
mm, %† 
13.0 19.5 0.03 83.7 <0.001 
Myocardial ischemia 
during exercise test, 1.0 
mm, %‡ 
6.5 6.1 0.86 11.5 0.001 
Respiratory exchange 
ratio at peak exercise 
below 1.00, % 
4.1 6.3 0.27 12.3 <0.001 
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Table 8. Continued      
Cause  of discontinuation  of exercise test 
      
Dizziness, % 0.6 0.0  1.1 0.67 
Dyspnea, % 2.7 2.1 0.51 8.2 0.001 
Chest pain, % 0.3 0.0  8.5 <0.001 
Symptoms of cardiac 
insufficiency, % 
0.0 0.0  0.3  
Arrhytmia, % 2.1 5.3 0.04 2.7 0.84 
Ischemic changes in 
electrocardiogram, % 
0.2 1.1 0.10 4.7 <0.001 
Change in blood  
pressure, % 
2.0 2.6 0.69 1.9 0.50 
 
* ((100 – resting heart rate) / (maximal heart rate – resting heart rate)) / (workload at heart rate of 
100 beats/min / maximal workload). 
† The criteria for myocardial ischemia in electrogram during exercise was horizontal or downsloping 
ST depression with 0.5 or more mm at 80 milliseconds after J point or any ST depression of more 
than 1.0 mm at 80 milliseconds after J point. 
‡        The criteria for myocardial ischemia in electrogram during exercise was any ST depression of more 
than 1.0 mm at 80 milliseconds after J point. 
|| CVD, cardiovascular disease; CHD, coronary heart disease.  
§ Difference between men with no coronary heart disease or cardiovascular disease history and men 
with no coronary heart disease history but positive cardiovascular disease history. Differences in 
continuous and dichotomized variables were tested with linear and logistic regression analysis, 
respectively, after adjustment for age.  
¶ Difference between men with no coronary heart disease history and men with known or suspected 
coronary heart disease Differences in continuous and dichotomized variables were tested with 
linear and logistic regression analysis, respectively, after adjustment for age and use of heart rate-
lowering medication. 
# ((Heart rate recorded at workload of 100 Watts – resting heart rate) / (age-adjusted expected 
maximal heart rate – resting heart rate)) / ((100 Watts – 0 Watts) / (Watts at maximal work – 0 
Watts)). 
** (Heart rate recorded at maximal work – resting heart rate) / (age-adjusted expected maximal heart 
rate – resting heart rate). 
†† Maximal heart rate minus resting heart rate. 
‡‡ MET denotes metabolic equivalent (1 MET equals 3.5 ml/kg/min oxygen consumption). 
|| || Systolic blood pressure at peak exercise minus systolic blood pressure measured immediately 
before the test.  
 
 
5.3 Heart rate increase from 40% to 100% of maximal work capacity and 
mortality in men without coronary heart disease (Study I) 
 
In ANOVA for repeated measures, the slope of HR increase was steeper in survivors as 
compared with those who died during follow-up due to CVD (F=12.9; df=1.757; 
p<0.001 for interaction effect adjusting for age and length of follow-up). By using 
Helmert contrasts, the difference in the steepness of HR slope between the groups was 
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the strongest at interval 40-100 % (F=19.6, p<0.001) as shown in Figure 3. Based on 
these results, a new variable called HR40-100 was constructed as maximal HR minus 
HR at the workload of 40% of maximal workload attained. The average (SD) HR40-100 
was 54 (13) beats/min in the whole study sample. HR40-100 correlated negatively with 
resting HR (r=-.33, p<0.001) and positively with HR reserve (r=.79, p<0.001) and 
maximal HR (r=.66, p<0.001).  
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Figure 3. Heart rate (mean ± standard deviation) as a function of relative intensity (% of maximal 
workload reached in exercise test) in men who died during follow-up due to cardiovascular disease (n=56, 
dashed line) and survivors (n=1322, continuous line). 
 
When adjusted for age and examination year, CVD mortality increased by 82% (95 % 
CI 39%-138%, p<0.001), CHD mortality by 127% (61%-213%, p<0.001), and all-cause 
mortality by 59% (35%-85%, p<0.001) for a 1-SD (13 beats/min) decrement in HR40-
100. To investigate independent associations of HR40-100, it was entered 
simultaneously with age, examination year and known risk factors for CVD death into 
Cox models. CVD mortality increased by 35% (95% CI 1%-79%, p=0.04), CHD 
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mortality by 69% (19%-144%, p=0.004), and all-cause mortality by 33% (11%-59%, 
p=0.002) for a 1-SD (13 beats/min) decrement in HR40-100 (Table 9).  
 
Table 9. Risk factors for cardiovascular disease, coronary heart disease, and all-cause 
death in 1378 men with no history of coronary heart disease at baseline* 
Risk factor Death due to 
cardiovascular disease 
Death due to coronary 
heart disease 
All-cause death 
 Relative risk 
(95 % CI) 
p-value Relative risk 
(95 % CI) 
p-value Relative risk 
(95 % CI) 
p-value 
Age, for each 
increment of 1 year 
1.08 
(1.02-1.16) 
0.02 1.04 
(0.97-1.12) 
0.31 1.08 
(1.04-1.13) 
<0.001 
Alcohol consumption  
≥ 91 g/week, highest 
fourth vs. others 
1.14 
(0.62-2.09) 
0.68 0.97 
(0.45-2.09) 
0.94 1.52 
(1.06-2.19) 
0.02 
Body mass index, for 
each increment of 3.4 
kg/m2 
1.20 
(0.93-1.54) 
0.16 1.19 
(0.88-1.60) 
0.26 1.07 
(0.91-1.26) 
0.42 
Cardiovascular disease 
history, yes vs. no 
1.81 
(0.98-3.34) 
0.06 1.66 
(0.77-3.57) 
0.20 1.02 
(0.66-1.58) 
0.93 
Cigarette smoking, for 
each increment of 301 
cigarette-years 
1.43 
(1.19-1.72) 
<0.001 1.41 
(1.11-1.78) 
0.004 1.43 
(1.29-1.60) 
<0.001 
Diabetes, yes vs. no 1.29 
(0.48-3.47) 
0.62 1.14 
(0.33-4.00) 
0.84 1.25 
(0.64-2.45) 
0.52 
Myocardial ischemia 
during exercise, yes vs. 
no 
2.35 
(1.32-4.19) 
0.004 3.32 
(1.68-6.59) 
0.001 1.25 
(0.83-1.90) 
0.29 
Serum LDL 
cholesterol, for each 
increment of 0.97 
mmol/l 
1.16 
(0.89-1.51) 
0.28 1.26 
(0.92-1.72) 
0.15 1.01 
(0.86-1.18) 
0.92 
Systolic blood pressure 
at rest, for each 
increment of 16 mmHg 
1.36 
(1.09-1.70) 
0.008 1.19 
(0.89-1.58) 
0.24 1.28 
(1.11-1.49) 
0.001 
HR increase from 40% 
to 100% of maximal 
work capacity, for 
each decrement of 13 
bpm 
1.35 
(1.01-1.79) 
0.04 1.69 
(1.19-2.44) 
0.004 1.33 
(1.11-1.59) 
0.002 
 
* From Cox regression model adjusted for age, examination year and all variables shown in a 
table. Except for age, alcohol consumption, cardiovascular disease history, diabetes and 
myocardial ischemia, the relative risks were calculated for a change of 1 standard deviation, as 
shown. CI, confidence interval; LDL, low-density lipoprotein; HR, heart rate; bpm, beats/min. 
 
To address specifically the late events, the analyses were restricted to 1367 subjects 
who had at least two years of event-free follow up. These analyses included 52 CVD 
deaths, 35 CHD deaths, and 135 all-cause deaths. The risk of CVD, CHD and all-cause 
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death increased by 33% (95% CI -1%-79%, p=0.06), 59% (10%-127%, p=0.01), and 
28% (8%-54%, p=0.007) for a 1-SD (13 beats/min) decrement in HR40-100, 
respectively. 
The best cut-off point of HR40-100 for predicting CVD mortality was 43 beats/min, 
and 272 (20%) subjects had low HR40-100 (<43 beats/min). Altogether 28 (50% of 
total) CVD deaths and 23 (62%) CHD deaths were observed among men with a low 
HR40-100. When HR40-100 was entered as a dichotomous variable into a Cox model, 
the strongest predictor of CVD death was smoking (p<0.001) followed by a low HR40-
100 (RR 2.4, 95% CI 1.4-4.2, p=0.002), myocardial ischemia during exercise (p=0.007), 
high systolic BP at rest (p=0.007), high age (p=0.01), and CVD history (p=0.05). The 
strongest predictor of CHD death was a low HR40-100 (RR 4.3, 95% CI 2.1-8.7, 
p<0.001), followed by myocardial ischemia during exercise (p=0.001), and smoking 
(p=0.002). 
The associations of HR40-100 with mortality were compared also with those of 
VO2max, resting HR, maximal HR, HR reserve and systolic blood pressure response. All 
variables were considered as continuous variables, and relative risks were calculated for 
1 SD increment. When HR40-100 and each of the other exercise test variables were 
entered into the fully adjusted model using the forward stepwise method, HR40-100 
remained in the model for CVD and CHD mortality, whereas other exercise test 
variables did not. In the corresponding model for all-cause mortality, both VO2max and 
HR40-100 were included in the model, but VO2max was a stronger predictor (p=0.008) 
than HR40-100 (p=0.05).   
Finally, 463 men who had cancer (n=29), submaximal effort at peak exercise (n=61), 
CVD (n=203), chronic obstructive pulmonary disease, bronchial asthma or pulmonary 
tuberculosis (n=157), or dizziness, dyspnea, chest pain, arrhythmia, ischemic ECG 
changes or change in BP as a cause for discontinuation of the test (n=118) were 
excluded. When adjusted for age, examination year, and known risk factors, CVD 
mortality increased by 33% (95% CI -7%-89%, p=0.11), CHD mortality by 61% (8%-
144%, p=0.02), and all-cause mortality by 15% (-5%-39%, p=0.14) with a 10 beats/min 
decrement in HR40-100. After exclusions, the study sample included 137 (15%) men 
who had a low HR40-100 (<43 beats/min). When expressed as dichotomized variable, a 
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low HR40-100 was an independent predictor of CVD (RR 2.9, 95% CI 1.2-6.9, p=0.01), 
CHD (RR 4.4, 1.6-12.2, p=0.005) and all-cause death (RR 2.0, 1.2-3.2, p=0.007). 
 
5.4 Workload at heart rate of 100 beats/min during exercise test and mortality in 
men without coronary heart disease (Study II) 
 
The mean (SD) WL100 was 63 (31) W. Resting HR explained 39%, chronotropic index 
at HR of 100 beats/min 21%, VO2max 5%, maximal HR 5%, and all these variables 
together 70% of the variance in WL100. Heart rate vs. workload for those who died 
during follow-up due to CVD and survivors is shown in Figure 4. CVD mortality 
increased by 72% (95% CI 27%-138%, p=0.001), CHD mortality by 96% (32%-186%, 
p=0.001), and all-cause mortality by 23% (2%-47%, p=0.03) with a decrement of 31 W 
(1 SD) in WL100 after adjustment for age, examination year, and exercise test protocol. 
After further adjustment for conventional risk factors, CVD mortality increased by 72% 
(95% CI 27%-138%, p=0.001) and CHD mortality by 89% (28%-178%, p=0.001) with 
a decrement of 31 W in WL100, but no association was found between WL100 and all-
cause mortality (Table 10). Entering the whole set of covariates into the model 
weakened the independent predictive value of WL100 for CVD (p=0.006) and CHD 
death (p=0.001) marginally. To address specifically the late events, the analyses were 
restricted to 1303 subjects who had at least two years of event-free follow-up. The 
analyses included 47 CVD deaths and 33 CHD deaths. The risk of CVD and CHD death 
increased by 67% (95% CI 20%-133%, p=0.002) and 96% (32%-194%, p=0.001) for a 
1-SD (31 W) decrement in WL100, respectively. 
The best WL100 cut-off point for predicting CVD mortality was 50 W, and 497 
(37.8%) men had WL100 <50 W. Altogether 32 (63% of total) CVD deaths and 24 (69%) 
CHD deaths were observed among men with WL100 <50 W. When WL100 was entered 
as a dichotomous variable with conventional risk factors into a backward stepwise Cox 
model, the strongest predictors of CVD death were smoking (p<0.001), WL100 <50 W 
(RR 3.2, 95% CI 1.8-5.8, p<0.001), myocardial ischemia during exercise test (p<0.001), 
a high BMI (p=0.001), a high age (p=0.001), and CVD history (p=0.008). The strongest 
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Table 10. The relative risk for cardiovascular disease, coronary heart disease, and all-
cause death in 1314 men with no history of coronary heart disease at baseline* 
Risk factor Death due to cardio-
vascular disease 
Death due to coronary 
heart disease 
All-cause death 
 Relative risk  
(95% CI) 
p-value Relative risk  
(95% CI) 
p-value Relative risk  
(95% CI) 
p-value 
Age, for increment 
of 1 year 
1.12  
(1.05-1.20) 
0.001 1.09  
(1.01-1.19) 
0.03 1.10  
(1.06-1.15) 
<0.001 
Alcohol 
consumption ≥91 
g/week, highest 
fourth vs. others 
    1.64  
(1.13-2.39) 
0.009 
Body mass index, 
for increment of 3.5 
kg/m2 
1.48  
(1.18-1.87) 
0.001 1.44  
(1.10-1.90) 
0.009 1.20  
(1.01-1.43) 
0.04 
Cardiovascular 
disease history, yes 
vs. no 
2.31  
(1.24-4.28) 
0.008 2.19  
(1.03-4.68) 
0.04   
Cigarette smoking, 
for increment of 299 
cigarette-years 
1.44  
(1.22-1.70) 
<0.001 1.43  
(1.15-1.76) 
0.001 1.45  
(1.30-1.61) 
<0.001 
Myocardial 
ischemia during 
exercise test, yes vs. 
no 
3.13  
(1.75-5.59) 
<0.001 4.29  
(2.17-8.49) 
<0.001   
Serum HDL 
cholesterol, for 
decrement of 0.29 
mmol/l 
    1.22  
(1.01-1.47) 
0.04 
Systolic blood 
pressure at rest, for 
increment of 15 
mmHg 
    1.32 
 (1.14-1.53) 
<0.001 
Workload at heart 
rate of 100 
beats/min, for 
decrement of 31 
Watts 
1.72  
(1.27-2.38) 
0.001 1.89  
(1.28-2.78) 
0.001   
 
* From Cox regression models adjusted for age, examination year, alcohol consumption, body mass 
index, cigarette smoking, cardiovascular disease history, diabetes, myocardial ischemia during 
exercise test, serum low-density and high-density lipoprotein cholesterol, systolic and diastolic 
blood pressure at rest, and exercise test protocol. The relative risks are shown only for variables 
included in the final model after a backward stepwise selection. Except for age, alcohol 
consumption, cardiovascular disease history, diabetes, and myocardial ischemia during exercise 
test, the relative risks were calculated for a change of 1 standard deviation, as shown. CI, 
confidence interval; HDL, high-density lipoprotein. 
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Figure 4. Heart rate (mean) as a function of workload in men who died during follow-up due to 
cardiovascular disease (n=51, dashed line) and survivors (n=1263, continuous line). Workload achieved 
at heart rate of 100 beats/min is indicated with vertical lines for each group. Standard deviations are not 
shown because the number of subjects in both groups gradually decreased along with increasing 
workload.  
 
predictors of CHD death were myocardial ischemia during exercise test (p<0.001), 
smoking (p<0.001), WL100 <50 W (RR 3.9, 95% CI 1.9-8.2, p<0.001), a high BMI 
(p=0.01), a high age (p=0.03), and CVD history (p=0.05). The Kaplan-Meier curves for 
cumulative incidence of CVD and CHD deaths between men with WL100 <50 W and 
men with WL100 ≥50 W continued to diverge with extended time of follow-up, as shown 
in Figure 5. 
 
5.4.1 Workload at heart rate of 100 beats/min, other heart rate-derived and 
exercise test variables, and mortality 
In a Cox model that included age, examination year, exercise test protocol, conventional 
risk factors chosen by stepwise selection, and the HR-derived and exercise test variables 
in turns, a 28-unit (1 SD) increment in the chronotropic index at HR of 100 beats/min   
 93
1614121086420
0,15
0,10
0,05
00,00
C
um
ul
at
iv
e
in
ci
de
nc
e
of
 C
V
D
 d
ea
th
s
Years of follow-up
WL100 <50 W
WL100 ≥50 W
 
C
um
ul
at
iv
e
in
ci
de
nc
e
of
 C
H
D
 d
ea
th
s
Years of follow-up
1614121086420
0,10
0,05
00,00
WL100 ≥50 W
WL100 <50 W
 
Figure 5. Kaplan-Meier curves for cumulative incidence of CVD (upper graph) and CHD (lower graph) 
deaths in men men with WL100 <50 W and men with WL100 ≥50 W. 
 
was associated with a 43% (95% CI 9%-88%, p=0.01) increase in CVD mortality and a 
65% (19%-128%, p=0.003) increase in CHD mortality; an increment of 10 beats/min (1 
SD) in resting HR was associated with a 39% (0%-92%, p=0.05) increase in CHD 
mortality; a decrement of 7.3 ml/kg/min (1 SD) in VO2max (about 2.1 metabolic 
equivalents) was associated with a 59% (0%-150%, p=0.05) increase in CHD mortality; 
and a decrement of 46 W (1 SD) in maximal workload was associated with a 52% (0%-
133%, p=0.05) increase in CHD mortality. WL100 improved the predictive value of all 
models, except the model predicting CVD mortality that included chronotropic index at 
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HR of 100 beats/min. Whereas the predictive value of WL100 was consistent across the 
models shown, no other HR-derived or exercise test variable remained a significant 
predictor of CVD and CHD death in models that included WL100.  
 
5.4.2 Workload at heart rate of 100 beats/min and mortality: further adjustments 
When a low blood hemoglobin concentration (<135 g/l) was entered into the model, the 
predictive value of WL100 for CVD and CHD death remained unchanged. The mean 
(SD) WL100 was 65 (29) W and 62 (32) W in men tested according to early and later 
testing protocol, respectively (p=0.30 for difference after adjustment for age). To 
address the effect of a testing protocol, the survival analysis was conducted separately 
for subjects performing the two different protocols. In 528 men tested according early 
protocol, WL100 as a continuous variable remained in the final model after stepwise 
selection for both CVD (p=0.04) and CHD (p=0.02) mortality. Among the 786 men 
tested according to the later protocol, WL100 also remained in the final model for both 
CVD (p=0.02) and CHD mortality (p=0.03). Finally, 400 men who had cancer (n=21), 
CVD (n=190), chronic obstructive pulmonary disease, bronchial asthma or pulmonary 
tuberculosis (n=149), or dizziness, dyspnea, chest pain, arrhythmia, ischemic ECG 
changes or change in BP as a cause of discontinuation of a test (n=109) were excluded. 
After stepwise selection CVD mortality increased by 59% (95% CI 4%-144%, p=0.03), 
and CHD mortality by 100% (25%-223%, p=0.004) with a 30 W decrement in WL100.  
 
5.5 Workload at heart rate of 100 beats/min during exercise test and mortality in 
men with coronary heart disease (Study III) 
 
The mean (SD) WL100 was 69 W (34 W). Resting HR explained 38%, chronotropic 
index at a HR of 100 beats/min 18%, maximal HR 11%, VO2max 5%, and all these 
variables together 72% of the variance in WL100 in a multiple stepwise regression 
analysis. 
The risk of death increased by 56% (95% CI 20%-100%, p=0.001) for a 1-SD (34 W) 
decrement in WL100 when adjusted for age, examination year, testing protocol, and use 
of HR-lowering medication. After further adjustment for conventional risk factors, the 
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risk of death increased by 72% (95% CI 32%-122%, p<0.001) for a 1-SD (34 W) 
decrement in WL100 (Table 11). Finally, entering the whole set of covariates did not 
affect WL100 as an independent predictor of death (p<0.001). WL100 was also predictive 
of CVD and CHD death. After adjustment for conventional risk factors, the risk of CVD 
death increased by 59% (95% CI 11%-127%, p=0.01), and the risk of CHD death 
increased by 56% (4%-138%, p=0.03) for a 1-SD (34 W) decrement in WL100. In men 
who had at least 2 years of event-free follow-up from baseline, the risk of death 
increased by 69% (95% CI 28%-127%, p<0.001) for a 1-SD (34 W) decrement in 
WL100 after adjustment for other risk factors.  
 
Table 11. Risk factors for death in 365 men with known or suspected coronary heart 
disease at baseline*  
Risk factor Relative risk 
(95% CI) 
p-value 
Age, for increment of 1 year 1.08 (1.01-1.15) 0.02 
Cardiac insufficiency, yes vs. no 2.42 (1.36-4.32) 0.003 
History of myocardial infarction, yes vs. no 2.21 (1.32-3.71) 0.003 
Workload at heart rate of 100 beats/min, for decrement of 
34 Watts 
1.72 (1.32-2.22) <0.001 
 
* From Cox regression adjusted for age, examination year, alcohol consumption, body mass index, 
cigarette smoking, cardiac insufficiency, diabetes, history of myocardial infarction, myocardial 
ischemia during exercise test, serum low-density and high-density lipoprotein cholesterol, systolic 
and diastolic blood pressure at rest, testing protocol, and use of heart rate-lowering medication. 
The relative risks are shown only to the variables which were included in the final model of a 
backward stepwise selection. Except for age, cardiac insufficiency, and history of myocardial 
infarction, the relative risks were calculated for a change of 1 standard deviation, as shown. CI, 
confidence interval. 
 
The best cut-off point for predicting mortality was 55 W, and 130 (35.6%) of all 365 
men had WL100 <55 W. Altogether 38 (51% of total) deaths were observed among men 
with WL100 <55 W. When WL100 was entered as a dichotomous variable into the 
backward stepwise Cox model including other risk factors, the strongest predictor of 
death was WL100 <55 W (RR 2.4, 95% CI 1.5-4.0, p<0.001), followed by a self-reported 
cardiac insufficiency (p=0.004), a history of myocardial infarction (p=0.006), a low 
diastolic BP at rest (p=0.03), and high age (p=0.04).  
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5.5.1 Workload at heart rate of 100 beats/min, other heart rate-derived and 
exercise test variables, and mortality 
In a Cox model that included age, examination year, testing protocol, use of HR-
lowering medication, conventional risk factors chosen by stepwise selection, and the 
HR-derived and exercise test variables in turns, the risk of death increased by 32% 
(95% CI 5%-66%, p=0.02) with 11 beats/min (1 SD) increment in resting HR; by 47% 
(10%-100%, p=0.01) with 7.0 ml/kg/min (1 SD) decrement in VO2max; and by 35% 
(3%-75%, p=0.03) with 43 W (1 SD) decrement in maximal workload. Entering WL100 
into these models improved the predictive value of the model statistically significantly 
in each case (Table 12). The predictive value of WL100 remained stable in various 
models. Of other HR-derived and exercise test variables, only VO2max remained a 
statistically significant predictor of death in the models including WL100. In that model, 
mortality increased by 35% (95% CI 1%-82%, p=0.05) with a 7.0 ml/kg/min decrement 
in VO2max, and WL100 was also an independent predictor (p=0.002). 
 
Table 12. Workload at heart rate of 100 beats/min and mortality after adjustment for 
heart rate -derived and exercise test variables in 365 men with known or suspected 
coronary heart disease at baseline* 
Heart rate –derived or exercise test variable 
entered into adjusted model before WL100  
Improvement of the 
model after entering 
WL100 into the 
model 
Relative risk (95% CI) of 
death per each decrement 
of 1 SD in WL100 
Resting heart rate 0.006 1.56 (1.12-2.17) 
Heart rate increase from rest to 50 Watts  0.001 1.59 (1.20-2.13) 
Heart rate increase from rest to 33% of maximal 
workload  
<0.001 1.61 (1.23-2.08) 
Maximal heart rate  <0.001 1.72 (1.32-2.27) 
Maximal oxygen consumption 0.001 1.52 (1.18-1.96) 
Chronotropic index at heart rate of 100 beats/min  0.001 1.64 (1.20-2.17) 
Heart rate reserve  <0.001 1.59 (1.23-2.04) 
Maximal workload  0.002 1.52 (1.16-2.00) 
 
* Adjusted for risk factors chosen after stepwise selection before the variables in the left column and 
workload at heart rate of 100 beats/min were entered into the model in turns. WL100, workload at 
heart rate of 100 beats/min; CI, confidence interval; SD standard deviation.   
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5.5.2 Workload at heart rate of 100 beats/min, the use of heart rate-lowering 
medication, and mortality 
The mean (SD) WL100 was 61 W (29 W) in 240 men not using HR-lowering medication 
and 86 Watts (36 W) in 125 men using the medication (p<0.001 for difference between 
groups). WL100 was chosen after stepwise selection among conventional risk factors to 
final models predicting mortality in both subgroups. In men not using HR-lowering 
medication, the strongest predictor of death was a history of myocardial infarction 
(p=0.001), followed by WL100 and age (p=0.01). The risk of death increased by 54% 
(95% CI 14%-108%, p=0.005) for a 1-SD (29 W) decrement in WL100. In men using 
HR-lowering medication, the strongest predictor of death was self-reported cardiac 
insufficiency (p=0.004), followed by WL100 and diastolic BP at rest (p=0.04). The risk 
of death increased by 72% (95% CI 14%-163%, p=0.01) for a 1-SD (36 W) decrement 
in WL100. There was no interaction between WL100 and the use of HR-lowering 
medication (p=0.94).  
 
5.5.3 Workload at heart rate of 100 beats/min and mortality: further adjustments 
When a low blood hemoglobin concentration (<135 g/l) was entered into the model the 
predictive value of WL100 for death remained unchanged. The mean (SD) WL100 was 69 
(31) W and 70 (36) W in men tested according to the early and later testing protocol, 
respectively (p=0.36 for difference after adjustment for age and use of HR-lowering 
medication). To address the effect of a testing protocol the survival analysis was 
conducted separately for subjects performing the two different protocols. In 169 men 
tested according to early protocol WL100 as a continuous variable remained in the final 
model after stepwise selection (p=0.04).  Among the 196 men tested according to later 
protocol WL100 also remained in the final model (p=0.001). Finally, 176 men who had 
cancer (n=7), cardiomyopathy, claudication, or a history of stroke (n=53), chronic 
obstructive pulmonary disease, bronchial asthma or pulmonary tuberculosis (n=61), or 
dizziness, dyspnea, chest pain, symptoms of cardiac insufficiency, arrhythmia, ischemic 
ECG changes or change in BP as a cause of discontinuation of the test (n=100) were 
excluded. After stepwise selection mortality increased by 89% (95% CI 28%-178%, 
p=0.001) with a 30 W decrement in WL100 among the remaining men.  
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5.6. Heart rate increase from 40% to 100% of maximal work capacity and the risk 
of acute myocardial infarction in men without cardiovascular disease (Study IV) 
 
The mean (SD) HR40-100 was 55 (13) beats/min. The correlation coefficients between 
all continuous chronotropic incompetence variables varied between 0.60 and 0.99, but 
the correlation coefficients between submaxCRI and other variables describing 
chronotropic incompetence were between -0.05 and 0.30. 
The risk of AMI increased by 45% (95% CI 20%-75%, p<0.001) for a 1-SD (13 
beats/min) decrement in HR40-100 when adjusted for age and examination year. After 
further adjustment for conventional risk factors, the risk of AMI increased by 33% 
(95% CI 9%-64%, p=0.006) for a 1-SD (13 beats/min) decrement in HR40-100 (Table 
13). Entering the whole set of covariates into the model weakened the independent 
predictive value of HR40-100 for AMI slightly (p=0.03). The increase in HR from rest 
to 40% of maximal work capacity did not remain in the final model after stepwise 
selection. To address specifically later events, the analyses were restricted to 1153 
subjects who had at least 2 years of event-free follow up. These analyses included 91 
AMIs, and the risk of AMI increased by 37% (95% CI 9%-72%, p=0.008) for a 1-SD 
(13 beats/min) decrement in HR40-100. 
Twenty of the 106 men who had an AMI during the follow-up died because of CHD 
within the next year after experiencing AMI. After excluding these 20 men from 
analyses, HR40-100 was still an independent predictor of AMI after stepwise selection: 
the risk of AMI increased by 33% (95% CI 5%-67%, p=0.02) for a 1-SD (13 beats/min) 
decrement in HR40-100.  
Altogether 140 men had either a respiratory exchange ratio at peak exercise <1.00 as 
an objective marker of premature termination of the test (n=50) or stopped the exercise 
test because of a reason (dizziness, dyspnea, chest pain, arrhythmia, ischemic ECG 
changes or change in BP) that could be interpreted to indicate latent CVD (n=99). 
HR40-100 was lower in these men compared with other men (45 beats/min vs. 56 
beats/min, p<0.001). After exclusion of 99 men with termination of the test because of 
suspicious symptoms or findings, HR40-100 remained a statistically significant 
predictor of AMI after stepwise selection: the risk of AMI increased 23% (95% CI 3%-
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49%, p=0.03) with a 10 beats/min decrement in HR40-100. Further exclusion of 41 men 
with a respiratory exchange ratio at peak exercise <1.00 weakened the predictive value 
of HR40-100 only marginally: the risk of AMI increased 22% (95% CI 1%-49%, 
p=0.04) with a 10 beats/min decrement in HR40-100.  
 
Table 13. The risk of acute myocardial infarction in 1176 men without cardiovascular 
disease or the use of heart rate -lowering medication at baseline* 
Risk factor Relative risk 
(95 % CI) 
p-value 
Cigarette smoking, for increment of 306 cigarette-years 1.33  
(1.15-1.54) 
<0.001 
Diabetes, yes vs. no 2.71  
(1.42-5.18) 
0.003 
Myocardial ischemia during exercise, yes vs. no 1.76  
(1.10-2.82) 
0.02 
Serum LDL cholesterol, for increment of 0.96 mmol/l 1.33  
(1.10-1.60) 
0.003 
Systolic blood pressure response, for increment of 24 mmHg 1.25  
(1.02-1.53) 
0.03 
Systolic blood pressure at 2 minutes after peak exercise, for increment of 
27 mmHg 
1.26  
(1.03-1.54) 
0.02 
HR increase from 40% to 100% of maximal work capacity, for decrement 
of 13 bpm 
1.33  
(1.09-1.64) 
0.006 
 
* From Cox regression adjusted for age, examination year, alcohol consumption, body mass index, 
cigarette smoking,, diabetes, maximal oxygen consumption, myocardial ischemia during exercise 
test, serum low-density and high-density lipoprotein cholesterol, systolic and diastolic blood 
pressure at rest, systolic blood pressure reserve, and systolic blood pressure at 2 minutes after 
peak exercise. The relative risks are shown only to the variables which were statistically 
significant predictors of acute myocardial infarction in the final model after a backward stepwise 
selection. Except for age, alcohol consumption, diabetes, and myocardial ischemia during 
exercise test, the relative risks were calculated for a change of 1 standard deviation, as shown. 
CI, confidence interval; LDL, low-density lipoprotein; HR, heart rate; bpm, beats/minute. 
 
5.6.1 Heart rate increase from 40% to 100% of maximal work capacity, other 
chronotropic incompetence variables, and the risk of acute myocardial infarction  
When HR40-100 was replaced by other chronotropic incompetence variables in separate 
stepwise selections all other chronotropic incompetence variables were chosen into the 
final models among statistically significant predictors except HR reserve, chronotropic 
response index at maximal work (maxCRI) as a dichotomous variable, and submaxCRI 
both as a continuous and dichotomous variable. The risk of AMI increased by 25% 
(95% CI 5%-49%, p=0.01) with 1 SD (0.09) decrement in maximal HR as a proportion 
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of age-adjusted expected maximal HR; by 30% (6%-59%, p=0.01) with a 1-SD (17 
beats/min) decrement in maximal HR; and by 27% (5%-52%, p=0.01) with a 1-SD 
(0.16) decrement in maxCRI. The risk of AMI was 1.8-fold (95% CI 1.2-2.8, p=0.005) 
in 228 (19.4%) men who were unable to reach 90% of age-adjusted expected maximal 
HR as compared with men who could reach the target value. The comparison among the 
variables describing chronotropic incompetence was performed by exploring how much 
additional information they bring to an optimal model constructed without them. After 
stepwise selection among the rest of the variables, only HR40-100 improved the 
constructed model both as a continuous and as a dichotomous (the lowest quartile vs. 
others) variable (p=0.05 and p=0.03 for improvement of the model, respectively).  
 
5.6.2 Heart rate increase from 40% to 100% of maximal work capacity, systolic 
blood pressure response and the risk of acute myocardial infarction 
Both HR40-100 and SBP response remaind in the model as independent predictors of 
AMI after stepwise selection (Table 13). The subjects were classified according to 
HR40-100 and SBP response so that 296 men with HR40-100 <46 beats/min (the lowest 
quartile) were categorized as having a low HR40-100, and 473 men with SBP response 
>67 mmHg (two highest quintiles) were categorized as having a heightened SBP 
response, respectively. After stepwise selection, men with a low HR40-100 had a 1.6-
fold (95% CI 1.0-2.5, p=0.03) higher risk of AMI than other men. In a separate stepwise 
selection, men with a heightened SBP response had a 1.7-fold (95% CI 1.1-2.6, p=0.01) 
higher risk of AMI than other men. After adjusting for age, examination year, cigarette 
smoking, diabetes, myocardial ischemia during exercise test, serum LDL cholesterol, 
and SBP at 2 minutes after peak exercise, 89 men with a low HR40-100 and a 
heightened SBP response had a 3.1-fold (95% CI 1.7-5.7, p<0.001) higher risk of AMI 
than the reference group consisting of men with both variables normal (Table 14). The 
interaction between HR40-100 and SBP response was not statistically significant 
(p=0.55) in an unadjusted model. 
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Table 14. The risk for acute myocardial infarction in 1176 men without cardiovascular 
disease or the use of heart rate -lowering medication at baseline according to heart rate 
increase from 40% to 100% of maximal work capacity and systolic blood pressure 
response* 
Group Number of acute myocardial 
infarctions/subjects 
Relative risk  
(95 % CI) 
Normal HR40-100, normal SBP response  28/496 1.00  
(reference group) 
Normal HR40-100, heightened SBP response 30/384 1.56  
(0.91-2.68) 
Low HR40-100, normal SBP response 29/207 1.73  
(1.01-2.96) 
Low HR40-100, heightened SBP response 19/89 3.07  
(1.66-5.66) 
 
* From Cox regression adjusted for age, examination year, cigarette smoking,, diabetes, myocardial 
ischemia during exercise test, serum low-density lipoprotein cholesterol, and systolic blood 
pressure at 2 minutes after peak exercise. CI, confidence interval; HR40-100, heart rate increase 
from 40% to 100% of maximal work capacity; SBP, systolic blood pressure. 
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6. DISCUSSION 
 
6.1 Methodological aspects 
 
6.1.1 Study design 
The prevention of diseases can only be achieved when factors that predict disease 
outcomes are identified and prevented or treated (455). Conduction of randomized 
controlled trials is the best way to determine if a variable causally contributes to an 
outcome, but for practical and ethical reasons, it is usually impossible to hold biological 
factors constant in human research (455). Additionally, several risk factors for a given 
outcome interact so that a particular variable may predict an outcome when considered 
univariately, but in reality the association may be through other variables (17).  
    Therefore, multivariable statistical models called survival analysis are used to assess 
possible causal factors for an outcome, permitting estimation of the unique effects of a 
particular variable on the outcome while statistically holding other variables constant 
(3,17,455). Such models help identify risk factors for an outcome, allow to formulate 
risk stratification tools, and often may suggest pathophysiological mechanisms (455). 
However, causation can never be definitively discerned from observational data sets, 
regardless of the statistical tools used, including testing for independence (455). The 
most common technique for multivariable survival analysis is the Cox proportional 
hazards model (3-5), which was also used in the present study. Seven 
(9,14,15,230,316,344,345,369,370,374,375,377) of 11 previous studies  exploring the 
association between HR at exercise test and CVD events in asymptomatic subjects 
(Tables 2 and 4) reported the result from multivariable models.     
The accepted way to analyze relationships between multiple risk factors and an 
outcome is, if possible, to include all relevant risk factors in the statistical model to 
determine the adjusted effect of each risk factor on the outcome (455). If, after 
adjustment, a risk factor maintains a statistically significant association with the 
outcome, it is called an independent risk factor for the outcome (455). However, no 
study will ever properly model all cardiovascular risk factors to assert that a particular 
variable is truly an independent risk factor for a given CVD outcome (455). For any 
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variable described as an independent risk factor for a given CVD outcome, residual 
counfounding may remain, ie. potential predictors also associated with a variable of 
main interest have been excluded, poorly measured or not measured at all, or incorrectly 
modeled (455). Hence, terms such as independent risk factor or independent predictor 
have meanings only in the context of a particular statistical model (455). Importantly, in 
the current study a large number of established and potential risk factors were measured 
at baseline. Consequently it was possible to evaluate their impact on the associations of 
WL100 and HR40-100 with outcomes thoroughly. However, the possibility of residual 
confounding due to some unmeasured factors can not be excluded. 
The length of follow-up may influence the results via opposing mechanisms. The 
short follow-up may weaken the associations if only a relatively small number of 
outcome events occur during the follow-up. A limited number of outcome events 
inevitably weakens the power of a study to find out whether the given difference in 
outcome is statistically significant. On the other hand, false positive findings can be 
made due to small number of outcome events. A long follow-up may weaken the 
associations if the values of variables measured at baseline change considerably during 
the follow-up although the statistical power increases along with the increasing number 
of outcome events (226). Because it is not known whether WL100 or HR40-100 changed 
during the follow-up of the present study, it is impossible to evaluate the relative effects 
of the aforesaid mechanisms. Nonetheless, the question can be addressed indirectly by 
recalculating the results according to a hypothetical situation where the follow-up would 
have been only eight years instead of true 11 years. The recalculation shows that the 
prognostic values of HR40-100 and WL100 are clearly attenuated with a follow-up 
shorter than eight years (data not shown). It can therefore be speculated that the 
prognostic values of WL100 and HR40-100 would have been even larger if the follow-up 
time had been extended longer than 11 years.    
Censoring refers to the removal of intervened subject from observation when the 
intervention occurs during follow-up because the intervention changes the natural 
course of a disease of a subject (3-5). In observational studies for cardiac events the 
interventions leading to censoring are coronary artery by-pass surgery and percutaneous 
transluminal coronary angioplasty with or without stenting (3-5). In the current study, 
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subjects who underwent coronary artery by-pass surgery or percutaneous transluminal 
coronary angioplasty during the follow-up were not censored at the time of intervention 
because we did not have a possibility to monitor those events during the long follow-up. 
However, in none of the 13 previous studies in asymptomatic subjects and patients with 
known or suspected CHD was such censoring performed either.  
Collinearity means that at least one of the covariates can be predicted well from the 
other covariates in the model (456). In the present study, collinearity was tried to 
minimize by utilizing a backward stepwise selection method in Cox models (studies II-
IV). This method effectively limits a number of variables so that only one of two highly 
correlated covariates is left in the final model, provided its predictive value is high 
enough. However, the main results of studies II-IV remained very much unchanged 
when all covariates were entered simultaneously into the model instead of stepwise 
selection method. In study I, the results were reported after entering all variables 
simultaneously into the model. Nonetheless, when the main analysis were repeated in 
study I with backward stepwise selection, HR40-100 remained as a statistically 
significant predictor in the final models predicting CVD, CHD and all-cause death (data 
not shown).      
 
6.1.2 Study population  
A strength of the current study is that subjects are a representative population-based 
sample of middle-aged men from eastern Finland, an area known for its high prevalence 
and incidence of CVD (432,433). Second, the participation rate was high, and there 
were no losses to follow-up. The representative sample of men makes it possible to 
generalize the observed results to male populations of European background. One 
limitation of the present study is that only men were enrolled. The extent to which age, 
gender, ethnic population, underlying diseases, and regular physical activity possibly 
modify the observed findings deserves further study.  
The baseline characteristics of the previous studies exploring the association between 
HR during the exercise test and CVD events in asymptomatic subjects and in subjects of 
the current study are gathered in Tables 2, 4 and 7. The age of the subjects in the present 
study is on the upper end of the range reported in previous studies. It is impossible to 
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evaluate the exact CVD or CHD death rates in all previous studies, but crude estimates 
can be calculated in studies which reported CVD or CHD death as an outcome and the 
average or median length of the follow-up: the number of outcome events divided by 
the number of subjects divided by the the length of the follow-up. According to this 
equation, in all three previous studies which reported CHD death as an outcome, the 
event rate was higher than in the present study. The lower CHD mortality rate in the 
present study as compared with three previous studies might be due to a considerably 
longer follow-up in two studies (9,15), the inclusion of men with a clinical evidence of 
definite or probable CHD in one study (341), and the intitiation of earlier studies in the 
1970s, when the incidence of CHD was higher. 
Because of the limited number of CVD deaths during the follow-up, men with a 
history of CVD (involving cardiac insufficiency, cardiomyopathy, arrhytmias, stroke or 
claudication) were included in studies I and II. This may potentially lead to selection 
bias, which means that the study sample includes individuals with symptomatic or 
asymptomatic CVD who perform poorly in the exercise test and have an increased risk 
of future CVD events during follow-up (457). The potential selection bias was taken 
into account by including a history of CVD as a covariate in the Cox models (studies I 
and II). Furthermore, when the main analyses were repeated after excluding men with 
CVD or other diseases or conditions potentially affecting the exercise test findings or 
the outcomes, the results did not change considerably (studies I, II and IV). Finally, two 
exercise HR variables of main interest in the present study, HR40-100 and WL100, were 
not different between men with CVD and those without it (Table 8). It is noteworthy, 
however, that by far the most common CVD was arrhythmias (Table 7), which are 
generally benign and usually have no prognostic value.  
The relationship of HR at submaximal workload with mortality and the risk of CVD 
events in patients with known or suspected CHD has not been investigated. 
Nonetheless, for descriptive purposes the present study can be compared with two 
recent studies (354,355) that explored HR increment from rest to submaximal workload 
as a predictor of death in men with known or suspected CHD. The sampling of subjects 
in the present study (study III) differs markedly from that of the previous two studies. 
The men in the present study were from a large population-based sample and the 
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inclusion criteria involved a self-reported history of myocardial infarction or angina 
pectoris, or a regular use of antianginal medication. However, the study was not carried 
out in a clinical setting, and therefore the complete medical records of subjects were not 
available.  
In contrast, in studies conducted in one or several academic clinics the detailed 
objective clinical history of participants can be gathered easily. The subjects in the two 
clinical studies were either patients with angiographically documented CHD (354), or 
consecutive patients referred for exercise testing (355). Self-reporting unavoidably 
involves inaccuracy and a risk of misclassification (17). However, in the present study 
the history of myocardial infarction or angina pectoris were based on a diagnosis made 
by a physician. Furthermore, the London School of Hygiene Cardiovascular 
Questionnaire (444) is a widely used and well validated tool for a standard, unbiased 
assessment of chest pain in epidemiological studies (458).  
It is therefore possible that the subjects in the present study represent a wide spectrum 
of severity of CHD, and consequently the results can be generalized to an even larger 
group of patients with known or suspected CHD than the results from studies involving 
subjects referred for exercise testing (457). Moreover, men in the current study III can 
be considered as patients who according to current guidelines (459) should be referred 
for exercise testing either for diagnostic purposes or for evaluation of prognosis and 
treatment options.  In this respect, the subjects of the current study III resemble those in 
the study by Leeper et al (355). The number of subjects was lower and the subjects were 
younger, but the length of follow-up was about twice as long in the current study III as 
in two previous studies in patients with known or suspected CHD (354,355), 
respectively. The estimated crude outcome rates for all-cause, CVD and CHD death 
were very similar in all these studies. 
We deliberately excluded men who used HR-lowering medication in studies which 
involved men without CHD at baseline (studies I, II and IV). This exclusion has been 
used also in previous studies exploring the association between HR at exercise test and 
CVD events in asymptomatic subjects. In seven (9,14,227,230,316,344,345, 
368,374,375) of 11 studies users of HR-lowering medication have been excluded, and in 
only one (341) study have they been included in the study sample (Tables 2 and 4). In 
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four (15,342,343,369,370,377) studies the presence of users of HR-lowering medication 
was not reported. Definitely future studies are needed to clarify the prognostic value of 
chronotropic incompetence also among the users of HR-lowering medication. In the 
current thesis, however, a low WL100 predicted all-cause deaths both in subjects who 
used and did not use HR-lowering medication among men with known or suspected 
CHD. 
 
6.1.3 Exercise testing 
A maximal, symptom limited exercise test was performed on an electrically braked 
cycle ergometer. The advantage of cycle ergometer is that an upper body motion is 
usually reduced, that makes it easier to measure BP and to record the ECG 
(10,190,319). It is argued that a major limitation to cycle ergometer testing is the fatigue 
of the quadriceps muscles in subjects who are not experienced cyclists, which may 
cause them to stop before reaching a true maximal HR (10,17,190).  
    Unfortunately the testing protocol was changed midway through the baseline data 
collection so that the increment of workloads during first minutes of a test was different 
between men tested earlier or later during the course of baseline data collection. 
Because WL100 characterizes the early rise of HR at the beginning of a test, two 
different protocols could affect WL100. However, WL100 was not different between men 
tested according to different protocols (studies II and III). Furthermore, the potential 
effect of two different protocols was taken into account by including testing protocol as 
a forced covariate in all Cox models in studies II and III. Finally, WL100 was included as 
a statistically significant predictor in the final Cox models after stepwise selection 
performed separately in men tested with both earlier and later protocol (studies II and 
III). These findings suggest that the difference in the testing protocols had no effect on 
the results in studies II and III. The different testing protocols should have no effect on 
HR40-100 or other chronotropic incompetence variables because they are determined 
by a HR increase during the latter half of the test which was identical in both testing 
protocols. The main results were unchanged when the analyses were performed with the 
testing protocol as a forced covariate in Cox models (data not shown). 
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HR was recorded from ECG as the reciprocal of the time interval between successive 
R peaks obtained from sample interval of approximately three seconds and measured 
digitally by ECG. The difference between the measured HR and the true HR 
(determined by the last 30 seconds of each minute during exercise) is inversely related 
to the sampling interval (281). It is possible that the measurement of HR would have 
been more accurate if a longer measurement interval had been used. Hence, the possible 
inaccuracy associated with a short sampling interval rather weakens than falsely 
strengtens the predictive value of HR variables observed in the present study. On the 
other hand, HR can climb steeply even in the final seconds of exercise (17,460), in 
which case an inappropriately long sample interval would prevent the detection of the 
true maximal HR.  
In studies I, II and IV myocardial ischemia during exercise test was defined as a 
horizontal or downsloping ST depression with 0.5 or more mm at 80 milliseconds after 
J point instead of conventionally used cut-off value of 1.0 mm. An ST depression of 0.5 
mm was used as a cut-off value for definition, as in the early reports from the KIHD 
data (434,441,461), because in univariate Cox models (studies I, II, III, IV) it was a 
stronger predictor of the outcome than a 1.0-mm cut-off for ST depression. In study III, 
a 1.0 mm ST-depression was used as a cut-off value, however, because the prevalence 
of ischemic change in exercise ECG would have been quite large (84%) had a 0.5 mm 
cut-off been used. More importantly, the main results were practically unchanged even 
when an ST-depression of 0.5 mm was replaced by 1.0 mm as a cut-off value in studies 
I, II and IV, and vice versa in study III.  
Another strength of the present study is that cardiorespiratory fitness was measured 
objectively by direct expiratory gas analysis instead of using predicted values. The use 
of direct expiratory gas analysis can greatly supplement exercise testing by adding 
precision and reproducibility as well as increasing the yield of information concerning 
cardiopulmonary function (319,363,460). Importantly, a submaximal effort at peak 
exercise can also be objectively evaluated based on respiratory exchange ratio 
(10,319,460). VO2max is considered the best index of aerobic capacity and maximal 
cardiorespiratory function (10,190,460). As VO2 is determined primarily by cardiac 
output in the absence of pulmonary or skeletal limitations, this allows for the use of 
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VO2max as an estimate of cardiovascular function during physical stress (18,319). 
Predicting VO2 from cycle ergometer workload is a common clinical practice, but such 
predictions can be misleading (319,363,460). In the current study, exercise testing with 
both the conventional indirect definition of exercise capacity and respiratory gas 
analysis was used, which is unique in a large cohort study. The accurate measurement of 
VO2max assured the reliable estimation of the predictive value of cardiorespiratory 
fitness. The predictive value of other exercise test variables independent of 
cardiorespiratory fitness could also be assessed more reliably as well.  
Maximal HR was relatively low in the current study compared with previous studies 
(9,230,342,344,368-370) exploring the association between HR at exercise test and 
CVD events in asymptomatic subjects. This might be explained by the higher age of our 
subjects, because the prevalence of chronotropic incompetence in the current study, as 
measured by variables that take age into account, was similar to those reported in 
previous studies (316,345,368,371,374,375). The exercise characteristics in the present 
study III were similar to those in two previous studies in patients with known or 
suspected CHD (354,355).  
 
6.1.4 Collection and classification of outcome events   
During the follow-up of the current study it was possible to to assess both cause-specific 
and overall mortality as hard end points. The present study is based on reliable data on 
outcome events because deaths were ascertained from the Finnish National Death 
Registry using personal identification codes. The coding of cause of death in the Finnish 
National Death Registry has been validated (462). Additionally, the validity of 
diagnoses of CHD deaths in the Finnish National Death Registry has been addressed 
and its use in endpoint assessment in epidemiological studies has been justified 
(463,464). Data on coronary events were obtained by computer linkage to the national 
hospital discharge and death registers. The source of this information was checked by 
interviews, hospital documents, death certificates, autopsy reports and medico-legal 
reports. The diagnosis of an acute coronary event was typically based on symptoms, 
ECG and cardiac enzymes or autopsy findings. 
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Five (227,342-345,368,371,375) of 11 previous studies exploring the association 
between HR at exercise test and CVD events in asymptomatic subjects (Tables 2 and 4) 
used composite end points (fatal or nonfatal CVD event) as an outcome. The several 
problems accompanying composite end point has been discussed thoroughly (465,466). 
One of the main problems is that variables predicting nonfatal CVD events can be 
different than those predicting CVD death, creating a situation where one variables’s 
contrasting effects with respect to two end points can cancel each other out (3-5). 
Among fatal end points, all-cause mortality is suggested to be objective, unbiased, and 
clinically relevant (467,468). On the other hand, CVD mortality has been proposed to 
be more appropriate for evaluating the prognostic value of exercise test variables 
because exercise test is used to assess the response of a cardiovascular system to a 
standardized stress (17). In the present study, to avoid inherent problems associated 
with composite end points, incident AMI and mortality from CHD, CVD and all causes 
were used as the main outcomes. When mortality was used as an outcome (studies I-
III), the results were reported separately for CHD, CVD and total mortality.  
 
6.2. Results 
 
The main finding of the current thesis is that both a low workload at HR of 100 
beats/min and an inability to raise HR appropriately during the latter half of the 
maximal exercise test are prognostically adverse findings in the population-based 
sample of middle aged-men without CHD at baseline. These observations are from two 
separate studies (studies I and II) which involved virtually the same subjects. The 
results support the main hypothesis that a bimodal relationship exists between HR and 
prognosis as presented in Figure 2. The actual HR-workload-curve shown in Figure 4 
resembles the hypothetical curve in Figure 2, although the distance between curves is 
exaggerated in the latter curve.Among asymptomatic subjects, only the Lipid Research 
Clinics Mortality Follow-up Study has shown that both a high HR at a fixed 
submaximal workload (14) and a low HR near maximal workload (316) are associated 
with an adverse prognosis. Although the two reports (14,316) are from a single study, it 
is impossible to derive the proportion of subjects that were included in both papers.  
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6.2.1 Heart rate increase from 40% to 100% of maximal work capacity, mortality 
and the risk of acute myocardial infarction in men without coronary heart disease 
(Studies I and IV) 
According to the hypothesis shown in Figure 2 we expected that a blunted increase in 
HR particularly during the latter half of the maximal exercise test predicts CVD events 
in a population-based sample of middle-aged men free of CHD. We observed that the 
HR response to exercise between those who died of CVD during follow-up and 
survivors began to diverge only after 40% of maximal work capacity was achieved. The 
survival analysis show that a blunted HR increase between 40 and 100 % of maximal 
work capacity (HR40-100) during an exercise test was associated with increased CHD, 
CVD and all-cause mortality and an increased risk of AMI. The magnitude of the 
association was comparable with that of other major CVD risk factors and exercise test 
variables, including other variables quantifying chronotropic incompetence.  
The present findings are in line with the results of previous studies in which 
chronotropic incompetence has predicted adverse cardiac events in asymptomatic 
persons (9,230,316,342,343,345,368,370,371,374,375,377) and confirm the hypothesis 
that chronotropic incompetence is an important risk factor for death and cardiac events 
regardless of the chronotropic incompetence variable used. A new chronotropic 
incompetence variable, HR40-100, was as strong predictor of mortality and AMI as 
previously established chronotropic incompetence variables. HR40-100 was formulated 
based on the finding that when compared with survivors, the blunted HR rise in subjects 
who died of CVD during follow-up was statistically significantly only when calculated 
during the latter half of the exercise test. This observation was confirmed in 
multivariable Cox models in which HR increase from rest to 40% of maximal work 
capacity was not associated with an increased risk of adverse outcome, whereas HR40-
100 was a strong independent predictor. The findings furthermore support the 
hypothesis of a bimodal relationship between exercise HR and prognosis (223).  
Symptoms originating from existing non-cardiovascular disease or latent CVD may 
interrupt the test prematurely, and in such case the underlying disease may explain the 
association between chronotropic incompetence and an outcome (230). In the present 
study, the exclusion of subjects who had an outcome event within two years after 
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baseline and those whose test was terminated because of symptoms or findings 
potentially due to existing disease or latent CVD did not weaken the prognostic value of 
HR40-100 dramatically. This suggests that neither existing baseline disease nor latent 
CVD explain the increased risk associated with a low HR40-100.  
The mechanism mediating the association between chronotropic incompetence and an 
increased risk of CVD events is unknown. The proposed mechanisms include abnormal 
myocardial wall motion and accumulation of metabolic by-products caused by ischemia 
which irritate ventricular mechano- and/or chemoreceptors (174) leading to vagal 
activation and consequently attenuation of normal HR increase during exercise (24,26); 
abnormal cardiovascular autonomic control (26,51,230), and more specifically sinus 
node β receptor down regulation caused by chronic heightened sympathetic activation 
(26,230); SA node dysfunction (171,320,379); reduced bioavailability of nitric oxide in 
sinus node (26); latent ischemia of sinus node (338,369); reduced carotid baroreflex 
sensitivity (377), possibly due to carotid atherosclerosis (376); and systemic low-grade 
inflammation (381). Numerous proposed mechanisms may simply mean that the 
prognostic value of chronotropic incompetence is based on several overlapping 
mechanisms instead of a single one.  
Three follow-up studies, the Norwegian Study (9), the Paris Prospective Study 
(228,377) and the KIHD Study, have shown that a heightened BP response and a 
blunted HR increase are independent predictors of CVD events in asymptomatic men 
(Table 13). The present findings add to current knowledge in that the heightened BP 
response and the blunted HR increase during the exercise test were independent risk 
factors for AMI and provided additional information for risk prediction beyond each of 
them alone (Table 14).  
The finding that the heightened BP response and the blunted HR increase during 
exercise test both were independent risk factors for AMI is somewhat puzzling, because 
they simultaneously reflect exaggerated and blunted hemodynamic response. We 
hypothesize that there is a common physiological link between the heightened BP 
response and the blunted HR increase during the exercise test, such as arterial 
dysfunction due to subclinical adverse vascular changes, e.g. atherosclerosis and media 
thickening. Arterial dysfunction leads to reduced arterial compliance, which is known to 
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heighten the increase of SBP in response to exercise (469,470). It may also interfere 
with the normal exercise-induced HR rise. Because of a nonlinear pressure-volume-
relationship in conduit arteries (471), a heightened SBP increase rapidly shifts the 
pressure-volume-curve towards an even more noncompliant region. With reduced 
arterial compliance, the pressure wave reflects back from peripheral circulation 
abnormally fast and results in an augmented central SBP in the latter half of systole 
(472). Both of these phenomena stretch aortic baroreceptors, the activation of which 
may lead to a vagally mediated inhibition of the normal increase in HR in response to 
exercise. These phenomena may be obscured at rest or during light dynamic work, but 
at higher workloads the inability to normally reduce total peripheral resistance may 
become evident. This could also explain the finding in the present study that a blunted 
HR rise during the latter, but not during the first half of the test predicted outcomes.  
Several prospective studies have shown that measures of arterial function and 
structure provide prognostic information incremental to conventional risk factors for 
CVD (472,473). We suggest that arterial dysfunction, indicated by the heightened BP 
increase and the blunted HR increase during the exercise test, is a potential and 
currently overlooked mechanism explaining partly, although not completely, the 
association between chronotropic incompetence and an increased risk of CVD events. 
Supporting this hypothesis, flow mediated vasodilatation as a marker of endothelial 
function in conduit arteries has been shown to be markedly lower in patients with 
chronotropic incompetence compared with patients with normal HR response to 
exercise (381). 
To address a potential overlapping between results of study I and study IV, the 
predictive value of HR40-100 for AMI was separately studied after excluding 20 men 
who died because of CHD within the next year after experiencing AMI. HR40-100 was 
still an independent predictor of AMI. This indicates that the main results of the studies 
I and IV do not overlap to a great extent, but instead represent two separate and 
clinically meaningful relationships.        
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6.2.2 Workload at heart rate of 100 beats/min during exercise test and mortality 
(Studies II and III) 
The workload achieved at a HR of 100 beats/min during exercise test (WL100) reflects 
physiological responses to early stages of the exercise test and is determined by resting 
HR, maximal HR, cardiorespiratory fitness and steepness of the early HR rise as related 
to the overall HR increase (Figure 6). Because both a high resting HR (377,474,475) 
and low cardiorespiratory fitness (339,346,360) are known risk factors for death and 
CVD events both in asymptomatic persons and in patients with known or suspected 
CHD, we hypothesized that a low WL100 is an independent predictor for adverse 
outcomes. 
The principal findings of this part of the study is that a low WL100 was associated 
with an increased CVD and CHD mortality in men who did not have prior CHD at 
baseline, and with an increased mortality in men with known suspected CHD at 
baseline. The association was independent of other HR-derived or other exercise test 
variables, and the magnitude of the association was comparable with that of 
conventional risk factors. In two previous studies with a similar finding (14,15), a high 
HR at a fixed submaximal workload, which equals a low workload at a fixed HR, has 
been considered as a surrogate measure of a low cardiorespiratory fitness, and the 
prognostic value of a high submaximal HR has been explained by this assumption 
(corresponding to graph c in Figure 6). Moreover, in those studies the actual maximal 
cardiorespiratory fitness was not measured and thereby could not be included as a 
covariate in the analysis. In the present study, a low WL100 was a strong predictor of 
premature CVD, CHD and all-cause death even after adjustment for directly measured 
VO2max, which means that low cardiorespiratory fitness did not explain the association 
of a low WL100 with outcomes. This interesting finding suggests that an exaggerated HR 
response at low workload indicates increased risk in and of itself, instead of being only 
a surrogate marker of low cardiorespiratory fitness.  
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Figure 6. The graph illustrating how a high resting heart rate (a), a high maximal heart rate (b), a low 
cardiorespiratory fitness (c), and a disproportionately increasing heart rate at light workloads (d) each can 
have a lowering effect on workload achieved at heart rate of 100 beats/min as shown by broken lines.    
 
Resting HR was the most significant individual determinant of WL100 and was also an 
independent predictor of outcomes. A high resting HR has been considered as a 
surrogate measure of reduced parasympathetic tone (476), which is a known risk factor 
for CVD events in asymptomatic subjects (418-420) and cardiac patients (51,430,431). 
Although the mechanism of the association is unknown, it has been suggested that a 
reduced parasympathetic tone makes an individual vulnerable to fatal ventricular 
arrhythmias in circumstances that may induce them, such as myocardial ischemia 
(430,431). It is possible that a high resting HR in men with a low WL100 reflects an 
impaired vagal control of the heart, but it is noteworthy that resting HR did not weaken 
the prognostic value of WL100 when entered in the same Cox model. Unfortunately, 
directly measured information on autonomic nervous system status (e.g. heart rate 
variability) is not available is the present study.  
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A continuosly elevated resting HR and exaggerated HR responses to daily stressful 
situations may burden cardiovascular system and enhance progression of athesclerosis 
(477,478) via several mechanisms (479-481). An elevated HR may be a sign of chronic 
sympathetic nervous system overactivity, which may induce numerous unfavorable 
changes from the viewpoint of cardiovascular health, as discussed previously. Because 
the cardiac work is a product of HR, stroke volume and BP, a consistently elevated HR 
will impose greater cardiac work (482).  
The direct atherosclerotic effect of a high HR on the arterial wall can be explained by 
the intensification of the pulsatile nature of the blood flow and the associated changes in 
the shear stress (479,481,483). High HR is associated with a longer time spent in 
systole, during which changes in the rate of blood flow and departures from laminar 
flow are largest (479,484). The increase in arterial wall stress caused by a high HR can 
also be the result of a higher mean BP in individuals with tachycardia (485), which is 
due to the progressive shortening of the diastolic phase of the cardiac cycle (480,486). 
The increased arterial wall stress may perturb intercellular junctions, increase 
permeability of the endothelial cells and favor the ingress of atherogenic particles, 
leading to atherosclerotic plaques (479,483,487).  
In rats, carotid artery compliance and distensibility have been shown to be markedly 
impaired by the progressive increase in HR caused by pacing (488). This might be due 
to the fact it takes a certain time for the arterial wall to distend fully in response to BP 
variations (480). On the other hand, pharmacologic HR reduction induced a significant 
decrease in thoracic aorta wall thickness in rats (489). In CHD patients, hemodynamic 
forces resulting from an increased HR may favor vulnerable coronary plaque disruption 
(490). In patients with restricted coronary blood flow a high HR can further increase 
cardiac ischemia and precipitate the occurrence of arrhythmias and impair left 
ventricular performance by increasing myocardial oxygen demand, facilitating 
desynchronization of ventricular myocardial cells and worsening coronary perfusion 
(480,491).     
WL100 was recorded directly at HR 100 beats/min or interpolated linearly as a 
function of HR by using resting HR and the nearest HR value above 100 beats/min. The 
advantage of this method for defining WL100 is that the lowest HR values at the early 
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phase of the exercise test are not required to be below 100 beats/min. An exaggerated 
HR rise above the level of 100 beats/min at the first workload is an actual phenomenon 
in individuals with a limited exercise capacity, particularly if the first workload is not 
adjusted for the reduced performance. Resting HR, when measured before the exercise 
test, is higher than the true resting HR because of nervousness, excitement and 
apprehension related to the testing environment (476). Because data on the true resting 
HR measured at less stressful conditions was not available in the present study, it is 
impossible to evaluate to what extent interindividual differences in pre-test excitement 
affects resting HR values measured before test and consequently on WL100. It is 
possible that a pronounced anticipatory HR response to test includes not only a high 
resting HR before the test, but also an exaggerated HR response at the first workloads 
(69,171,217), indicated by a low WL100.  
In previous reports from the KIHD Study, an exaggerated anticipatory BP response to 
exercise test has been linked to an increased left ventricular mass assessed by 
echocardiography (492), and a heightened BP response during mental stress has been 
linked to enhanced carotid atherosclerosis (493,494). Furthermore, a trend was observed 
between an exaggerated HR response during mental stress and enhanced carotid 
atherosclerosis in 4-year follow-up (493), but no association was observed to a 
progression of atherosclerosis from the fourth to eleventh follow-up year (494). Thus, a 
low WL100 may represent a trait characterized by an exaggerated cardiovascular 
responsiveness to stressful situations (corresponding to graph d in Figure 6). 
 A high chronotropic index at HR of 100 beats/min, reflecting a disproportionately 
steep HR rise at the early phase of a test, was an independent predictor of CVD and 
CHD death in men without CHD at baseline. This observation may further suggest that 
a trait characterized by an exaggerated cardiovascular responsiveness to stressful 
situations can to some extent explain the association of a low WL100 with an increased 
risk of outcomes in the current study.  
To recapitulate, we suggest that a low WL100 concurrently reflects a high resting HR, 
an exaggerated HR increase at the beginning of an exercise test, and a low 
cardiorespiratory performance. While these variables separately had only a limited 
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predictive value in the present study, the combined variable WL100 provided valuable 
prognostic information beyond these variables. 
We intentionally used the workload achieved at a fixed submaximal HR instead of 
using HR at a fixed submaximal workload. This approach has a solid physiological 
basis, as explained. Use of the workload achieved at a fixed submaximal HR enables the 
testing of subjects at approximately the same relative intensity independent of age, 
gender, size of body or fitness level, unlike when a fixed workload is used. However, 
careful inspection of Figure 4 suggest that the maximal predictive value might be found 
if a slightly lower HR value than 100 beats/min was used to quantify a submaximal HR 
response. Among asymptomatic subjects the association between a high HR at 
submaximal work and an increased risk of CVD death has been observed in studies that 
have used a treadmill as a testing mode (14,15), but not in studies using a cycle 
ergometer (227,342-344). In contrast, in patients with known or suspected CHD the 
findings have been just opposite (354,355). Therefore it is unclear whether the testing 
mode affects the prognostic value of a high HR at submaximal work or that of WL100, 
and further studies are needed to address the issue. 
Submaximal exercise tests have some benefits over maximal tests. A low level of 
exercise enables testing of individuals with a limited exercise capacity, and 
cardiovascular risks associated with high-intensity exertion can be largely avoided 
(17,69). This is an important aspect in subjects who have any contraindication for 
maximal test. If necessary, the exercise test can also be repeated frequently because of 
the short recovery period needed. 
 
6.2.2.1 Workload at heart rate of 100 beats/min during exercise test and 
cardiovascular disease mortality in men without coronary heart disease at baseline 
The results of the present study are in accordance with two previous population-based 
studies (14,15) which reported that a high HR at a fixed submaximal workload predicts 
CVD and CHD deaths. As explained, cardiorespiratory fitness did not explain the 
association of a low WL100 with outcomes. Furthermore, the level of exercise used to 
explore the association of a submaximal HR and workload with outcomes was lower in 
the present study compared with two previous studies (14,15). While the minimum HR 
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required for risk assessment was 116 (15) and 133 beats/min (14) in two previous 
studies, the mean HR to enable the risk assessment (ie. the first HR value above 100 
beats/min) was only 104 beats/min in the present study. 
Interestingly, three of the four studies (14,15,341), including the present study, 
investigating CVD and CHD death as an outcome have found a submaximal HR 
variable to be a statistically significant predictor. Conversely, all three (227,342-344) 
previous studies exploring a composite end point, including fatal and nonfatal CVD 
events, as an outcome have not found a submaximal HR variable to be a statistically 
significant predictor. It has been suggested that variables predicting nonfatal CVD 
events can be different than those predicting death, creating a situation where a 
variables’s contrasting effects with respect to the two end points can cancel each other 
out (3-5). Because of a limited number of studies it is precipitated to state that a 
submaximal HR predicts fatal CVD events more potently than nonfatal CVD events. 
However, in the current study a low WL100 was not associated with an increased risk of 
AMI or nonfatal AMI, but it was an independent predictor of fatal AMI (15% of all 
AMIs). 
One previous study (227) did not find the association between a low workload 
attained at HR of 150 beats/min and an increased risk of CHD event, but the association 
was observed when the workload attained was expressed as divided by body weight. 
The association may not have been observed because at the HR of 150 beats/min the 
difference in workload between groups with adverse and good prognosis had already 
narrowed considerably, although the difference might have been observed at lower HR 
levels. According to Figure 4 this could also have been the case in the study II of the 
current thesis. We did not divide WL100 by body weight, although there is a theroretical 
basis for it (69). Furthermore, because a high BMI was a risk factor for death in study 
II, it is possible that the prognostic value of WL100 would have improved if it had been 
expressed in relation to body weight.  
A low stroke volume may be a common denominator for a high resting HR, an 
exaggerated HR increase at the beginning of an exercise test, and a low 
cardiorespiratory performance (18,69). We could not, however, directly assess stroke 
volume in the present study, and thereby its role in the association between WL100 and 
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mortality can not be considered any further. The exclusion of subjects who had an 
outcome event within two years after baseline and those whose test was terminated 
because of symptoms or findings potentially due to latent CVD did not weaken the 
prognostic value of WL100 much. This suggests that latent CVD probably does not 
explain the increased risk associated with a low WL100. 
 
6.2.2.2 Workload at heart rate of 100 beats/min during exercise test and mortality 
in men with known or suspected coronary heart disease at baseline 
The results of the present study basically agree with the findings of a recent study in 
which a large HR increase from rest to a workload of 25 W at the onset of an exercise 
test was a strong predictor of adverse cardiac events and cardiac deaths in patients with 
CHD verified by angiography (354). In the present study, HR increase from rest to a 
workload of 50 W was associated with a nonsignificant trend (p=0.11) toward increased 
risk of death after stepwise selection (data not shown). Because of the testing protocol, 
the workload of 50 W was used instead of 25 W that hampers the comparison of the 
results of these two studies. Although WL100 was not measured in the study by Falcone 
et al (354), closer inspection indicates that men with an exaggerated HR response 
obviously had a low WL100. The researchers suggested that a rapid HR increase was 
caused by a rapid vagal withdrawal reflecting an autonomic imbalance. Exercise 
capacity was lower in men with an exaggerated HR response. Unfortunately, exercise 
capacity was not included in the Cox model as a covariate, leaving open the possibility 
that an exaggerated HR response was caused by a low cardiorespiratory fitness.  
The results of the present study also agree with the findings of two previous studies in 
dogs (365,366). The rise of HR at the early phase of an exercise stress was steeper in 
dogs with a healed myocardial infarction that were susceptible to ventricular fibrillation 
after experimentally induced coronary occlusion than in dogs that were resistant to 
ventricular fibrillation. The susceptibility to ventricular fibrillation was associated with 
a greater degree of left ventricular dysfunction (365), which probably also explains the 
higher HR at submaximal workloads.   
On the contrary, in another recent study a HR increase from rest to 2 METs workload 
in treadmill was not associated with an increased risk of CVD death in patients referred 
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for exercise testing (355). Again, WL100 was not measured in the study by Leeper et al 
(355), but closer inspection shows that WL100 obviously was not different between 
subjects who died of CVD during the follow-up and survivors. One disparity between 
the present study and the study by Leeper et al (355) is that the latter used an 
individualized ramp treadmill protocol in which workload increments are tailored 
according to the estimated work capacity of a patient (268). It has been discussed that a 
prognostic value of an exaggerated BP response to submaximal exercise is directly 
related to the strain of the first workload(s) as related to the total exercise capacity of a 
subject (16). If a similar relationship exists for HR response too, then a discrepancy 
between the findings in the present study and in the study by Leeper et al (355) could to 
some extent be attributed to the different testing protocols used in these studies.  
A low WL100 could result from left ventricular dysfunction in subjects with a more 
severe CHD (362-364). Although this possibility cannot be ruled out in the current 
study, an argument against this notion is that a low WL100 was not associated with a 
more prevalent history of myocardial infarction or self-reported cardiac insufficiency 
either in men using HR-lowering medication or in nonusers (data not shown). More 
specifically, a low WL100 could originate from myocardial ischemia beginning already 
at early exercise when HR is below 100 beats/min (361-363). An early appearance of 
myocardial ischemia has been shown to be associated with an adverse prognosis 
(495,496) and angiographically more severe CHD (496). Because the data on ST-
segment depression at workloads below HR of 100 beats/min is not available, the role 
of early ischemia as a link between a low WL100 and an increased risk of death in the 
present study can not be excluded either.  
 
6.3 Clinical implications  
 
The recent consensus statements from the American Heart Association, the American 
College of Cardiology (10) and from the US Preventive Services Task Force (497) have 
led to recommendation against the use of exercise testing as a screening tool for 
detecting latent CHD in asymptomatic persons at low to intermediate risk. These 
recommendations have been largely based on an extensive body of literature 
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documenting the limitations of the ST-segment for diagnosing CHD in asymptomatic 
subjects (339). Still, reports on evaluation of the exercise test as a prognostic rather than 
a diagnostic test suggest that the prognostic value of the screening exercise test may 
have been underestimated (11,12,339). The latest version of the textbook written by 
major authorities in the field (17) states, indeed, that exercise testing should be used for 
screening healthy, asymptomatic individuals along with risk factor assessment (498). In 
this context assessment of exercise test result includes not only ST-segment diagnostics, 
but also other exercise test variables shown to have a prognostic value (17).  
    Nonetheless, no consensus exists whether this further risk stratification should be 
targeted to persons at an intermediate or high risk of events based on office tools such 
as the Framingham Risk Score or European Systematic Coronary Risk Evaluation 
(SCORE). Some authors have suggested that the current risk assessments based on 
conventional risk factors are especially ineffective among persons at an intermediate 
risk of events, and these individuals may benefit from further risk stratification 
(472,499). Recent prospective studies in asymptomatic persons have shown, however, 
that an additional prognostic value from exercise testing above conventional risk factors 
seems to be the largest in persons at a high risk of events (9,375,500). Whatever the 
target group, the primary aim of enhanced risk stratification is to detect those 
individuals who would benefit most from targeted aggressive treatment of risk factors 
(501). The recent expert statement concluded that the next major priority is the design 
and implementation of large-scale randomized trials to determine whether an exercise 
screening strategy leads to an improvement in outcomes (339). Additionally, these trials 
would provide much-needed evidence about the cost-effectiveness in execise testing in 
asymptomatic persons (339). 
Because in patients with known or suspected CHD the value of exercise testing is 
more clearly established, the post-exercise test risk assessment serves as a guide to a 
particulatr management strategy that is viewed as most appropriate, based on expected 
outcomes (10,190). According to the guidelines of the American Heart Association and 
the American College of Cardiology (10), patients with a low-risk exercise test result 
can be treated medically without need for referral to cardiac catheterization. Patients 
with a high-risk exercise test result should usually be referred for cardiac 
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catheterization. Patients with an intermediate-risk exercise test result should be referred 
for additional testing, either cardiac catheterization or an exercise imaging study, 
depending on other clinical variables (10).  
An obvious question with regard to the clinical use of WL100 or HR40-100 is whether 
it is a modifiable risk factor. For WL100, the existing literature shows that physical 
activity or training lowers HR at a fixed submaximal workload (190), and thus also 
increases WL100. This has been observed both in healthy subjects (29,298,299) and in 
patients with CHD (502-504). Weight loss in obese subjects is another physiological 
means to increase WL100. This effect is especially pronounced in activities involving 
weight-bearing, such as walking on a treadmill.  
As far as HR40-100 and other chronotropic incompetence variables are concerned, 
the effects induced by physical training are not as straightforward. In healthy persons, 
physical training lowers resting HR, but usually has no effect on maximal HR (17,190). 
Hence, chronotropic incompetence variables (Table 3) which are based solely on 
maximal HR (inability to achieve the fixed %-value of age-adjusted expected maximal 
HR or maximal HR) do not change as a consequence of training. On the other hand, 
chronotropic incompetence variables that do not depend exclusively on maximal HR 
(HR reserve, submaxCRI, maxCRI, HR40-100) may change towards values attributed 
to a lower risk after training, depending on whether resting HR decreases. Cessation of 
smoking has been speculated to improve chronotropic incompetence variables to a 
favorable direction, but direct evidence of this is lacking (315,316). In contrast to 
healthy persons, maximal HR may increase as a result of physical training in CHD 
patients (190). Changes in maximal HR may reflect a greater level of effort applied after 
training (190). Whether it is due to habituation to the testing situation, improved self-
confidence to exercise until a true maximum is achieved, or physiological alterations 
induced by training, is not known. 
In the current study, several exercise test variables predicted outcomes independent of 
each other or conventional risk factors. This highlights the fact the maximal prognostic 
yield from exercise test is obtained by measuring several variables at submaximal and 
maximal workload and during the recovery phase. The underestimation of exercise 
testing as a prognostic tool has been based on a constricted assessment of solely the ST-
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segment response to exercise. Several studies conducted during the last 15 years in 
healthy individuals and patients have shown without doubt that exercise testing can 
offer additional prognostic information beyond conventional risk markers. 
Consequently, multivariable equations and scores derived from clinical variables and 
exercise test results are considered to be a highly recommended method to evaluate an 
individual’s risk for adverse CVD events in the future (12,339,340).   
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7. SUMMARY AND CONCLUSIONS 
 
1. Both a low workload achieved at HR of 100 beats/min and a blunted HR increase 
particularly in the latter half of the maximal exercise test are associated with an adverse 
prognosis in men without CHD at baseline. The findings support the main hypothesis 
that a bimodal relationship exists between HR and prognosis in which both an 
exaggerated HR response at submaximal workload and a blunted HR response at 
maximal or near maximal workload are associated with an unfavorable prognosis. 
 
2. The heart rate increase from 40% to 100% of maximal work capacity (HR40-100) is a 
strong predictor of all-cause, CVD and CHD mortality in middle-aged men without 
CHD at baseline. Additionally, a low HR40-100 is associated with an increased risk of 
future myocardial infarction in the same population. The magnitude of the association is 
comparable with that of other major CVD risk factors and exercise test variables, 
including other variables quantifying chronotropic incompetence. 
 
3. A low workload achieved at HR of 100 beats/min during an exercise test predicts 
CVD and CHD death in middle-aged men without CHD at baseline, and also all-cause 
death in men with known or suspected CHD at baseline. The association between 
workload achieved at HR of 100 beats/min and mortality is not explained solely by 
cardiorespiratory fitness, as previously assumed. 
 
4. Several exercise test variables predict CVD events independently of each other and 
conventional risk factors. This emphasizes that the maximal prognostic yield from an 
exercise test is obtained by measuring several variables at submaximal and maximal 
workloads and during the recovery phase. 
 
5. A complex interplay exists between an exaggerated BP response to exercise and a 
blunted HR increase during the latter half of maximal exercise test so that their 
simultaneous presence is related to a markedly increased risk of future myocardial 
infaction. Arterial dysfunction may be a link between an exaggerated blood pressure 
response, a blunted HR increase and an increased risk of future myocardial infarction.  
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